
<html lang="en"     class="pb-page"  data-request-id="6351a190-8eab-4ea9-8f46-76928578c8b7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b02134;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models" /></meta><meta name="dc.Creator" content="Uma Gayathri  Kamakolanu" /></meta><meta name="dc.Creator" content="Michael E.  Meyer" /></meta><meta name="dc.Creator" content="Dennis  Yasuda" /></meta><meta name="dc.Creator" content="Willma E.  Polgar" /></meta><meta name="dc.Creator" content="Matteo  Marti" /></meta><meta name="dc.Creator" content="Daniela  Mercatelli" /></meta><meta name="dc.Creator" content="Clarissa Anna  Pisanò" /></meta><meta name="dc.Creator" content="Alberto  Brugnoli" /></meta><meta name="dc.Creator" content="Michele  Morari" /></meta><meta name="dc.Creator" content="Nurulain T.  Zaveri" /></meta><meta name="dc.Description" content="A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would affo..." /></meta><meta name="Description" content="A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would affo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 17, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02134" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02134" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02134" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02134" /></link>
        
    
    

<title>Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02134" /></meta><meta property="og:title" content="Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0007.jpeg" /></meta><meta property="og:description" content="A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson’s disease (PD) motor symptoms and development of levodopa-induced dyskinesias. SAR around the C-3 substituents investigated effects on NOP binding, intrinsic activity, and selectivity and showed that while the C(3)-substituted indoles are selective, high affinity NOP ligands, the steric, polar, and cationic nature of the C-3 substituents affected intrinsic activity to afford partial agonists with a range of efficacies. Compounds 4, 5, and 9 with agonist efficacies between 25% and 35% significantly attenuated motor deficits in the 6-OHDA-hemilesioned rat model of PD. Further, unlike NOP antagonists, which appear to worsen dyskinesia expression, these NOP partial agonists did not attenuate or worsen dyskinesia expression. The NOP partial agonists and their SAR reported here may be useful to develop nondopaminergic treatments for PD." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02134"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02134">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02134&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02134&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02134&amp;href=/doi/10.1021/acs.jmedchem.9b02134" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2688-2704</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01963" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jmv063i005_1361406" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Uma Gayathri Kamakolanu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Uma Gayathri Kamakolanu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Uma+Gayathri++Kamakolanu">Uma Gayathri Kamakolanu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4741-7164" title="Orcid link">http://orcid.org/0000-0003-4741-7164</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael E. Meyer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael E. Meyer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+E.++Meyer">Michael E. Meyer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dennis Yasuda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis Yasuda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis++Yasuda">Dennis Yasuda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Willma E. Polgar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Willma E. Polgar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Willma+E.++Polgar">Willma E. Polgar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matteo Marti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matteo Marti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Morphology, Surgery and Experimental Medicine, Section of Legal Medicine, University of Ferrara, Ferrara 44100, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matteo++Marti">Matteo Marti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniela Mercatelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniela Mercatelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Mercatelli">Daniela Mercatelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Clarissa Anna Pisanò</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Clarissa Anna Pisanò</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Clarissa+Anna++Pisan%C3%B2">Clarissa Anna Pisanò</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alberto Brugnoli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alberto Brugnoli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alberto++Brugnoli">Alberto Brugnoli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michele Morari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michele Morari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michele++Morari">Michele Morari</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Nurulain T. Zaveri</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nurulain T. Zaveri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Astraea Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 650-254-0786. E-mail: <a href="/cdn-cgi/l/email-protection#026c7770776e636b6c4263717670636763766a677063726777766b61712c616d6f"><span class="__cf_email__" data-cfemail="8ce2f9fef9e0ede5e2ccedfff8feede9edf8e4e9feedfce9f9f8e5efffa2efe3e1">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nurulain+T.++Zaveri">Nurulain T. Zaveri</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02134&amp;href=/doi/10.1021%2Facs.jmedchem.9b02134" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2688–2704</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 17, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 December 2019</li><li><span class="item_label"><b>Published</b> online</span>17 January 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02134" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02134</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2688%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DUma%2BGayathri%2BKamakolanu%252C%2BMichael%2BE.%2BMeyer%252C%2BDennis%2BYasuda%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b02134%26title%3DDiscovery%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BNociceptin%2BReceptor%2BPartial%2BAgonists%2BThat%2BAfford%2BSymptom%2BAblation%2Bin%2BParkinson%25E2%2580%2599s%2BDisease%2BModels%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2704%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02134"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">741</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02134" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Structure–Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson’s Disease Models&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Uma&quot;,&quot;last_name&quot;:&quot;Gayathri Kamakolanu&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;E. Meyer&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;Yasuda&quot;},{&quot;first_name&quot;:&quot;Willma&quot;,&quot;last_name&quot;:&quot;E. Polgar&quot;},{&quot;first_name&quot;:&quot;Matteo&quot;,&quot;last_name&quot;:&quot;Marti&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Mercatelli&quot;},{&quot;first_name&quot;:&quot;Clarissa&quot;,&quot;last_name&quot;:&quot;Anna Pisanò&quot;},{&quot;first_name&quot;:&quot;Alberto&quot;,&quot;last_name&quot;:&quot;Brugnoli&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;Morari&quot;},{&quot;first_name&quot;:&quot;Nurulain&quot;,&quot;last_name&quot;:&quot;T. Zaveri&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2688-2704&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02134&quot;},&quot;abstract&quot;:&quot;A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson’s disease (PD) motor symptoms and development of levodopa-induced dyskinesias. SAR around the C-3 substituents investigated effects on NOP binding, intrinsic activity, and selectivity and showed that while the C(3)-substituted indoles are selective, high affinity NOP ligands, the steric, polar, and cationic nature of the C-3 substituents affected intrinsic activity to afford partial agonists with a range of efficacies. Compounds 4, 5, and 9 with agonist efficacies between 25% and 35% significantly attenuated motor deficits in the 6-OHDA-hemilesioned rat model of PD. Further, unlike NOP antagonists, which appear to worsen dyskinesia expression, these NOP partial agonists did not attenuate or worsen dyskinesia expression. The NOP partial agonists and their SAR &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02134&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02134" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02134&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02134" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02134&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02134" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02134&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02134&amp;href=/doi/10.1021/acs.jmedchem.9b02134" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02134" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02134" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02134%26sid%3Dliteratum%253Aachs%26pmid%3D31951130%26genre%3Darticle%26aulast%3DKamakolanu%26date%3D2020%26atitle%3DDiscovery%2Band%2BStructure%25E2%2580%2593Activity%2BRelationships%2Bof%2BNociceptin%2BReceptor%2BPartial%2BAgonists%2BThat%2BAfford%2BSymptom%2BAblation%2Bin%2BParkinson%25E2%2580%2599s%2BDisease%2BModels%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2688%26epage%3D2704%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson’s disease (PD) motor symptoms and development of levodopa-induced dyskinesias. SAR around the C-3 substituents investigated effects on NOP binding, intrinsic activity, and selectivity and showed that while the C(3)-substituted indoles are selective, high affinity NOP ligands, the steric, polar, and cationic nature of the C-3 substituents affected intrinsic activity to afford partial agonists with a range of efficacies. Compounds <b>4</b>, <b>5</b>, and <b>9</b> with agonist efficacies between 25% and 35% significantly attenuated motor deficits in the 6-OHDA-hemilesioned rat model of PD. Further, unlike NOP antagonists, which appear to worsen dyskinesia expression, these NOP partial agonists did not attenuate or worsen dyskinesia expression. The NOP partial agonists and their SAR reported here may be useful to develop nondopaminergic treatments for PD.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting over 6 million individuals worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> PD is clinically characterized as having classic motor symptoms (hypo/akinesia, rigidity, gait disturbance, and resting tremor), as well as nonmotor complications such as depression and cognitive decline.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The dopamine (DA) precursor levodopa (<span class="smallcaps smallerCapital">l</span>-3,4-dihydroxyphenylalanine; L-DOPA) is the cornerstone of PD therapy, often given in combination with COMT and MAO inhibitors to extend its bioavailability and therapeutic action.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, chronic L-DOPA therapy is associated with the eventual appearance (within 10 years in ∼80% of patients) of motor fluctuations and dyskinesias (involuntary movements) that limit its clinical effectiveness and greatly reduce the quality of life of patients.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The pathogenic hallmark of PD is the neurodegeneration of dopamine producing neurons in the substantia nigra pars compacta leading to striatal dopamine depletion, which leads to the classic motor features. On the other hand, long-term manifestations of PD treatment, such as the levodopa-induced dyskinesias (LID), are the result of an irreversible brain sensitization to L-DOPA. There is only one marketed antidyskinetic drug, amantadine, a glutamate antagonist, which has poor and short-lasting clinical efficacy.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Current strategies to minimize LID involve reducing the L-DOPA dosage and combining it with a dopaminomimetic (e.g., DA receptor agonists) to maintain symptomatic benefit. Thus, newly developed drugs that can effectively treat PD symptoms and delay or even prevent the development of dyskinesia would provide significant relief to PD patients and fill in a gap of unmet medical need in PD therapy.</div><div class="NLM_p">Previous studies by Morari and co-workers have demonstrated the involvement of the nociceptin/orphanin FQ peptide receptor (NOP, known previously as ORL-1 (opioid receptor-like-1 receptor)) in Parkinson’s disease, particularly in development of motor symptoms.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> The NOP receptor, a G-protein-coupled receptor (GPCR), is the fourth member of the opioid receptor family having close homology to the classical opioid receptors (μ, δ, κ).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The endogenous ligand for the NOP receptor is the heptadecapeptide nociceptin/orphanin FQ (N/OFQ), which is similar to the endogenous κ opioid peptide dynorphin but has no binding affinity to the three classic opioid receptors. NOP activation by endogenous N/OFQ is implicated in many physiological functions and pathologies, including pain and analgesia, anxiety, learning, and memory, as well as modulation of tolerance development and reward.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The NOP receptor is found throughout the brain, specifically, in brain cortical and subcortical areas, particularly in striatum, globus pallidus, and substantia nigra (SNr) neurons.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Morari et al. have shown that endogenous N/OFQ contributes to the development of PD symptoms based on the following findings: (1) increased levels of N/OFQ were found in the SNr following dopamine (DA) cell loss or impairment of DA transmission;<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> (2) NOP receptor antagonists reverse parkinsonian symptoms in neurodegenerative (6-hydroxydopamine (6-OHDA) hemilesioned rat, MPTP-treated mouse and macaque) and functional (reserpinized or haloperidol-treated animals) models of PD;<a onclick="showRef(event, 'ref10 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref12 ref13">(10,12,13)</a> (3) genetic deletion of the N/OFQ or NOP genes, or pharmacological blockade of the NOP receptor protects mice from the neurotoxic action of MPTP.<a onclick="showRef(event, 'ref10 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref14">(10,14)</a> Mechanistic studies revealed that the antiparkinsonian action of NOP antagonists is accomplished through normalization of the imbalance between excitatory (Glu) and inhibitory (GABA) inputs to the nigrothalamic neurons, generated by striatal DA deafferentation.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> This suggests that NOP antagonists may provide a nondopaminergic approach for the symptomatic and neuroprotective therapy of PD.</div><div class="NLM_p">Morari and colleagues also showed that NOP receptor agonists attenuate the expression of abnormal involuntary movements (AIMs, a rodent correlate of LID) in dyskinetic rats and non-human primates challenged with L-DOPA, by acting in the striatum where, contrary to SNr, the N/OFQ tone is reduced and NOP receptors are up-regulated following DA cell loss.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> This action can be dissociated from the typical motor inhibiting effects of NOP agonists since antidyskinetic doses were 100-fold lower than doses that caused hypolocomotion. Morari et al. showed that N/OFQ and NOP agonists specifically target dyskinesia pathways, preventing D1 receptor-mediated correlates of LID such as pERK phosphorylation and loss of depotentiation of synaptic plasticity in striatal GABA neurons.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a></div><div class="NLM_p last">On the basis of the above evidence from NOP antagonists targeting PD symptoms by blocking nigral NOP receptors, and NOP agonists attenuating LID symptoms by stimulating up-regulated striatal NOP receptors, we hypothesized that NOP partial agonists could provide a balanced action in both areas affected in PD. A NOP partial agonist would be expected to function as an antagonist under conditions of high extracellular levels of endogenous N/OFQ (as in SNr) and alleviate parkinsonian motor dysfunction. On the other hand, in areas where the endogenous N/OFQ tone is low or absent and NOP receptors are upregulated (i.e., in striatum during LID development), NOP partial agonists would function as agonists. On the basis of this, we explored the discovery and structure–activity relationships of NOP partial agonists to identify suitable compounds to validate our hypothesis that NOP partial agonists may be a viable approach for PD and LID treatment and to gain further insights into the role of the NOP-N/OFQ system in the pathophysiology of PD and dyskinesias.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Zaveri et al. previously disclosed NOP ligands with an indolinone motif (piperidinyl-indolinones) that provide both full and partial agonist efficacy and modest selectivity over the μ opioid receptor (MOP).<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> A SAR exploration was initiated with other similar bicyclic heterocycles, such as an indole and indoline ring in place of the indolinone moiety. This resulted in two new lead compounds <b>4</b> (AT-001) and <b>5</b> (AT-004), which were found to have partial agonist efficacy at NOP and >30-fold selectivity over the classical opioid receptors (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Further SAR investigation of these lead compounds to improve binding affinity and modulate intrinsic activity focused on the C(3) substituent of the indole ring is discussed below.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Binding Affinities and Functional Efficacies of C(3)-Substituted Piperidinylindoles at Human Opioid Receptors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0006.gif" alt="" id="GRAPHIC-d7e352-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Binding affinities were determined using radioligand displacement assays performed in membranes of CHO cells stably expressing the human NOP, MOP, KOP, and DOP receptors and their respective radioligands, [<sup>3</sup>H]N/OFQ-NOP, [<sup>3</sup>H]U69,593-KOP, [<sup>3</sup>H]DAMGO-MOP, and [<sup>3</sup>H]DPDPE-DOP receptor. Equilibrium dissociation constants (<i>K</i><sub>i</sub>) were derived from IC<sub>50</sub> values using the Cheng–Prusoff equation. Each <i>K</i><sub>i</sub> value represents the arithmetic mean ± SEM from at least three independent experiments, each performed in triplicate. ND = not determined.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Compounds with <i>K</i><sub>i</sub> values of >100 nM were not tested in functional assays (ND). At the DOP and KOP receptor, all compounds showed binding affinity <i>K</i><sub>i</sub> > 100 nM; hence functional efficacy at KOP and DOP was not determined. Functional activity was determined by stimulation of [<sup>35</sup>S]GTPγS binding to cell membranes. EC<sub>50</sub> is the ligand concentration producing half maximal stimulation. % stimulation was obtained as a percentage of stimulation of the standard full agonists, N/OFQ (for NOP), and DAMGO (for MOP), which showed at least 2- to 5-fold stimulation over basal. Results are the mean ± SEM for at least three independent experiments each performed in triplicate.</p></div></div><div></div></div><div class="NLM_p">The synthesis of lead compounds indoline <b>4</b> and indole <b>5</b> is shown in <a class="ref internalNav" href="#schI" aria-label="Scheme 1">Scheme 1</a>. Commercially available indoline <b>1</b> and <i>N</i>-Boc-4-piperidone <b>2</b> were subjected to standard reductive animation to provide intermediate <b>3</b> in 96% yield. Subsequent Boc removal followed by a reductive alkylation of the piperidine nitrogen with 4-<i>i</i>Pr-cyclohexanone provided indoline <b>4</b> as a mixture of approximately 1.5:1 cis:trans isomers (with respect to the disubstituted cyclohexyl ring). The diastereomers could be separated via column chromatography to provide indoline <b>4</b> as a single diastereomer in 28% yield over two steps. Oxidation of <b>4</b> with MnO<sub>2</sub> in dichloromethane smoothly provided indole <b>5</b> in 79% yield.</div><figure id="schI" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0002.jpeg" id="GRAPHIC-d7e456-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schI"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AcOH, STAB, DCE, rt, 16 h, 96%; (b) (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 1 h, (ii) 4-<i>i</i>Pr-cyclohexanone, STAB, AcOH, DCE, rt, 1–2 days, 28% over 2 steps; (c) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 79%; (d) ClSO<sub>2</sub>NCO, MeCN, 0 °C, 30 min, 37%; (e) POCl<sub>3</sub>, DMF, 0 °C, 1 h, 74%; (f) NH<sub>2</sub>OH·HCl, NaOAc·3H<sub>2</sub>O, EtOH:H<sub>2</sub>O (2:1), 110 °C, 20 min, 96%; (g) H<sub>2</sub>(g) (55 psi), 100 wt % Ra-Ni, MeOH, 16 h, 78% for <b>9</b>, 10–15% for <b>10</b>; (h) (i) BzNCS, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 58%; (i) NaBH<sub>4</sub>, EtOH, rt, 2 h, 86%.</p></p></figure><div class="NLM_p">To explore the SAR of different functionalities at the C-3 of the indole ring, several C-3 substituted indole analogs were synthesized using chemical transformations of indole <b>5</b>. Treating <b>5</b> with chlorosulfonyl isocyanate (ClSO<sub>2</sub>NCO) in MeCN provided C(3)-substituted amide <b>6</b> in modest yield. Aldehyde <b>7</b> was synthesized from indole <b>5</b> using Vilsmeier–Haack conditions (<a class="ref internalNav" href="#schI" aria-label="Scheme 1">Scheme 1</a>). Conversion of aldehyde <b>7</b> to oxime <b>8</b> using standard conditions occurred readily in 96% yield. Oxime <b>8</b> was subsequently reduced using Ra (Ni) hydrogenation to afford amine <b>9</b> (AT-035) in 78% yield and dimethylamine <b>10</b> in low yield as a minor byproduct (<a class="ref internalNav" href="#schI" aria-label="Scheme 1">Scheme 1</a>). In addition, reaction of amine <b>9</b> with benzoyl thioisocyanate (BzNCS) followed by exposure to K<sub>2</sub>CO<sub>3</sub> in MeOH readily provided thiourea <b>11</b> in moderate yield. Lastly, aldehyde <b>7</b> was smoothly converted to alcohol <b>12</b> via NaBH<sub>4</sub> reduction in 86% yield.</div><div class="NLM_p">To explore longer alkyl substitution at the indole C(3) position (e.g., <b>21</b>–<b>24</b>), the route was amended so that the indole ring was constructed using a Larock heteroannulation reaction between a terminally silated alkyne and a N-substituted iodoaniline (<a class="ref internalNav" href="#schII" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The <i>N</i>-Boc protected aminoalkynes <b>15</b> and <b>16</b> were obtained from the corresponding alkynyl alcohols (<b>13</b> and <b>14</b>, respectively) in four straightforward steps: (1) alcohol conversion into a tosylate group, (2) S<sub>N</sub>2 displacement of the tosylate group with phthalimide, (3) removal of the phthalimide group using hydrazine, and (4) Boc-protection of the amine.<named-content content-type="anchor" rid="schI" type="simple"></named-content><named-content content-type="anchor" rid="schII" type="simple"></named-content></div><figure id="schII" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0003.jpeg" id="GRAPHIC-d7e632-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsCl, TEA, cat. DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 93–99%; (b) phthalimide, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 6 h, 67–94%; (c) NH<sub>2</sub>NH<sub>2</sub>, MeOH, rt, 16 h, 59–70%; (d) (Boc)<sub>2</sub>O, cat. DMAP, THF, rt, 85–88%; (e) AcOH, STAB, DCE, rt, 16 h; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 1 h; (g) 4-<i>i</i>Pr-cyclohexanone, AcOH, STAB, DCE, rt, 1–2 days, 39% over 3 steps; (h) alkyne <b>15</b> or <b>16</b>, cat. Pd(OAc)<sub>2</sub>, LiCl, K<sub>2</sub>CO<sub>3</sub>, DMF, 102 °C, 2.5 h, 65–76%; (i) AcCl, MeOH, 0 °C to rt, then EtOAc, 78–80%; (j) (i) BzNCS, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 47–50%.</p></p></figure><div class="NLM_p">The synthesis of the requisite iodoaniline <b>18</b> and the formation of the indole ring are shown in <a class="ref internalNav" href="#schII" aria-label="Scheme 2">Scheme 2</a>. Commercially available 2-iodoaniline (<b>17</b>) was converted to intermediate <b>18</b> in a three-step sequence consisting of (1) reductive amination with <i>N</i>-Boc-4-piperidone (<b>2</b>), (2) removal of the Boc group, and (3) reductive amination of the piperidine nitrogen with 4-isopropylcyclohexanone in 39% yield over the three steps. At this stage, the key Larock heteroannulation reaction between iodoaniline <b>18</b> and either alkyne <b>15</b> or <b>16</b> proceeded in good yield to provide indole intermediates <b>19</b> and <b>20</b>, respectively. When indoles <b>19</b> and <b>20</b> were separately exposed to AcCl/MeOH conditions, clean removal of both the silyl group and the Boc moiety occurred to provide amines <b>21</b> and <b>22</b><i>in situ</i> as bis HCl salts (<a class="ref internalNav" href="#schII" aria-label="Scheme 2">Scheme 2</a>). Finally, ethyl-, and propyl-linked amines <b>21</b> and <b>22</b> each reacted with benzoyl thioisocyanate (BzNCS) to give the respective ethyl- and propyl-linked thioureas <b>23</b> and <b>24</b> in moderate yields (<a class="ref internalNav" href="#schII" aria-label="Scheme 2">Scheme 2</a>).</div><div class="NLM_p">Other C-3 substituents were introduced through further functionalization of aldehyde <b>7</b> via reductive amination with various nitrogen nucleophiles to provide C(3)-substituted cyclic and acyclic amines (<b>25</b>, <b>27</b>–<b>31)</b> in moderate to good yields (<a class="ref internalNav" href="#schIII" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="schIII" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0004.jpeg" id="GRAPHIC-d7e797-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schIII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) amine, AcOH, STAB, DCE or MeOH, rt, 1–2 days, 22–98%; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 20 min, 78%.</p></p></figure><div class="NLM_p">The synthesis of amides <b>33</b>, <b>35</b>, and <b>37</b> was accomplished in good yield from amine <b>9</b> via EDCI coupling with the corresponding <i>N</i>-Cbz-protected acid, followed by removal of the Cbz protecting group (<a class="ref internalNav" href="#schIV" aria-label="Scheme 4">Scheme 4</a>). The use of the Cbz protecting group was critical in synthesizing amides <b>33</b>, <b>35</b>, and <b>37</b>, as the Boc-protected substrate degraded upon exposure to acidic conditions during deprotection.</div><figure id="schIV" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0005.jpeg" id="GRAPHIC-d7e848-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schIV"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HOBT, EDCI, TEA, <i>N</i>-Cbz acid, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 67–88%; (b) H<sub>2</sub> balloon, 10 wt % Pd/C (10%), THF or EtOH, 3 h, 39–87%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Binding and Functional Efficacy</h3><div class="NLM_p">The compounds were tested in vitro for binding affinity at the four opioid receptor subtypes in radioligand displacement assays in membranes from human NOP, MOP, KOP, and DOP receptor-transfected Chinese hamster ovary (CHO) cells, using methods we have described in detail previously.<a onclick="showRef(event, 'ref21 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref23">(21,23)</a> Binding affinity was calculated as the binding constant <i>K</i><sub>i</sub> (nM), shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The intrinsic activity (functional efficacy) was determined using the [<sup>35</sup>S]GTPγS binding assay in membranes prepared from the opioid receptor-transfected CHO cells, using methods we have previously published.<a onclick="showRef(event, 'ref21 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref23 ref24">(21,23,24)</a> The intrinsic activities shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> are reported as the % stimulation compared to that of the full agonist N/OFQ taken as 100%. The agonist potencies are reported as the EC<sub>50</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). All compounds showed weak binding affinity for the δ opioid receptor (DOP) and κ opioid receptor (KOP) and were not further tested for intrinsic activity at these receptors.</div><div class="NLM_p">Compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were designed to explore the SAR of the indole moiety on the N-substituted piperidine scaffold, the latter of which is a common motif in most NOP ligands.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> SARs for small-molecule NOP partial agonists have not been extensively explored previously with respect to the effects of structure modification on NOP binding affinity, opioid selectivity, or intrinsic efficacy.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> To explore the SAR of the <i>N</i>-piperidinylindoles for high affinity NOP partial agonists, we focused on the C-3 substituent and maintained the <i>N</i>-isopropylcyclohexylpiperidinyl moiety in all the analogs synthesized, as this piperidinyl substituent has afforded high NOP binding affinity in other scaffolds we have investigated.<a onclick="showRef(event, 'ref20 ref21 ref29'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref29">(20,21,29)</a></div><div class="NLM_p">The C(3)-unsubstituted lead compounds indoline <b>4</b> and indole <b>5</b> show nanomolar affinity for NOP (10 nM) and weak affinity for the three classical opioid receptors (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entries 1 and 2), giving at least >40-fold selectivity for the NOP receptor. Both compounds show partial agonist efficacy at NOP in the [<sup>35</sup>S]GTPγS functional assay. Indoline <b>4</b> showed a 3-fold higher potency (EC<sub>50</sub>) as an agonist at NOP than indole <b>5</b>. From the C(3)-substituted indoles bearing a polar substituent on a single methylene linker (compounds <b>9</b>, <b>10</b>, and <b>12</b>), primary amine <b>9</b> has high binding affinity (NOP <i>K</i><sub>i</sub> = 3 nM), ∼20-fold selectivity versus MOP, and modest potency as a NOP partial agonist. Alcohol <b>12</b> and dimethylamino (tertiary amine substituent) <b>10</b> have 10-fold lower affinity than primary amine <b>9</b>, although alcohol <b>12</b> has comparable intrinsic activity to amine <b>9</b>, whereas dimethylamine <b>10</b> showed significantly reduced agonist potency. We performed a chain-length SAR of amine <b>9</b> to the ethyl- and propyl-linked amines <b>21</b> and <b>22</b>, respectively. Both methyl-(<b>9</b>), and ethyl-linked (<b>21</b>) amines are optimal for NOP affinity, and the increase in chain length to the ethyl-linked amine <b>21</b> also results in a 10-fold higher NOP selectivity compared to <b>9</b>. Functionally, the two compounds are both partial agonists at NOP, with similar potency. However, a further extension of the chain length to the propylamine <b>22</b> was not optimal for NOP binding.</div><div class="NLM_p">There appears to be a steric size tolerance for a cationic amino group at the C(3) indole position. The pyrrolidinomethylene at C(3), as in compound <b>25</b>, showed high binding affinity for NOP (<i>K</i><sub>i</sub> = 1.47 nM) and >200-fold selectivity versus the other opioid receptors. Interestingly, amine <b>25</b> also had high intrinsic activity, to a nearly full agonist (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). However, a larger 4-amino-substituted piperidine moiety (as in compound <b>27</b>) resulted in a significant drop in affinity, although the 4-hydroxypiperidine analog <b>28</b> showed higher binding affinity than <b>27</b>. Interestingly, however, 2-hydroxypyrrolidine <b>29</b> showed an even higher NOP binding affinity than hydroxypiperidine <b>28</b>, and an increase in intrinsic activity. It appears that pyrrolidine <b>25</b> and hydroxypyrrolidine <b>29</b> show higher agonist efficacy than the open-chain primary amines <b>9</b>, <b>21</b>, and <b>22</b>, suggesting that these compounds may be binding in different orientations to the receptor due to steric reasons, differentially affecting the activation of the receptor toward higher intrinsic activity. Further contraction of the hydroxypyrrolidine ring of <b>29</b> to azetidine <b>30</b> retains modest binding affinity at NOP (<i>K</i><sub>i</sub> = 23 nM) but shows very low agonist potency in the [<sup>35</sup>S]GTPγS functional assay (EC<sub>50</sub> = 1559 nM). In addition, acyclic alkylamine <b>31</b>, an acyclic variant of hydroxypyrrolidine <b>29</b>, showed weak binding affinity toward all four opioid receptors. When compounds <b>9</b>, <b>10</b>, <b>12</b>, <b>21</b>, and <b>22</b> are compared to compounds <b>25</b> and <b>29</b>, it appears that cationic cyclic C(3) substituents, particularly pyrrolidinyl, show higher intrinsic activity (toward full agonist efficacy) compared to cationic open-chained C(3) substituents which show partial agonist activity.</div><div class="NLM_p">Thiourea analogs <b>11</b>, <b>23</b>, <b>24</b> and amide analogs <b>33</b>, <b>35</b>, <b>37</b> were synthesized to investigate the importance of a cationic amine moiety at the C-3 substituent of the piperidinylindoles. The thiourea analogs <b>11</b>, <b>23</b>, and <b>24</b> showed only a modest (2- to 3-fold) drop in NOP binding affinity and agonist potency, suggesting that it may be the hydrogen bonding or polar interactions of the C-3 substituent that is important for high affinity rather than a charged interaction.</div><div class="NLM_p">Amides at the C-3 substituent containing an arginine unit (as in <b>33</b>), a lysine-like 6-aminohexanamide side chain (as in <b>35</b>), or a ethylaminomethylamide (as in <b>37</b>) were also found to have only modest binding affinities (11–23 nM) at NOP, suggesting that a charged interaction of the guanidinium group in <b>33</b> or the amino group in <b>35</b> is likely not an important contributor to the binding affinity at NOP. Further, these compounds had poor agonist potencies and showed low intrinsic activity.</div><div class="NLM_p">Compound <b>6</b>, containing an sp<sup>2</sup> hybridized C(3) substituent in the form of an amide, showed weak binding affinity for all the opioid receptors (<i>K</i><sub>i</sub> > 100 nM). However, the C(3)-oxime <b>8</b>, on the other hand, was found to be a high-affinity (<i>K</i><sub>i</sub> = 2 nM), NOP-selective (NOP/MOP ≈ 25-fold) potent full agonist.</div><div class="NLM_p">Overall, our SAR showed that the C(3)-substituted piperidinylindoles afforded selective NOP agonists of varying efficacies, ranging from partial agonists (>20%) to nearly full agonist efficacy (>80%). It is possible that high intrinsic efficacy seen with C(3)-substituted indoles <b>8</b>, <b>25</b>, and <b>29</b> may arise from a different binding mode of these indoles (bearing a bulkier C(3) polar substituent, as for <b>25</b> and <b>29</b>) than the smaller alkyl-linked or unsubstituted indole <b>5</b> or <b>9</b>. We have shown, using molecular dynamics simulations, that polar interactions between a NOP agonist ligand and NOP receptor residues at the extracellular end of the transmembrane helices and EL2 loop result in agonist-induced reorganization of polar networks, during receptor activation.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Further SAR development supported by molecular docking and site-directed mutagenesis is needed to explain the observed NOP full agonism for compounds <b>8</b> and <b>25</b>.</div><div class="NLM_p last">To explore our hypothesis that NOP partial agonists would have dual efficacy in blocking PD symptoms and attenuating LID symptoms, four compounds were selected for further testing, based on the criteria of having high NOP binding affinity (<i>K</i><sub>i</sub> less than or equal to 10 nM) and partial agonist efficacy (20–35%) with agonist potency EC<sub>50</sub> < 150 nM. On the basis of our in vitro pharmacological characterization, compounds <b>4</b>, <b>5</b>, <b>9</b>, and <b>21</b> were selected for further in vitro ADME characterization and compounds <b>4</b>, <b>5</b>, and <b>9</b> were advanced to in vivo pharmacokinetic evaluation for further investigation in vivo in PD models.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro ADME Characterization and in Vivo PK</h3><div class="NLM_p">Selected compounds were evaluated in vitro in ADME assays to characterize intestinal permeability, blood–brain barrier permeability, and liver microsomal stability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Indoline <b>4</b> and indole <b>5</b> show high permeability and low efflux in the Caco-2 intestinal permeability assay as well as in the MDR1-MDCK assay for BBB permeability (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Primary amines <b>9</b> and <b>21</b> showed lower permeability in the Caco-2 and BBB assay and high efflux in the BBB permeability assay. However, both primary amines <b>9</b> and <b>21</b> show excellent stability in rodent liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), whereas indole <b>5</b> has a short half-life in rat liver microsomes. From the in vitro microsomal stability of the amine <b>9</b> compared to that of unsubstituted indole <b>5</b>, it appears that the unsubstituted C(3)-position in indole <b>5</b> may be a site of metabolic liability and that the high permeability of indole <b>5</b>, which arises from its high lipophilicity, comes at the expense of solubility and metabolism.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro ADME Data for Indoles <b>4</b>, <b>5</b>, <b>9</b>, and <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">Caco-2 bidirectional<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center">MDR1-MDCK permeability<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>P</i><sub>app</sub> (×10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>P</i><sub>app</sub> (×10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">A–B</th><th class="colsep0 rowsep0" align="center">B–A</th><th class="colsep0 rowsep0" align="center">efflux ratio (perm/efflux)</th><th class="colsep0 rowsep0" align="center">A–B</th><th class="colsep0 rowsep0" align="center">B–A</th><th class="colsep0 rowsep0" align="center">efflux ratio (perm/efflux)</th><th class="colsep0 rowsep0" align="center">human liver microsomal stability (<i>t</i><sub>1/2</sub>, min)</th><th class="colsep0 rowsep0" align="center">rat liver microsomal stability (<i>t</i><sub>1/2</sub>, min)</th><th class="colsep0 rowsep0" align="center">mouse liver microsomal stability (<i>t</i><sub>1/2</sub>, min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">0.8 (hi/no)</td><td class="colsep0 rowsep0" align="left">26.8</td><td class="colsep0 rowsep0" align="left">33.8</td><td class="colsep0 rowsep0" align="left">1.3 (hi/no)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">19.1</td><td class="colsep0 rowsep0" align="left">0.8 (hi/no)</td><td class="colsep0 rowsep0" align="left">28.8</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">0.5 (hi/no)</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">4.64</td><td class="colsep0 rowsep0" align="left">4.92</td><td class="colsep0 rowsep0" align="left">1.1 (hi/no)</td><td class="colsep0 rowsep0" align="left">0.34</td><td class="colsep0 rowsep0" align="left">14.4</td><td class="colsep0 rowsep0" align="left">43 (low/hi)</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left">>60</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">4.36</td><td class="colsep0 rowsep0" align="left">6.49</td><td class="colsep0 rowsep0" align="left">1.5 (hi/no)</td><td class="colsep0 rowsep0" align="left">0.60</td><td class="colsep0 rowsep0" align="left">22.1</td><td class="colsep0 rowsep0" align="left">37 (low/hi)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>60</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>P</i><sub>app</sub> > 1.0 × 10<sup>–6</sup> cm/s. Efflux ratio < 3: high perm/no efflux.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last"><i>P</i><sub>app</sub>(A–B) > 3.0. Efflux ratio < 3: high BBB permeability. Efflux ratio > 3: high efflux. These experiments were conducted according to methods described briefly in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div></div></div><div class="NLM_p">The plasma and brain concentrations of compounds <b>4</b>, <b>5</b>, and <b>9</b> were determined in an in vivo pharmacokinetic study after subcutaneous administration to rats. As seen in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compounds <b>4</b> and <b>5</b> showed high total plasma and brain concentrations, with <i>B</i>/<i>P</i> ratios of >6, suggesting high brain permeability of these compounds. Compound <b>9</b>, which showed poor BBB permeability and high efflux in the in vitro BBB assay (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), also showed a <i>B</i>/<i>P</i> ratio of >1, although it showed overall lower concentrations than <b>4</b> or <b>5</b>, consistent with its lower permeability.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vivo Pharmacokinetics for Selected Indoles <b>4</b>, <b>5</b>, and <b>9</b> after sc Administration to Sprague-Dawley Rats<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">plasma</th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">brain<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (nM·h)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (nM·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>B</i>/<i>P</i> ratio (at <i>C</i><sub>max</sub>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">3 (sc)</td><td class="colsep0 rowsep0" align="char" char=".">456</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">1246</td><td class="colsep0 rowsep0" align="char" char=".">2.13</td><td class="colsep0 rowsep0" align="char" char=".">3069</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">6695</td><td class="colsep0 rowsep0" align="char" char=".">2.71</td><td class="colsep0 rowsep0" align="char" char=".">6.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">3 (sc)</td><td class="colsep0 rowsep0" align="char" char=".">626</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1960</td><td class="colsep0 rowsep0" align="char" char=".">2.19</td><td class="colsep0 rowsep0" align="char" char=".">4166</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">10104</td><td class="colsep0 rowsep0" align="char" char=".">2.43</td><td class="colsep0 rowsep0" align="char" char=".">6.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">3 (sc)</td><td class="colsep0 rowsep0" align="char" char=".">529</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">1004</td><td class="colsep0 rowsep0" align="char" char=".">2.61</td><td class="colsep0 rowsep0" align="char" char=".">956</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td><td class="colsep0 rowsep0" align="char" char=".">6129</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td><td class="colsep0 rowsep0" align="char" char=".">1.81</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">These experiments were conducted according to methods described briefly in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Time point for AUC<sub>last</sub> is 8 h.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Concentrations represent total brain concentrations.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Assessment of in Vivo Efficacy of NOP Partial Agonists in Rat Models of Parkinson’s Disease and Levodopa-Induced Dyskinesia</h3><div class="NLM_p">NOP receptor partial agonists <b>4</b>, <b>5</b>, and <b>9</b> were evaluated in vivo for their efficacy in improving parkinsonian motor disabilities in a rodent neurodegenerative model of PD, i.e., the 6-OHDA-induced hemilesioned rat model, that we have extensively used to characterize NOP antagonists.<a onclick="showRef(event, 'ref10 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref15 ref16">(10,15,16)</a> The compounds were administered intraperitoneally (ip) in a range of doses.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> shows that NOP partial agonists <b>4</b>, <b>5</b>, and <b>9</b> attenuate parkinsonian disabilities in 6-OHDA hemilesioned rats. Parkinsonian motor deficits were assessed using three different measures of motor activity.<a onclick="showRef(event, 'ref10 ref15 ref16 ref31'); return false;" href="javascript:void(0);" class="ref ref10 ref15 ref16 ref31">(10,15,16,31)</a> Acute administration of <b>5</b> (0.1–3 mg/kg, ip) improved motor deficits, partially reversing (∼25%) the increase of immobility time (a measure of akinesia) at the contralateral (parkinsonian) paw in the bar test (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> panel D) and doubling stepping activity at the contralateral paw (a measure of akinesia/bradykinesia) in the drag test (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> panel E). Moreover, it enhanced by ∼20% the time spent on the rotarod (a measure of overall gait ability) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, panel F). This profile is predictive of antiparkinsonian activity since it is replicated by L-DOPA<a onclick="showRef(event, 'ref10 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref16">(10,16)</a> and by NOP antagonists.<a onclick="showRef(event, 'ref12 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref12 ref15 ref16">(12,15,16)</a> Compounds <b>4</b> and <b>9</b> also showed similar patterns in improving parkinsonian motor deficits, although with some differences in efficacy in the three tests, at doses of 0.01–1 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, panels A–C and G–I), suggesting that the NOP partial agonists may actually be counteracting endogenous N/OFQ action at the NOP receptor, as predicted by our working hypothesis.</div><figure id="fig1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Effect of NOP partial agonists <b>4</b> (AT-001), <b>5</b> (AT-004), and <b>9</b> (AT-035) on parkinsonian disabilities in the 6-OHDA hemilesioned rat model of PD. Acute systemic administration of <b>4</b>, <b>5</b>, and <b>9</b> in a range of doses (panels A–C, <b>4</b>, AT-001, 0.001–3 mg/kg, ip) (panels D–F, <b>5</b>, AT-004, 0.1–3 mg/kg, ip) or (panels G–I, <b>9</b>, AT-035, 0.01–3 mg/kg, ip) attenuated motor deficits in three behavioral measures, (A) the bar test (left graphs), (B) the drag test (middle graphs), and (C) rotarod test (right graphs). AT-001 data (panels A–C) are the mean ± SEM values of 17–23 mice per group. AT-004 data (panels D–F) are the mean ± SEM values of 6–12 mice per group, and AT-035 data (G–I) are the mean ± SEM values of 6–7 mice per group. Essential statistical values: treatment effect panels A–C (<i>F</i><sub>5,2</sub> = 4.60, <i>p</i> = 0.0007, <i>F</i><sub>5,2</sub> = 4.52, <i>p</i> = 0.0008, <i>F</i><sub>5,1</sub> = 13.72, <i>p</i> < 0.0001, respectively), panels D–F (<i>F</i><sub>3,2</sub> = 4.39, <i>p</i> = 0.0051, <i>F</i><sub>3,2</sub> = 8.45, <i>p</i> < 0.0001, F<sub>3,1</sub> = 7.59, <i>p</i> < 0.0001, respectively), panels G–I (<i>F</i><sub>4,2</sub> = 14.31, <i>p</i> < 0.0001, <i>F</i><sub>4,2</sub> = 3.79, <i>p</i> = 0.0071, <i>F</i><sub>4,1</sub> = 11.51, <i>p</i> < 0.0001, respectively); *<i>P</i> < 0.05, **<i>P</i> < 0.01 different from vehicle (saline + 5% Tween 80 and 1% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">However, in the same dose ranges, all three compounds had no effect on the “expression” of LID in fully dyskinetic rats challenged with L-DOPA, using methods previously reported by us (data not shown).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> It is possible that the partial agonist efficacy of about 25–35% in all three compounds is too low to elicit an antidyskinetic effect seen with NOP full agonists that we have previously reported.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> SAR studies to obtain suitable higher efficacy NOP partial agonists from the piperidinylindole and other novel NOP ligand scaffolds are underway to address this hypothesis and will be reported in due course.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35520" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35520" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we report the discovery and SAR of a novel series of 4-piperidinyl-1<i>H</i>-indoles as NOP receptor partial agonists. The SAR studies reported here represent the first systematic SAR study around NOP partial agonists and a novel NOP ligand scaffold, the piperidinyl-indoles. SAR analysis showed that the C(3)-substituted piperidinylindoles show significantly lower affinity for the classical opioid receptors μ, δ, and κ, resulting in selective NOP ligands with a range of intrinsic efficacies, ranging from partial agonists to nearly full agonists. Our SAR further indicates that size and polar nature of the C(3) substituent of the indole moiety influence the binding affinity and intrinsic activity of these ligands such that smaller alkyl-linked C(3) substituents on the indole have partial agonist efficacy (e.g., compounds <b>9</b>, <b>21</b>) whereas bulkier polar substituents have higher agonist efficacy (e.g., compound <b>25</b>), possibly arising from different binding modes favoring receptor activation. Selected NOP partial agonists <b>4</b>, <b>5</b>, and <b>9</b> also reduced parkinsonian motor symptoms in the 6-OHDA-hemilesioned rat model but were ineffective in reducing LID symptoms at the same dose range. Together with our previous studies, these results provide further evidence that the NOP receptor is a possible nondopaminergic target for the symptomatic treatment of PD and that NOP receptor partial agonists are promising for development of new symptomatic PD therapies. The SAR of novel NOP partial agonists reported here will assist in future lead optimization efforts in this regard.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56352" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56352" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry Methods</h3><div class="NLM_p last">Thin layer chromatography was performed on Analtech silica gel GF 250 μm TLC plates. The plates were visualized with a 254 nm UV light and iodine. Flash chromatography was carried out on F60 silica gel, 43–60 μm (230–400 mesh), 60 Å (Silicycle SiliaFlash). All solvents and chemicals were purchased from commercial suppliers and used without further purification. All reactions were capped from the atmosphere unless otherwise stated. NMR was recorded on a Varian Mercury Plus NMR (300 MHz) using CDCl<sub>3</sub> (7.27 ppm standard) or DMSO-<i>d</i><sub>6</sub> (2.50 ppm standard). Data for <sup>1</sup>H NMR were recorded as follows: δ chemical shift (ppm), multiplicity (s, singlet; d, doublet; t, triplet; dd, doublet of doublets; dt, doublet of triplets; q, quartet; dq, doublet of quartets; m, multiplet; br, broad; etc.), coupling constant (Hz), integration. Mass spectra were obtained on a LCQ Fleet ion trap LCMS, a micromass ZMD 1000, or PE Sciex API 150EX LCMS using electrospray ionization (ESI) or APCI mode. Elemental analyses were performed by Atlantic Microlabs, Norcross, GA. HRMS analyses were performed by the Mass Spectrometry Service Laboratory, University of Minnesota Department of Chemistry, Minneapolis, MN, on a Bruker BioTOF II HRMS using ESI mode. HPLC analysis was performed on a reverse phase Agilent Zorbax SB-Phenyl column (5 μm, 2.1 mm × 150 mm), using a binary gradient of 95:5 → 5:95 solvent A (95/5 H<sub>2</sub>O/ACN + 0.1% formic acid):solvent B (5/95 H<sub>2</sub>O/ACN + 0.1% formic acid) for 12 min at a flow rate of 0.40 mL/min. Eluted peaks were monitored at 254 nm with a Shimadzu SPD-10AVP UV–vis detector. All final compounds were confirmed to be of ≥95% purity by the HPLC method described above. Purity of final compounds was confirmed by elemental analysis and was within ±0.4% of the theoretical value. Molecular weights of selected compounds were also confirmed by HRMS, as indicated in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. On the basis of <sup>1</sup>H NMR, HPLC, combustion analysis data, and HRMS, all final compounds were ≥95% pure.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Synthesis. General Procedure A: Reductive Amination</h3><div class="NLM_p last">The aniline or amine substrate (1.00–2.00 equiv) and carbonyl compound (1.00–1.50 equiv) were charged into a round-bottom flask. 1,2-DCE (0.030–0.25 M) was added, and the mixture was stirred until both components dissolved. NOTE: If amine was a salt, <i>i</i>Pr<sub>2</sub>NEt (2.30 equiv) was added at this stage to freebase. To this solution was added glacial AcOH (1.00–2.30 equiv) at ambient temperature, and the solution was stirred for 60 min. At this stage, sodium triacetoxyborohydride (STAB) (1.50–3.00 equiv) was added. The reaction was allowed to stir at room temperature and monitored by TLC (EtOAc/hexanes). After 1–2 days, the reaction was ≥90% complete by TLC analysis. The reaction was quenched with saturated NaHCO<sub>3</sub> (aq) and stirred until the reaction mixture was basic and bubbling had ceased. The biphasic layer was separated, and the organic layer was washed 2× with H<sub>2</sub>O, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude product that was purified via flash chromatography to provide the desired product.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedure B: Boc Removal (Step 1) and Reductive Amination with 4-Isopropylcylohexanone (Step 2)</h3><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Step 1</h4><div class="NLM_p last">A solution of <i>N</i>-Boc intermediate (1.00 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (0.25–0.30M) was cooled to 0 °C, and then TFA (6–30 equiv) was added over several minutes. Upon completion of addition, the ice-bath was removed and the reaction was allowed to warm to room temperature and monitored by TLC (EtOAc/hexanes). After 2 h, the reaction was complete. The reaction was concentrated in vacuo, followed by the addition of EtOAc, which was consequently removed in vacuo to ensure the majority of excess TFA was removed. The resulting oily residue was dissolved in EtOAc and was stirred as saturated NaHCO<sub>3</sub> (aq) was added until the aqueous layer remained basic. The layers were separated, and the aqueous layer was extracted with EtOAc until UV activity in the aqueous layer was minimal (3–8×). The EtOAc layers were combined, washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide the piperidine intermediate.</div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Step 2</h4><div class="NLM_p last">The piperidine intermediate from the previous step (1.00 equiv) and 4-<i>i</i>Pr-cyclohexanone (1.00–1.50 equiv) were dissolved in 1,2-DCE (0.070 M). To the reaction was added glacial AcOH (1.00–2.30 equiv), and the reaction was stirred for 30 min. After 30 min, STAB (1.50–2.30 equiv) was added. An Ar balloon was fitted on top of the reaction, and the reaction was monitored by TLC (MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq)). After 2–3 days, the reaction was ≥95% complete. Saturated NaHCO<sub>3</sub> (aq) was added until the aqueous layer remained basic. At this stage, the layers were separated, and the aqueous layer was extracted 2× with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were combined and washed 2× with H<sub>2</sub>O, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude residue that was purified via flash chromatography using EtOAc/hexanes/NH<sub>4</sub>OH (aq).</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure C: Formation of Thiourea from Amine</h3><div class="NLM_p last">The amine (1.00 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (0.10 M) at room temperature, and then the reaction was placed in an ice-bath and cooled to 0 °C. Benzoyl isothiocyanate (1.05–1.10 equiv) was added, and after several minutes of stirring at 0 °C, the reaction was allowed to warm to room temperature and monitored by TLC (EtOAc/hexanes). After 1–3 h, the reaction was complete by TLC. The reaction was concentrated in vacuo, the remaining residue was dissolved in MeOH (0.050 M), and to this was added K<sub>2</sub>CO<sub>3</sub> (7.00 equiv). The reaction was stirred at room temperature and monitored by TLC (EtOAc/hexanes). Once the reaction was complete, it was filtered over a pad of Celite, rinsed with MeOH, and then concentrated in vacuo to provide a crude material that was purified via flash chromatography using EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide the desired thiourea product.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>tert</i>-Butyl 4-(Indolin-1-yl)piperidine-1-carboxylate (<b>3</b>)</h3><div class="NLM_p last">See general procedure A, using indoline <b>1</b> (10.0 g, 83.9 mmol, 1.00 equiv), <i>N</i>-Boc piperidone <b>2</b> (17.6 g, 88.1 mmol, 1.05 equiv), AcOH, 4.80 mL, 83.9 mmol, 1.00 equiv), STAB (26.7 g, 12.6 mmol, 1.50 equiv), DCE (352 mL, 0.25M). The crude oil was purified via flash chromatography using 10:90 EtOAc/hexanes to provide indoline <b>3</b> as a white solid (24.3 g, 96% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.06 (t, <i>J</i> = 6.0 Hz, 2H), 6.03 (t, <i>J</i> = 6.0 Hz, 1H), 6.43 (d, <i>J</i> = 6.0 Hz, 1H), 4.25 (m, 2H), 3.52 (m, 1H), 3.35 (t, <i>J</i> = 6.3 Hz, 2H), 2.79 (m, 2H), 1.80 (d, <i>J</i> = 9.3 Hz, 2H), 1.60 (m, 4H), 1.49 (s, 9H). MS (APCI) <i>m</i>/<i>z</i>: 303.06 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>cis</i>-1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)indoline (<b>4</b>)</h3><div class="NLM_p last">See general procedure B, step 1 (Boc removal), using indoline <b>3</b> (24.4 g, 80.5 mmol, 1.00 equiv), TFA (38.0 mL, 496 mmol, 6.20 equiv), CH<sub>2</sub>Cl<sub>2</sub> (300 mL, 0.27M). NOTE: Combined EtOAc layers were dried immediately with MgSO<sub>4</sub> and were not washed with water or brine, as the product is water-soluble. The product was obtained as a gray solid (13.6 g, 84% yield). Step 2 (reductive amination) used N-H piperidine from the previous step (13.6 g, 67.2 mmol, 1.00 equiv), <i>i</i>Pr-cyclohexanone (9.40 g, 67.2 mmol, 1.00 equiv), AcOH (3.85 mL, 67.2 mmol, 1.00 equiv), STAB (21.3 g, 101 mmol, 1.50 equiv), DCE (960 mL, 0.070M). The sample was purified via flash chromatography using 10:90:1.5 EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide compound <b>4</b> as a light-gold oil (33% yield). <i><i>R<sub>f</sub></i></i> = 0.25 (20:80:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, pAA, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.05 (t, <i>J</i> = 5.7 Hz, 2H), 6.60 (t, <i>J</i> = 5.7 Hz, 1H), 6.41 (d, <i>J</i> = 5.7 Hz, 1H), 3.37 (m, 3H), 3.10 (d, <i>J</i> = 8.7 Hz, 2H), 2.94 (t, <i>J</i> = 6.3 Hz, 2H), 2.27 (m, 1H), 2.14 (t, <i>J</i> = 8.7 Hz, 2H), 1.82–1.54 (m, 11H), 1.38 (m, 2H), 1.13 (m, 1H), 0.88 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 327.4 [M + H]<sup>+</sup>. The HCl salt of amine <b>4</b> was formed by dissolving the amine in CH<sub>2</sub>Cl<sub>2</sub> (0.10M) at room temperature and cooling the reaction in a 0 °C ice-bath. To this solution was added HCl (2.0 M in Et<sub>2</sub>O, 1.50 equiv), and the resulting mixture was allowed to warm to room temperature and stir for 10 min. At this time, the reaction was concentrated in vacuo, Et<sub>2</sub>O was added, and the mixture was concentrated in vacuo to provide a brown solid (repeat 3× total). This solid was then triturated with about 5–10% MeOH/Et<sub>2</sub>O to provide the HCl salt of compound <b>4</b> as a cream solid. Anal. Calcd for C<sub>22</sub>H<sub>34</sub>N<sub>2</sub>·1.00HCl·0.10H<sub>2</sub>O: C, 72.44; H, 9.73; N, 7.68. Found: C, 72.39; H, 9.79; N, 7.34.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>cis</i>-1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indole (<b>5</b>)</h3><div class="NLM_p last">Indoline <b>4</b> (4.63 g, 14.2 mmol, 1.00 equiv) was dissolved in 180 mL of CH<sub>2</sub>Cl<sub>2</sub>. To this solution was added 4 Å MS (56.8 g, 4 g/mmol of indoline), followed by MnO<sub>2</sub> (12.3 g, 142 mmol, 10.0 equiv) and another 20 mL of CH<sub>2</sub>Cl<sub>2</sub>. A balloon filled with argon was fitted on the reaction, and the thick suspension was stirred and monitored by TLC (20:80:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq)). After 16 h, the reaction was complete. The mixture was filtered over a large pad of Celite, and the remaining solid was washed 5× with CH<sub>2</sub>Cl<sub>2</sub>. The filtrate was concentrated in vacuo to provide a crude oil. This material was dissolved in EtOAc, and 10% HCl (aq) was added with vigorous stirring, which resulted in a white precipitate. The white solid was filtered, and washed 3× with EtOAc, and was then air-dried over 1 h. The white solid was then suspended in EtOAc, 70% NaHCO<sub>3</sub> (aq) was added, and the mixture stirred until >90% of the solid had dissolved (usually overnight). The EtOAc layer was separated, washed with H<sub>2</sub>O, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a thick oil that was purified via flash chromatography using 10:90:1.5 EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide indole <b>5</b> as an off-white solid (3.65 g, 79% yield). <i>R<sub>f</sub></i> = 0.25 (10:90:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, pAA, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.64 (d, <i>J</i> = 6.0 Hz, 1H), 7.39 (d, <i>J</i> = 6.0 Hz, 1H), 7.26 (m, 1H), 7.20 (t, <i>J</i> = 6.0 Hz, 1H), 7.11 (t, <i>J</i> = 6.0 Hz, 1H), 6.52 (d, <i>J</i> = 2.4 Hz, 1H), 4.23 (m, 1H), 3.20 (d, <i>J</i> = 9.0 Hz, 2H), 2.30 (m, 3H), 2.08 (m, 4H), 1.51–1.78 (m, 7H), 1.40 (m, 2H), 1.17 (m, 1H), 0.90 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 325.4 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>22</sub>H<sub>32</sub>N<sub>2</sub>: C, 81.43; H, 9.94; N, 8.63. Found: C, 81.54; H, 9.87; N, 8.45.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>cis</i>-1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indole-3-carboxamide (<b>6</b>)</h3><div class="NLM_p last">Indole <b>5</b> (60.0 mg, 0.185 mmol, 1.00 equiv) was dissolved in 1.00 mL of MeCN (0.19M) with the aid of heat. The solution was allowed to cool to room temperature, and then it was placed in an ice bath for several minutes. Chlorosulfonyl isocyanate (20.1 μL, 0.231 mmol, 1.25 equiv) was then added, turning the reaction light-yellow. The reaction was stirred at 0 °C and monitored by TLC (20:80 EtOAc/hexanes). After 30 min, TLC showed full consumption of indole <b>5</b>. Water was added to the reaction, temporarily resulting in a white precipitate. The ice-bath was removed, and the mixture was allowed to warm to room temperature and stir overnight, resulting in a light-yellow solution. The reaction was then quenched with saturated NaHCO<sub>3</sub> (aq) and diluted with EtOAc. The layers were separated, and the aqueous layer was extracted 2× with EtOAc. The EtOAc layers were combined, washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide the crude product. Amide <b>6</b> was purified via flash chromatography using 2:96:1 MeOH/EtOAc/NH<sub>4</sub>OH (aq) to provide amide <b>6</b> as a white solid (25 mg, 37% yield). <i>R<sub>f</sub></i> = 0.30 (5:95:3 drops MeOH/EtOAc/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.99 (m, 1H), 7.90 (s, 1H), 7.46–7.43 (m, 1H), 7.30–7.27 (m, 2H), 5.78 (br s, 2H), 4.23 (m, 1H), 3.22 (d, <i>J</i> = 8.7 Hz, 2H), 2.37 (m, 2H), 2.28 (t, <i>J</i> = 8.7 Hz, 2H), 2.1 (m, 4H), 1.75–1.52 (m, 7H), 1.40 (m, 2H), 1.16 (m, 1H), 0.90 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 368.5 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>23</sub>H<sub>33</sub>N<sub>3</sub>O·0.50MeOH: C, 73.59; H, 9.20; N, 10.96. Found: C, 73.64; H, 8.82; N, 10.57.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>cis</i>-1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indole-3-carbaldehyde (<b>7</b>)</h3><div class="NLM_p last">To a stirred solution of 25.0 mL of DMF at 0 °C was added POCl<sub>3</sub> (3.66 mL, 40.0 mmol, 4.00 equiv). The solution was stirred at 0 °C for 15 min. At this stage, indole <b>5</b> (3.10 g, 10.0 mmol, 1.00 equiv) was dissolved in 10 mL of DMF with the assistance of heat. The warm solution of indole <b>5</b> was then added to the reaction, and the reaction was rinsed with 5.00 mL of DMF. The addition of indole <b>5</b> leads to a red solution, and the reaction was allowed to stir for 15–20 min at 0 °C. TLC (50:50:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq)) showed the reaction was complete. The reaction was poured into a saturated NaHCO<sub>3</sub> (aq) ice-bath, followed by the addition of CH<sub>2</sub>Cl<sub>2</sub>. The mixture was stirred vigorously for 30 min, upon which the layers were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> until UV activity was minimal (5–6×). The organic layer was then washed 3× with H<sub>2</sub>O, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a dark red oil, which was purified via flash chromatography using 50:50:1.5 EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide aldehyde <b>7</b> as a light-yellow solid (2.15 g, 74% yield). <i>R<sub>f</sub></i> = 0.20 (50:50:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.0 (s, 1H), 8.33 (m, 1H), 7.89 (s, 1H), 7.43 (m, 1H), 7.33 (m, 2H), 4.29 (m, 1H), 3.28 (d, <i>J</i> = 7.8 Hz, 2H), 2.40 (m, 3H), 2.19 (m, 3H), 1.55–1.78 (m, 8H), 1.42 (m, 2H), 1.17 (m, 1H), 0.90 (d, <i>J</i> = 5.7 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 353.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>cis</i>-1-(1-(4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indole-3-carbaldehyde Oxime (<b>8</b>)</h3><div class="NLM_p last">Aldehyde <b>7</b> (2.15 g, 6.10 mmol, 1.00 equiv), NH<sub>2</sub>OH·HCl (551 mg, 7.93 mmol, 1.30 equiv), and NaOAc·3H<sub>2</sub>O (1.08 g, 7.93 mmol, 1.30 equiv) were charged into a round-bottom flask. Absolute EtOH (20.5 mL) and 10 mL of H<sub>2</sub>O were added, and the reaction was fitted with a condenser and an Ar balloon on top. The suspension was heated to reflux (∼110 °C oil bath) and monitored by TLC (40:60:3drops EtOAc/hexanes/NH<sub>4</sub>OH (aq)). After 2 h, the reaction was complete. The reaction was allowed to cool to room temperature upon which a white precipitate formed. The mixture was diluted with EtOAc and saturated NaHCO<sub>3</sub> (aq) and stirred until the mixture became a biphasic solution. The layers were separated, and the organic layer was washed 2× with H<sub>2</sub>O, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide oxime <b>8</b> as a white solid (2.13 g, 96% yield). The two isomers of the oxime are in approximately 3:2 ratio and can be enriched via flash chromatography using 40:60:1 → 50:50:1 EtOAc/hexanes/NH<sub>4</sub>OH (aq). <i>R<sub>f</sub></i> = 0.40 (top spot), 0.45 (bottom spot) (50:50:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). Isomer 1: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 10.8 (br s, 1H), 8.47 (s, 1H), 7.77 (m, 1H), 7.41 (d, <i>J</i> = 6.0 Hz, 1H), 7.28–7.20 (m, 3H), 4.31 (m, 1H), 3.30 (d, <i>J</i> = 8.7 Hz, 2H), 2.55 (m, 1H), 2.46 (t, <i>J</i> = 8.4 Hz, 2H), 2.22 (m, 3H), 1.86 (m, 2H), 1.78–1.57 (m, 6H), 1.43 (m, 2H), 1.18 (m, 1H), 0.91 (d, <i>J</i> = 5.1 Hz, 6H). Isomer 2: <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.30 (s, 1H), 8.07 (d, <i>J</i> = 6.0 Hz, 1H), 7.48 (s, 1H), 7.40 (d, <i>J</i> = 6.0 Hz, 1H), 7.28 (m, 1H), 7.20 (t, <i>J</i> = 5.4 Hz, 1H), 4.23 (m, 1H), 3.21 (d, <i>J</i> = 8.7 Hz, 2H), 2.35 (m, 3H), 2.13 (m, 4H), 1.80–1.55 (m, 7H), 1.43 (m, 2H), 1.18 (m, 1H), 0.90 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 368.5 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>23</sub>H<sub>33</sub>N<sub>3</sub>O: C, 75.16; H, 9.05; N, 11.43. Found: C, 75.27; H, 8.88; N, 11.30.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>cis</i>-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methanamine (<b>9</b>)</h3><div class="NLM_p last">In a 500 mL Parr bottle was added oxime <b>8</b> (2.00 g, 5.44 mmol, 1.00 equiv), and it was then suspended in MeOH (46 mL). To this mixture was added Raney nickel (2.00 g, 100 wt %, prewashed with MeOH) and concentrated NH<sub>4</sub>OH (aq) (23 mL). The reaction mixture was placed on the Parr hydrogenator, and the Parr vessel was pressurized with H<sub>2</sub> (g) at ∼20 psi, then purged under vacuo. This was repeated a total of 3×. The vessel was the pressurized at 50 psi for 18 h. The reaction mixture was filtered over Celite and washed thoroughly with MeOH. The resulting filtrate was concentrated in vacuo, and the crude product was purified by flash chromatography using 8:92 MeOH/CH<sub>2</sub>Cl<sub>2</sub> to provide amine <b>9</b> as a white solid (1.52 g, 78% yield). <i>R<sub>f</sub></i> = 0.30 (10:90:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.58 (d, <i>J</i> = 6.0 Hz, 1H), 7.44 (d, <i>J</i> = 6.3 Hz, 1H), 7.37 (s, 1H), 7.10 (t, <i>J</i> = 5.7 Hz, 1H), 6.98 (t, <i>J</i> = 5.7 Hz, 1H), 4.26 (m, 1H), 3.86 (s, 1H), 3.16 (s, 2H), 3.08 (d, <i>J</i> = 8.7 Hz, 3H), 2.27 (br s, 1H), 2.18 (t, <i>J</i> = 8.4 Hz, 2H), 1.91–1.86 (m, 4H), 1.71 (br s, 2H), 1.55–1.50 (m, 3H), 1.38 (dd, <i>J</i> = 18.3, 9.3 Hz, 4H), 1.10 (s, 1H), 0.86 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 354.5 [M + H]<sup>+</sup>. The bis HCl salt of amine <b>9</b> was formed by dissolving the amine in CH<sub>2</sub>Cl<sub>2</sub> (0.10M) at room temperature, followed by the addition of HCl (2.0 M in Et<sub>2</sub>O, 2.20 equiv). The reaction was allowed to stir for 10 min. At this time, the reaction was concentrated in vacuo, Et<sub>2</sub>O was added to the mixture, followed by concentrating the mixture in vacuo (repeat 3× total) to provide the HCl salt of amine <b>9</b>. Anal. Calcd for C<sub>23</sub>H<sub>35</sub>N<sub>3</sub>·2.00HCl·1.50H<sub>2</sub>O: C, 60.92; H, 8.89; N, 9.27. Found: C, 60.94; H, 8.76; N, 9.11.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>cis</i>-1-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylmethanamine (<b>10</b>)</h3><div class="NLM_p last">In the reduction of of oxime <b>8</b> to amine <b>9</b>, a nonpolar byproduct formed. Purification via flash chromatography using 3:97:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) provided the byproduct in low yield (10–15%) as a white solid, and the structure was elucidated as dimethylamine <b>10</b>. <i>R<sub>f</sub></i> = 0.70 (10:90:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.73 (d, <i>J</i> = 6.0 Hz, 1H), 7.62 (d, <i>J</i> = 6.0 Hz, 1H), 7.37 (d, <i>J</i> = 6.0 Hz, 1H), 7.22 (d, <i>J</i> = 5.1 Hz, 1H), 7.16 (m, 1H), 5.61–5.43 (m, 6H), 4.87 (s, 1H), 4.65 (d, <i>J</i> = 3.9 Hz, 1H), 4.59 (d, <i>J</i> = 3.6 Hz, 1H), 4.19 (t, <i>J</i> = 5.4 Hz, 1H), 3.21 (d, <i>J</i> = 7.5 Hz, 2H), 2.38–2.30 (m, 3H), 2.18–1.98 (m, 6H), 1.71–1.60 (m, 5H), 1.43–1.37 (m, 2H), 1.14 (t, <i>J</i> = 3.3 Hz, 1H), 0.89 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 382.27 [M + H]<sup>+</sup>. HRMS calcd for C<sub>25</sub>H<sub>39</sub>N<sub>3</sub> (M + H)<sup>+</sup> 382.3144, found 382.2866.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>cis</i>-1-((1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)thiourea (<b>11</b>)</h3><div class="NLM_p last">See general procedure C. Step 1 used amine <b>9</b> (200 mg, 0.565 mmol, 1.00 equiv), benzoyl isothiocyanate (83.6 mg, 0.622 mmol, 1.10 equiv), CH<sub>2</sub>Cl<sub>2</sub> (5.60 mL, 0.10 M). Step 2 used K<sub>2</sub>CO<sub>3</sub> (547 mg, 3.96 mmol, 7.00 equiv), MeOH (5.80 mL, 0.050 M). Thiourea <b>11</b> was obtained as a light-yellow glue (70.0 mg, 58% yield). <i>R<sub>f</sub></i> = 0.50 (10:90:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.61 (br s, 1H), 7.37 (d, <i>J</i> = 6 Hz, 1H), 7.24 (s, 2H), 7.11 (t, <i>J</i> = 5.1 Hz, 1H), 6.58 (br s, 1H), 5.82 (s, 2H), 4.88 (br s, 1H), 4.45 (br s, 1H), 4.18 (s, 1H), 3.14 (d, <i>J</i> = 6.9 Hz, 2H), 2.33 (s, 1H), 2.22 (t, <i>J</i> = 9.3 Hz, 2H), 2.02–1.97 (m, 4H), 1.71–1.61 (m, 5H), 1.55 (m, 2H), 1.41 (m, 2H), 1.14 (m, 1H), 0.89 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 413.11 [M + H]<sup>+</sup>. The bis HCl salt of urea <b>11</b> was formed by dissolving the amine in CH<sub>2</sub>Cl<sub>2</sub> (0.10M) at room temperature, followed by the addition of HCl (2.0 M in Et<sub>2</sub>O, 2.20 equiv). The reaction was allowed to stir for 10 min. At this time, the reaction was concentrated in vacuo, Et<sub>2</sub>O was added to the mixture, followed by concentrating the mixture in vacuo (repeat 3× total) to provide the HCl salt of urea <b>11</b>. Anal. Calcd for C<sub>24</sub>H<sub>36</sub>N<sub>4</sub>S·2.00HCl·1.00CH<sub>2</sub>Cl<sub>2</sub>: C, 55.76; H, 7.48; N, 10.40. Found: C, 55.66; H, 7.52; N, 10.74.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>cis</i>-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methanol (<b>12</b>)</h3><div class="NLM_p last">Aldehyde <b>7</b> (1.50 g, 4.26 mmol, 1.00 equiv) was taken up in absolute EtOH (50 mL, 0.085M), and sodium borohydride (806 mg, 21.3 mmol, 5.00 equiv) was then added in several portions at room temperature. After bubbling had subsided, the reaction was stirred for an addition 30 min and then concentrated in vacuo. The resulting white residue was suspended in a 5% NaOH (aq) solution (20 mL) and extracted 3× with EtOAc. The EtOAc layer was washed with water, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude product that was purified via a 2 in. long filter column using 8:92 EtOAc/hexanes to provide alcohol <b>12</b> as a pale white solid (1.4 g, 86% yield). <i>R<sub>f</sub></i> = 0.30 (10:90 EA/hexanes, UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.73 (d, <i>J</i> = 5.7 Hz, 1H), 7.37 (d, <i>J</i> = 6.0 Hz, 1H), 7.26 (s, 1H), 7.22 (d, <i>J</i> = 6.0 Hz, 1H), 7.13 (t, <i>J</i> = 5.4 Hz, 1H), 4.87 (s, 2H), 4.20 (m, 1H), 3.15 (d, <i>J</i> = 8.7 Hz, 2H), 2.33 (br s, 1H), 2.23 (t, <i>J</i> = 8.4 Hz, 2H), 1.98 (dd, <i>J</i> = 18.3, 9.0 Hz, 4H), 1.73–1.69 (m, 4H), 1.61 (t, <i>J</i> = 4.8 Hz, 2H), 1.57 (m, 1H), 1.41 (m, 2H), 1.26 (br s, 1H), 1.02 (br s, 1H), 0.86 (dd, <i>J</i> = 4.8, 6.9 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 355.22 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>23</sub>H<sub>34</sub>N<sub>2</sub>O·0.20CH<sub>2</sub>Cl<sub>2</sub>: C, 75.00; H, 9.33; N, 7.54. Found: C, 74.62; H, 9.62; N, 7.34.</div></div><div id="sec4_2_14_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Synthesis of Alkynes <b>15</b> and <b>16</b>. <i>tert</i>-Butyl (4-(Triethylsilyl)but-3-yn-1-yl)carbamate (<b>15</b>)</h3><div class="NLM_p last">Alkyne <b>15</b> was obtained as a light-yellow oil using the same 4-step synthesis that provided alkyne <b>16</b>. Step 1: 99% yield. Step 2: 94% yield. Step 3: 70% yield. Step 4: 78% yield. <i>R<sub>f</sub></i> = 0.10 (5:95 EtOAc/hexanes, I<sub>2</sub> and pAA). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.80 (br, 1H), 3.28 (q, <i>J</i> = 6.6 Hz, 2H), 2.45 (t, <i>J</i> = 6.6 Hz, 2H), 1.45 (s, 9H), 0.99 (t, <i>J</i> = 7.8 Hz, 9H), 0.58 (q, <i>J</i> = 7.8 Hz, 6H).</div></div><div id="sec4_2_14_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>tert</i>-Butyl (5-(Trimethylsilyl)pent-4-yn-1-yl)carbamate (<b>16</b>)</h3><div class="NLM_p">To a solution of 5-(trimethylsilyl)pent-4-yn-1-ol (<b>14</b>) (2.55 g, 16.3 mmol, 1.00 equiv) (GFS Chemicals) in 65.2 mL of CH<sub>2</sub>Cl<sub>2</sub> (0.25 M) at room temperature were added triethylamine (2.95 mL, 21.2 mmol, 1.30 equiv) and DMAP (99.6 mg, 0.815 mmol, 0.050 equiv). The solution was stirred for several minutes, and then TsCl (3.36 g, 17.6 mmol, 1.08 equiv) was added at room temperature. The reaction was fitted with an Ar balloon and allowed to stir for 16 h. At this stage, TLC (10:90 EtOAc/hexanes) showed the reaction was complete. The reaction was concentrated in vacuo to half of the initial reaction volume, then diluted with EtOAc and water, and the biphasic solution stirred for 5 min. The layers were then separated, and the aqueous layer was extracted 2× with EtOAc. The EtOAc layers were combined, washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide the tosylate intermediate used directly in the following step (4.70 g, 93% yield).</div><div class="NLM_p">The tosylate intermediate (4.70 g, 15.1 mmol, 1.00 equiv) and phthalimide (2.78 g, 18.9 mmol, 1.25 equiv) were dissolved in 60.0 mL of DMF (0.25M) at room temperature. K<sub>2</sub>CO<sub>3</sub> (6.27 g, 45.4 mmol, 3.00 equiv) was added, the reaction was fitted with an Ar balloon, and the reaction was heated to 50 °C for 6 h. At this time, TLC (10:90 EtOAc/hexanes) shows the reaction is complete. The reaction was allowed to cool to room temperature, and then it was diluted with EtOAc and water. The layers were separated, and the aqueous layer was extracted 2× with EtOAc. The EtOAc layers were combined, washed 3× with water, 1× with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide semicrude material. This material was purified via flash chromatography using 8:92 EtOAc/hexanes to provide the phthalimide intermediate as a white solid (2.89 g, 67% yield). This material was used directly in the following step.</div><div class="NLM_p">The phthalimide intermediate (2.20 g, 7.71 mmol, 1.00 equiv) from the previous step was dissolved in 77.0 mL of MeOH (0.10M) at room temperature, and then hydrazine (0.966 mL, 30.8 mmol, 4.00 equiv) was added, and the reaction was allowed to stir at room temperature overnight. At this stage, a large amount of a white precipitate had formed. The white precipitate was filtered, washed thoroughly with MeOH, and the resulting filtrate was concentrated in vacuo to provide a solid–liquid mixture. This mixture was diluted with EtOAc, stirred several minutes, and the resulting solids were filtered and washed thoroughly with EtOAc. The filtrate (EtOAc) was then washed with water, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide the desired amine (863 mg, 72% yield), which is used directly in the following step.</div><div class="NLM_p last">The amine intermediate (863 mg, 5.56 mmol, 1.00 equiv) and DMAP (34.0 mg, 0.278 mmol, 0.050 equiv) were dissolved in 37 mL of THF (0.15 M) at room temperature. To this solution was added Boc anhydride (1.33 g, 6.11 mmol, 1.10 equiv), and the reaction was allowed to stir overnight. At this stage, TLC (2:98:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq)) showed the reaction was complete. The reaction was concentrated in vacuo, and the crude mixture was purified via flash chromatography using 5:95 EtOAc/hexanes to provide alkyne <b>16</b> as a clear oil (1.25 g, 88% yield). <i>R<sub>f</sub></i> = 0.10 (5:95 EtOAc/hexanes, I<sub>2</sub> and pAA). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.80 (br, 1H), 3.23 (m, 2H), 2.29 (t, <i>J</i> = 5.4 Hz, 2H), 1.71 (m, 2H), 1.49 (s, 9H), 0.16 (s, 9H).</div></div><div id="sec4_2_14_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>cis</i>-<i>N</i>-(2-Iodophenyl)-1-(-4-isopropylcyclohexyl)piperidin-4-amine (<b>18</b>)</h3><div class="NLM_p">(i) See general procedure A, using 2-iodoaniline (<b>17</b>) (15.0 g, 63.3 mmol, 1.00 equiv), <i>N</i>-Boc-piperidone (<b>2</b>) (18.5 g, 95.0 mmol, 1.50 equiv), glacial AcOH (8.40 mL, 146 mmol, 2.30 equiv), STAB (30.9 g, 146 mmol, 2.30 equiv), DCE (250 mL, 0.25M). The sample was purified via flash chromatography using 5:95 EtOAc/hexanes to provide the secondary aniline intermediate as a white solid (19.1 g, 75% yield).</div><div class="NLM_p last">(ii) See general procedure B. Step 1 used aniline intermediate (43.5 g, 0.108 mol, 1.00 equiv), TFA (200 mL, 2.61 mol, 24.0 equiv), CH<sub>2</sub>Cl<sub>2</sub> (300 mL, 0.36M). The N-H piperidine intermediate was obtained as a light-tan solid (42.0 g, 128% yield, due to NaTFA) and was used directly in the next step. Step 2 used N-H piperidine (assume 0.108 mol, 1.00 equiv), 4-<i>i</i>Pr-cyclohexanone (22.7 g, 0.162 mol, 1.50 equiv), glacial AcOH (14.2 mL, 0.248 mol, 2.30 equiv), STAB (52.6 g, 0.248 mol, 2.30 equiv), DCE (1.54 L, 0.070M). Compound <b>18</b> was separated from its anti-diastereomer via flash chromatography using 6:94:1.5 → 9:91:1.5 EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide a golden oil. (The syn diastereomer has a higher <i>R<sub>f</sub></i> value compared to the anti-diastereomer.) Although the product is pure when viewed under UV light (short wave), the product contains non-UV active impurities (viewable with pAA) related to 4-<i>i</i>Pr-cyclohexanone. Thus, to remove these impurities, the golden oil was dissolved in EtOAc (∼300 mL) and transferred to an erlenmeyer flask. At this stage, 10% HCl (aq) (∼200 mL) was added. Upon addition of the 10% HCl (aq), a white precipitate formed, and the suspension was stirred for 10 min. The white precipitate was then filtered, washed 2× with EtOAc, and then air-dried over 1 h. The white precipitate was then placed in an Erlenmeyer flask and suspended in EtOAc, and 70% NaHCO<sub>3</sub> (aq) was added until basic. The mixture was then stirred overnight. At this stage, the mixture is now a clear biphasic solution (add water and stir if a significant amount of white precipitate remains). The layers were separated, and the EtOAc layer was washed with water, brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide iodoaniline <b>18</b> as a light-gold oil (24.0 g, 39% yield over 3 steps). <i>R<sub>f</sub></i> = 0.30 (10:90:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.65 (dd, <i>J</i> = 5.7, 0.9, 1H), 7.18 (t, <i>J</i> = 6.0, 1H), 6.58 (d, <i>J</i> = 6.0, 1H), 6.41 (dt, <i>J</i> = 5.7, 0.9, 1H), 4.12 (d, <i>J</i> = 5.7 Hz, 1H), 3.36 (m, 1H), 2.93 (m, 2H), 2.25 (m, 3H), 2.15 (d, <i>J</i> = 8.4 Hz, 2H), 1.47–1.74 (m, 8H), 1.38 (m, 2H), 1.13 (m, 1H), 0.89 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 427 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_14_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>cis</i>-<i>tert</i>-Butyl (2-(1-(1-(−4-Isopropylcyclohexyl)piperidin-4-yl)-2-(triethylsilyl)-1<i>H</i>-indol-3-yl)ethyl)carbamate (<b>19</b>)</h3><div class="NLM_p last">Iodoaniline <b>18</b> (1.00 g, 2.35 mmol, 1.00 equiv) and alkyne <b>15</b> (797 mg, 2.81 mmol, 1.20 equiv) were charged into a round-bottom flask. LiCl (99.4 mg, 2.35 mmol, 1.00 equiv) was added, and the mixture was diluted with 33.5 mL of DMF (0.070M). K<sub>2</sub>CO<sub>3</sub> (973 mg, 7.04 mmol, 3.00 equiv) was added to the reaction, followed by a catalytic amount of Pd(OAc)<sub>2</sub> (26.3 mg, 0.117 mmol, 0.050 equiv). The reaction was fitted with an Ar balloon, purged 3× under vacuum, backfilled with Ar, and heated in a 102 °C oil bath. The reaction was monitored by TLC and was complete at ∼2.5 h. NOTE: Pd<sup>0</sup> (black) was observed ∼2 h into reaction. Once the reaction was complete, the mixture was allowed to cool to room temperature and was diluted with EtOAc and water. The mixture was stirred for several minutes and then filtered. The filtrate layers were separated, and the aqueous layer was extracted 1× with EtOAc. The EtOAc layers were combined and washed 2× with water, 1× with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude product that was purified via flash chromatography using 7:93:1 → 10:90:1 EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide indole <b>19</b> as a white foam (1.04 g, 76% yield). <i>R<sub>f</sub></i> = 0.25 (10:90:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.69 (d, <i>J</i> = 6.3 Hz, 1H), 7.62 (d, <i>J</i> = 5.7 Hz, 1H), 7.16 (t, <i>J</i> = 5.7 Hz, 1H), 7.06 (t, <i>J</i> = 5.7 Hz, 1H), 4.56 (br, 1H), 4.25 (m, 1H), 3.40 (m, 2H), 3.21 (d, <i>J</i> = 8.4 Hz, 2H), 3.02 (t, <i>J</i> = 5.1 Hz, 2H), 2.71 (dq, <i>J</i> = 9.0, 2.1 Hz, 2H), 2.35 (m, 1H), 2.17 (t, <i>J</i> = 9.0 Hz, 2H), 1.38–1.75 (m, 20H), 1.16 (m, 1H), 0.90–1.03 (m, 21H). MS (ESI) <i>m</i>/<i>z</i>: 582.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_14_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>cis</i>-<i>tert</i>-Butyl (3-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-2-(trimethylsilyl)-1<i>H</i>-indol-3-yl)propyl)carbamate (<b>20</b>)</h3><div class="NLM_p last">Indole <b>20</b> was synthesized in a similar manner as indole <b>19</b>. Iodoaniline <b>20</b> (720 mg, 1.69 mmol, 1.00 equiv), alkyne <b>16</b> (475 mg, 1.86 mmol, 1.10 equiv), LiCl (71.6 mg, 1.69 mmol, 1.00 equiv), K<sub>2</sub>CO<sub>3</sub> (700 mg, 5.07 mmol, 3.00 equiv), Pd(OAc)<sub>2</sub> (38.0 mg, 0.169 mmol, 0.100 equiv), and DMF (24.0 mL, 0.070M). Reaction time was ∼6 h. Purification was via flash chromatography using 10:90:1 EtOAc/hexanes/NH<sub>4</sub>OH (aq) to provide indole <b>20</b> in ∼90% purity as light-beige solid (88% yield). Trituration using MeOH provided pure indole <b>20</b> as a white solid (585 mg, 65% yield). <i>R<sub>f</sub></i> = 0.10 (10:90:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i>: 554.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_14_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>cis</i>-2-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)ethan-1-amine (<b>21</b>)</h3><div class="NLM_p last">AcCl (806 μL, 11.3 mmol, 6.00 equiv) was added to 19.0 mL of MeOH (0.10M) at 0 °C, and the mixture was stirred for several minutes at 0 °C. At this stage, indole intermediate <b>19</b> (1.10 g, 1.89 mmol, 1.00 equiv) was added, resulting in a slurry. The ice-bath was then removed, and the reaction was allowed to warm to room temperature and stir overnight. Once TLC confirmed the reaction was complete, EtOAc (∼5× the amount of MeOH) was added and the reaction was allowed to stir for 60 min, during which a white precipitate formed. The white precipitate was then filtered and washed 3× with EtOAc. The white solid was then collected and dried in vacuo to provide the bis HCl salt of indole <b>21</b> as a white solid (665 mg, 80% yield). <i>R<sub>f</sub></i> = 0.10 (10:90:3 drops <i>i</i>PrOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.61 (d, <i>J</i> = 6.0 Hz, 1H), 7.36 (d, <i>J</i> = 6.3 Hz, 1H), 7.21 (t, <i>J</i> = 6.0 Hz, 1H), 7.11 (m, 2H), 4.18 (m, 1H), 3.19 (d, <i>J</i> = 8.7 Hz, 2H), 3.03 (t, <i>J</i> = 4.8 Hz, 2H), 2.93 (t, <i>J</i> = 4.8 Hz, 2H), 2.35 (m, 1H), 2.26 (dt, <i>J</i> = 8.4, 1.8 Hz, 2H), 2.07 (br, 6H), 1.76–1.53 (m, 7H), 1.42 (m, 2H), 1.14 (m, 1H), 0.90 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 368.6 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>24</sub>H<sub>37</sub>N<sub>3</sub>·2.00HCl·0.50H<sub>2</sub>O: C, 64.12; H, 8.97; N, 9.35. Found: C, 64.23; H, 8.73; N, 9.32.</div></div><div id="sec4_2_14_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>cis</i>-3-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)propan-1-amine (<b>22</b>)</h3><div class="NLM_p last">Compound <b>22</b> was synthesized in a similar manner as indole <b>21</b>, using indole intermediate <b>20</b> (582 mg, 1.09 mmol, 1.00 equiv), AcCl (466 μL, 6.55 mmol, 6.00 equiv), MeOH (7.3 mL, 0.15 M). The bis HCl salt of indole <b>22</b> was obtained as a white solid (388 mg, 78% yield). <i>R<sub>f</sub></i> = 0.10 (5:95:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz) δ 7.58 (d, <i>J</i> = 6.0 Hz, 1H), 7.50 (d, <i>J</i> = 6.3 Hz, 1H), 7.25 (s, 1H), 7.19 (t, <i>J</i> = 6.0 Hz, 1H), 7.07 (t, <i>J</i> = 6.0 Hz, 1H), 4.72 (m, 1H), 3.74 (d, <i>J</i> = 9.6 Hz, 2H), 3.40–3.30 (m, 5H), 2.98 (t, <i>J</i> = 5.7 Hz, 2H), 2.88 (t, <i>J</i> = 5.7 Hz, 2H), 2.50 (dq, <i>J</i> = 9.6, 2.4 Hz, 2H), 2.28 (d, <i>J</i> = 9.9 Hz, 2H), 2.10–1.95 (m, 6H), 1.80 (m, 3H), 1.57 (t, <i>J</i> = 9.9 Hz, 2H), 1.28 (m, 1H), 0.97 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 382.6 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>25</sub>H<sub>39</sub>N<sub>3</sub>·2.00HCl·0.50H<sub>2</sub>O: C, 64.78; H, 9.13; N, 9.07. Found: C, 64.93; H, 9.11; N, 9.04.</div></div><div id="sec4_2_14_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>cis</i>-1-(2-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)ethyl)thiourea (<b>23</b>)</h3><div class="NLM_p last">See General procedure C. Step 1 used amine <b>21</b> (35.0 mg, 95.2 μmol, 1.00 equiv), benzoyl isothiocyanate (13.5 μL, 100 μmol, 1.05 equiv), CH<sub>2</sub>Cl<sub>2</sub> (950 μL, 0.10 M). Step 2 used K<sub>2</sub>CO<sub>3</sub> (92.0 mg, 666 μmol, 7.00 equiv), MeOH (1.90 mL, 0.050 M). Thiourea <b>23</b> was obtained as a light-yellow glue (20.2 mg, 50% yield). <i>R<sub>f</sub></i> = 0.15 (60:40:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.57 (br s, 1H), 7.37 (d, <i>J</i> = 6.3 Hz, 1H), 7.23 (t, <i>J</i> = 5.4 Hz, 1H), 7.12 (m, 2H), 6.27 (br s, 1H), 5.84 (br s, 2H), 4.20 (m, 1H), 3.22 (d, <i>J</i> = 8.4 Hz, 2H), 3.06 (t, <i>J</i> = 4.8 Hz, 2H), 2.42–2.07 (m, 7H), 1.78–1.56 (m, 7H), 1.41 (m, 2H), 1.27 (m, 2H), 1.16 (m, 1H), 0.91 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 427.7 [M + H]<sup>+</sup>. HRMS (ESI) calcd for C<sub>25</sub>H<sub>39</sub>N<sub>4</sub>S (M + H), 427.2895; found, 427.2896.</div></div><div id="sec4_2_14_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>cis</i>-1-(3-(1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)propyl)thiourea (<b>24</b>)</h3><div class="NLM_p last">See general procedure C. Step 1 used amine <b>22</b> (20.0 mg, 52.4 μmol, 1.00 equiv), benzoyl isothiocyanate (7.40 μL, 55.0 μmol, 1.05 equiv), CH<sub>2</sub>Cl<sub>2</sub> (525 μL, 0.10 M). Step 2 used K<sub>2</sub>CO<sub>3</sub> (50.0 mg, 0.367 mmol, 7.00 equiv), MeOH (1.05 mL, 0.050 M). Thiourea <b>24</b> was obtained as a clear oil (10.8 mg, 47% yield). <i>R<sub>f</sub></i> = 0.20 (50:50:3 drops EtOAc/hexanes/NH<sub>4</sub>OH (aq), UV, pAA, I<sub>2</sub>). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.56 (d, <i>J</i> = 6.0 Hz, 1H), 7.36 (d, <i>J</i> = 6.0 Hz, 1H), 7.21 (t, <i>J</i> = 5.7 Hz, 1H), 7.10 (m, 2H), 6.26 (br s, 1H), 5.66 (br s, 2H), 4.18 (m, 1H), 3.18 (m, 3H), 2.85 (t, <i>J</i> = 5.4 Hz, 2H), 2.40–2.25 (m, 3H), 2.12–1.90 (m, 6H), 1.77–1.54 (m, 6H), 1.42 (m, 2H), 1.26 (m, 2H), 1.15 (m, 1H), 0.90 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 427.7 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>26</sub>H<sub>40</sub>N<sub>4</sub>S·0.50H<sub>2</sub>O: C, 69.44; H, 9.19; N, 12.46. Found: C, 69.43; H, 9.13; N, 12.07.</div></div><div id="sec4_2_14_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>cis</i>-1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-3-(pyrrolidin-1-ylmethyl)-1<i>H</i>-indole (<b>25</b>)</h3><div class="NLM_p last">See general procedure A. Conditions were use of aldehyde <b>7</b> (150 mg, 0.426 mmol, 1.00 equiv), pyrrolidine (57.0 μL, 0.682 mmol, 1.60 equiv), glacial AcOH (56.1 μL, 0.980 mmol, 2.30 equiv), STAB (208 mg, 0.980 mmol, 2.30 equiv), DCE (4.30 mL, 0.10M). The crude product was purified via flash chromatography using 0:100:1 → 2:98:1 MeOH/EtOAc/NH<sub>4</sub>OH (aq) to provide indole <b>25</b> as an oil (93 mg, 53% yield). <i>R<sub>f</sub></i> = 0.10 (100:3 drops EtOAc/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.69 (d, <i>J</i> = 7.8 Hz, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.24 (s, 1H), 7.20 (t, <i>J</i> = 7.5 Hz, 1H), 7.11 (t, <i>J</i> = 7.5 Hz, 1H), 4.19 (m, 1H), 3.84 (s, 2H), 3.18 (d, <i>J</i> = 11.7 Hz, 2H), 2.60 (m, 4H), 2.35–2.19 (m, 3H), 2.12–1.97 (m, 4H), 1.81–1.48 (m, 11H), 1.40 (m, 2H), 1.16 (m, 1H), 0.91 (d, <i>J</i> = 6.6 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 408.6 [M + H]<sup>+</sup>. The HCl salt of amine <b>25</b> was formed by dissolving the amine in CH<sub>2</sub>Cl<sub>2</sub> (0.10 M) at room temperature and cooling the reaction in a 0 °C ice-bath. To this solution was added HCl (2.0 M in Et<sub>2</sub>O, 3.00 equiv), and the reaction was allowed to warm to room temperature and stir for 30 min. At this time, the reaction was concentrated in vacuo, Et<sub>2</sub>O was added, and the mixture was concentrated in vacuo (repeat 3× total) to provide an off-white solid. Anal. Calcd for C<sub>27</sub>H<sub>41</sub>N<sub>3</sub>·2.00HCl·1.50H<sub>2</sub>O: C, 63.89; H, 9.14; N, 8.28. Found: C, 63.92; H, 8.92; N, 8.26.</div></div><div id="sec4_2_14_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>cis</i>-1-((1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)piperidin-4-amine (<b>27</b>)</h3><div class="NLM_p">Step 1. See general procedure A. Conditions were use of aldehyde <b>7</b> (100 mg, 0.284 mmol, 1.00 equiv), 4-(<i>N</i>-Boc-amino)piperidine (56.0 mg, 0.284 mmol, 1.00 equiv) (note, glacial AcOH not used), STAB (180 mg, 0.851 mmol, 3.00 equiv), DCE (10.0 mL, 0.03 M). The crude Boc-protected amine (<b>26</b>) (0.153 g, 98% yield) was taken directly into the Boc removal step.</div><div class="NLM_p last">Step 2. Boc-protected amine <b>26</b> (85.0 mg, 0.160 mmol, 1.00 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL, 0.030M), followed by the addition of excess TFA (4.00 mL). The reaction mixture was stirred for 10 min, and then the solvent was evaporated to provide a yellow oily product. This was triturated with Et<sub>2</sub>O to provide the TFA salt of indole <b>27</b> as a solid (97.5 mg, 78% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.70 (dd, <i>J</i> = 4.2, 2.4 Hz, 2H), 7.53 (dd, <i>J</i> = 4.2, 2.4 Hz, 2H), 7.40 (br s, 1H), 4.22 (m, 3H), 3.48 (dd, <i>J</i> = 10.5, 5.1 Hz, 4H), 2.08 (s, 14H), 1.69 (m, 2H), 1.43 (m, 3H), 1.35–1.29 (m, 4H), 1.20 (t, <i>J</i> = 5.1 Hz, 3H), 0.94–0.88 (m, 6H). MS (ESI) <i>m</i>/<i>z</i>: 437.50 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>28</sub>H<sub>44</sub>N<sub>4</sub>·3.00TFA·1.00Et<sub>2</sub>O·1.00CH<sub>2</sub>Cl<sub>2</sub>: C, 50.25; H, 6.22; N, 5.77. Found: C, 50.26; H, 6.01; N, 5.60.</div></div><div id="sec4_2_14_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>cis</i>-1-((1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)piperidin-4-ol (<b>28</b>)</h3><div class="NLM_p last">See general procedure A. Conditions were use of aldehyde <b>7</b> (205 mg, 0.630 mmol, 1.00 equiv), piperin-4-ol·HCl (173 mg, 1.26 mmol, 2.00 equiv), <i>i</i>Pr<sub>2</sub>NEt (253 μL, 1.45 mmol, 2.30 equiv), glacial AcOH (83.0 μL, 1.45 mmol, 2.30 equiv), STAB (307 mg, 1.45 mmol, 2.30 equiv), DCE (6.30 mL, 0.10M). The crude product was purified via flash chromatography using 3:97:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to afford indole <b>28</b> as a light-yellow foam (140 mg, 51% yield). <i>R<sub>f</sub></i> = 0.15 (5:95:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.71 (d, <i>J</i> = 7.8 Hz, 1H), 7.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.24–7.17 (m, 2H), 7.11 (t, <i>J</i> = 6.9 Hz, 1H), 4.42 (m, 1H), 3.75 (m, 3H), 3.19 (d, <i>J</i> = 12.0 Hz, 2H), 2.85 (m, 2H), 2.38–2.20 (m, 4H), 2.18–1.85 (m, 4H), 1.78–1.35 (m, 14H), 1.17 (m, 1H), 0.91 (d, <i>J</i> = 6.6 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 438.7 [M + H]<sup>+</sup>. The bis tartrate salt of amine <b>28</b> was formed by dissolving the amine in MeOH (0.10M) at room temperature. To the reaction was added <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (2.00 equiv) in a MeOH solution. The reaction was allowed to stir for 30 min. At this time, the reaction was concentrated in vacuo, and then Et<sub>2</sub>O was added to the mixture, followed by concentrating the mixture in vacuo (repeat 3× total) to provide a light-yellow solid. Anal. Calcd for C<sub>28</sub>H<sub>43</sub>N<sub>3</sub>O·2.00 tartaric acid·1.50H<sub>2</sub>O: C, 56.53; H, 7.64; N, 5.49. Found: C, 56.91; H, 7.83; N, 5.12.</div></div><div id="sec4_2_14_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>cis</i>-(<i>R</i>)-1-((1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)pyrrolidin-3-ol (<b>29</b>)</h3><div class="NLM_p last">See general procedure A. Conditions were use of aldehyde <b>7</b> (97.0 mg, 0.275 mmol, 1.00 equiv), pyrrolidin-3-ol (47.9 mg, 0.550 mmol, 2.00 equiv), glacial AcOH (36.2 μL, 0.633 mmol, 2.30 equiv), STAB (134 mg, 0.633 mmol, 2.30 equiv), DCE (2.75 mL, 0.10M). The crude product was purified via flash chromatography using 5:95:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide indole <b>29</b> as a light-yellow foam (112 mg, 97% yield). <i>R<sub>f</sub></i> = 0.20 (5:95:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.69 (d, <i>J</i> = 6.0 Hz, 1H), 7.36 (d, <i>J</i> = 6.0 Hz, 1H), 7.21 (m, 2H), 7.11 (t, <i>J</i> = 5.1 Hz, 1H), 4.32 (m, 1H), 4.18 (m, 1H), 3.86 (s, 2H), 3.18 (d, <i>J</i> = 9.0 Hz, 2H), 2.93 (m, 1H), 2.74 (m, 1H), 2.60 (m, 1H), 2.43–1.98 (m, 10H), 1.78–1.52 (m, 8H), 1.57 (m, 2H), 1.15 (m, 1H), 0.90 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 424.6 [M + H]<sup>+</sup>. The bis tartrate salt of amine <b>29</b> was formed by dissolving the amine in MeOH (0.10 M) at room temperature. To the reaction was added <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (2.50 equiv) in a MeOH solution. The reaction was allowed to stir for 30 min. At this time, the reaction was concentrated in vacuo, and then Et<sub>2</sub>O was added to the mixture, followed by concentrating the mixture in vacuo (repeat 3× total) to provide a tan solid. Anal. Calcd for C<sub>27</sub>H<sub>41</sub>N<sub>3</sub>O·2.50 tartaric acid·2.00H<sub>2</sub>O: C, 53.23; H, 7.24; N, 5.03. Found: C, 53.60; H, 6.96; N, 4.95.</div></div><div id="sec4_2_14_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>cis</i>-1-((1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)azetidin-3-ol (<b>30</b>)</h3><div class="NLM_p last">See general procedure A. Conditions were use of aldehyde <b>7</b> (40 mg, 0.113 mmol, 1.00 equiv), azetidin-3-ol·HCl (24.8 mg, 0.226 mmol, 2.00 equiv), <i>i</i>Pr<sub>2</sub>NEt (45.3 μL, 0.260 mmol, 2.30 equiv), glacial AcOH (14.9 μL, 0.260 mmol, 2.30 equiv), STAB (55.1 mg, 0.260 mmol, 2.30 equiv), DCE (1.10 mL, 0.10M). The crude product was purified via flash chromatography using 5:95:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide indole <b>30</b> as a light-golden oil (37.4 mg, 81% yield). <i>R<sub>f</sub></i> = 0.15 (5:95:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.65 (d, <i>J</i> = 5.7 Hz, 1H), 7.58 (br, 1H), 7.36 (d, <i>J</i> = 6.3 Hz, 1H), 7.21 (m, 2H), 7.12 (t, <i>J</i> = 5.4 Hz, 1H), 4.44 (p, <i>J</i> = 4.2 Hz, 1H), 4.19 (m, 1H), 3.84 (s, 2H), 3.69 (m, 2H), 3.18 (d, <i>J</i> = 9.0 Hz, 2H), 3.07 (m, 2H), 2.36–2.22 (m, 3H), 2.10–1.88 (m, 4H), 1.78–1.46 (m, 7H), 1.40 (m, 2H), 1.14 (m, 1H), 0.90 (d, <i>J</i> = 5.1 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 410.6 [M + H]<sup>+</sup>. The bis tartrate salt of amine <b>30</b> was formed by dissolving the amine in MeOH/CH<sub>2</sub>Cl<sub>2</sub> (3:2, 0.10M) at room temperature. To the reaction was added <span class="smallcaps smallerCapital">l</span>-(+)-tartaric acid (2.00 equiv) in a MeOH solution. The reaction was allowed to stir for 30 min. At this time, the reaction was concentrated in vacuo, and then Et<sub>2</sub>O was added to the mixture, followed by concentrating the mixture in vacuo (repeat 3× total) to provide an off-white solid. Anal. Calcd for C<sub>26</sub>H<sub>39</sub>N<sub>3</sub>O·2.00 tartaric acid·2.00H<sub>2</sub>O: C, 54.75; H, 7.43; N, 5.63. Found: C, 54.92; H, 7.27; N, 5.35.</div></div><div id="sec4_2_14_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>cis</i>-2-(((1-(1-(-4-Isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)amino)ethan-1-ol (<b>31</b>)</h3><div class="NLM_p last">See general procedure A. Conditions were use of aldehyde <b>7</b> (100 mg, 0.284 mmol, 1.00 equiv), ethanolamine (17.0 μL, 0.284 mmol, 1.00 equiv) (note, glacial AcOH not used), STAB (180 mg, 0.851 mmol, 3.00 equiv), DCE (6.00 mL, 0.050M). The crude product was purified via flash chromatography using 8:92:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide indole <b>31</b> as a liquid (25 mg, 22% yield). <i>R<sub>f</sub></i> = 0.30 (10:90 MeOH/CH<sub>2</sub>Cl<sub>2</sub>, UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.56 (d, <i>J</i> = 5.7 Hz, 1H), 7.36 (d, <i>J</i> = 6.3 Hz, 1H), 7.18 (t, <i>J</i> = 5.1 Hz, 2H), 7.06 (d, <i>J</i> = 5.7 Hz, 1H), 4.21 (m, 1H), 3.66 (br s, 1H), 3.22 (s, 1H), 2.79 (s, 1H), 2.32 (br s, 3H), 2.10 (s, 4H), 1.72–1.61 (m, 7H), 1.43–1.32 (m, 2H), 1.26 (s, 2H), 1.15 (s, 1H), 0.89 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 398.24 [M + H]<sup>+</sup>. HRMS Calcd for C<sub>25</sub>H<sub>39</sub>N<sub>3</sub>O (M + H)<sup>+</sup> 398.3093, found 398.3173.</div></div><div id="sec4_2_14_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>cis</i>-2-Amino-5-guanidino-<i>N</i>-((1-(1-(−4-isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)pentanamide (<b>33</b>)</h3><div class="NLM_p">Z-Arg-OH (0.39 g, 0.68 mmol, 1.20 equiv), HOBT (0.099 g, 0.65 mmol, 1.15 equiv), and triethylamine (0.110 mL, 0.79 mmol, 1.40 equiv) were added to 10 mL of CH<sub>2</sub>Cl<sub>2</sub> (0.057M) at room temperature and stirred until the entire solid dissolved. The reaction was cooled in an ice-bath at 5 °C, and EDCI (0.13 g, 0.68 mmol, 1.20 equiv) was added and stirred at 5 °C for 2 h. At this stage, a solution of amine <b>9</b> (0.20 g, 0.57 mmol, 1.00 equiv) in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> was added to the reaction, and then the reaction was allowed to warm to room temperature and was monitored by TLC (10:90:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq)). After 2 h, the reaction was complete by TLC. The reaction was quenched with saturated NaHCO<sub>3</sub> (aq), stirred 5 min, and the layers were then separated. The aqueous layer was extracted 2× with CH<sub>2</sub>Cl<sub>2</sub>, the organic layers were combined, washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude residue that was purified via flash chromatography using 3:96:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide Cbz intermediate <b>32</b> as a white solid (0.35 g, 67% yield). <i>R<sub>f</sub></i> = 0.50 (10:90:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>).</div><div class="NLM_p last">To a solution of Cbz intermediate <b>32</b> (150 mg, 0.160 mmol, 1.00 equiv) in THF (1.60 mL, 0.10 M) was added 10% Pd/C (15.0 mg, 10 wt %), and then the reaction was fitted with a 3-way adapter containing a H<sub>2</sub> (g) balloon. The reaction atmosphere was purged and then backfilled with H<sub>2</sub> (g). This was repeated 3× total. The reaction was stirred at room temperature and monitored by TLC. After 3 h, TLC showed full consumption of the starting material. The reaction was poured over a pad of Celite, filtered, and the Celite was washed thoroughly with THF. The resulting filtrate was concentrated in vacuo, and the residue was purified by trituration with CH<sub>2</sub>Cl<sub>2</sub> and Et<sub>2</sub>O to provide amide <b>33</b> as a white solid (73 mg, 87% yield). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.32 (s, 2H), 7.72 (br s, 1H), 7.50 (d, <i>J</i> = 6.0 Hz, 1H), 7.44 (d, <i>J</i> = 6.3 Hz, 1H), 7.41 (s, 1H), 7.08 (t, <i>J</i> = 6.0 Hz, 1H), 6.95 (t, <i>J</i> = 5.7 Hz, 1H), 4.39 (dd, <i>J</i> = 10.8, 3.6 Hz, 1H), 4.31–4.24 (m, 2H), 3.83 (br s, 1H), 3.07 (br s, 3H), 2.90 (m, 1H), 2.66 (s, 2H), 2.28 (d, <i>J</i> = 13.5, 2H), 2.16 (t, <i>J</i> = 8.4 Hz, 3H), 1.91–1.85 (m, 4H), 1.70 (br s, 2H), 1.54 (br s, 4H), 1.41–1.35 (m, 4H), 1.12 (m, 1H), 0.85 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 510.36 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>29</sub>H<sub>47</sub>N<sub>7</sub>O·2.00CH<sub>2</sub>Cl<sub>2</sub>: C, 54.79; H, 7.56; N, 14.43. Found: C, 54.89; H, 7.31; N, 14.46.</div></div><div id="sec4_2_14_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>cis</i>-6-Amino-<i>N</i>-((1-(1-(-4-isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)hexanamide (<b>35</b>)</h3><div class="NLM_p">6-(((Benzyloxy)carbonyl)amino)hexanoic acid (0.18 g, 0.68 mmol, 1.20 equiv), HOBT (0.099 g, 0.65 mmol, 1.15 equiv), and triethylamine (0.110 mL, 0.79 mmol, 1.40 equiv) were added to 10 mL of CH<sub>2</sub>Cl<sub>2</sub> (0.057 M) at room temperature and stirred until the entire solid dissolved. The reaction was then cooled in an ice-bath at 5 °C, and EDCI (0.13 g, 0.68 mmol, 1.20 equiv) was added and stirred at 5 °C for 2 h. At this stage, amine <b>9</b> (0.20 g, 0.57 mmol, 1.00 equiv) was dissolved in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> and added to the reaction at 5 °C. The reaction was stirred at 5 °C for 1 h, and then it was allowed to warm to room temperature and stir for an additional 12 h. The reaction was quenched with saturated NaHCO<sub>3</sub> (aq), stirred 5 min, and the layers were then separated. The aqueous layer was extracted 2× with CH<sub>2</sub>Cl<sub>2</sub>, the organic layers were combined, washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude residue that was purified via flash chromatography using 3:96:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide carbamate intermediate <b>34</b> as an oil (0.30 g, 88% yield). <i>R<sub>f</sub></i> = 0.50 (10:90:3 drops MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>).</div><div class="NLM_p last">To a solution of Cbz intermediate <b>34</b> (140 mg, 0.23 mmol, 1.00 equiv) in 2.30 mL of THF (0.10M) was added 10% Pd/C (14.0 mg, 10 wt %), and then the reaction was fitted with a 3-way adapter containing a H<sub>2</sub> (g) balloon. The reaction atmosphere was purged and then backfilled with H<sub>2</sub> (g). This was repeated 3× total. The reaction was stirred at room temperature and monitored by TLC. After 3 h, TLC showed full consumption of the starting material. The reaction was poured over a pad of Celite, filtered, and the Celite was washed thoroughly with THF. The resulting filtrate was concentrated in vacuo, and the residue was purified by trituration with CH<sub>2</sub>Cl<sub>2</sub> and Et<sub>2</sub>O to provide amide <b>35</b> as a white solid (42 mg, 39% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.61 (d, <i>J</i> = 7.5 Hz, 1H), 7.36 (d, <i>J</i> = 8.1 Hz, 1H), 7.20 (t, <i>J</i> = 5.1 Hz, 2H), 7.10 (t, <i>J</i> = 7.5 Hz, 1H), 5.93 (s, 1H), 4.59 (d, <i>J</i> = 5.1 Hz, 2H), 4.21 (m, 1H), 3.57 (t, <i>J</i> = 5.4 Hz, 4H), 3.22 (d, <i>J</i> = 11.4 Hz, 2H), 2.56–2.50 (m, 3H), 2.43–2.32 (m, 2H), 2.17 (t, <i>J</i> = 7.5 Hz, 2H), 2.12 (s, 2H), 1.78–1.51 (m, 11H), 1.45–1.31 (m, 4H), 1.29–1.16 (m, 1H), 0.90 (d, <i>J</i> = 6.6 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 467.30 [M + H]<sup>+</sup>. The bis HCl salt of amine <b>35</b> was formed by dissolving the amine in CH<sub>2</sub>Cl<sub>2</sub> (0.10 M) at room temperature, followed by the addition of HCl (2.0 M in Et<sub>2</sub>O, 2.20 equiv). The reaction was allowed to stir for 10 min. At this time, the reaction was concentrated in vacuo, Et<sub>2</sub>O was added to the mixture, followed by concentrating the mixture in vacuo (repeat 3× total) to provide the HCl salt of amine <b>35</b>. Anal. Calcd for C<sub>29</sub>H<sub>46</sub>N<sub>4</sub>O·2.00HCl·2.00CH<sub>2</sub>Cl<sub>2</sub>·2.00Et<sub>2</sub>O·1.00H<sub>2</sub>O: C, 53.49; H, 8.52; N 6.40. Found: C, 53.73; H, 8.39; N, 6.20.</div></div><div id="sec4_2_14_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>cis</i>-2-(Ethylamino)-<i>N</i>-((1-(1-(-4-isopropylcyclohexyl)piperidin-4-yl)-1<i>H</i>-indol-3-yl)methyl)acetamide (<b>37</b>)</h3><div class="NLM_p">Z-glycine-OH (0.20 g, 0.67 mmol, 1.20 equiv), HOBT (0.099 g, 0.65 mmol, 1.15 equiv), and triethylamine (0.110 mL, 0.79 mmol, 1.40 equiv) were added to 10 mL CH<sub>2</sub>Cl<sub>2</sub> (0.057 M) and stirred until the entire solid dissolved. The reaction was then cooled in an ice-bath at 5 °C, and EDCI (0.13 g, 0.68 mmol, 1.20 equiv) was added and stirred at 5 °C for 2 h. At this stage, amine <b>9</b> (0.20 g, 0.57 mmol, 1.00 equiv) was dissolved in 5 mL of CH<sub>2</sub>Cl<sub>2</sub> and added to the reaction at 5 °C. The reaction was allowed to warm to room temperature and stir for an additional 2 h. The reaction was quenched with saturated NaHCO<sub>3</sub> (aq), stirred 5 min, and the layers were then separated. The aqueous layer was extracted 2× with CH<sub>2</sub>Cl<sub>2</sub>, the organic layers were combined, washed with brine, dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to provide a crude residue that was purified via flash chromatography using 1:98:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide Cbz intermediate <b>36</b> (0.21 g, 68% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (d, <i>J</i> = 5.7 Hz, 1H), 7.36 (d, <i>J</i> = 6.3 Hz, 1H), 7.32 (s, 5H), 7.24 (m, 2H), 7.11 (t, <i>J</i> = 5.7 Hz, 1H), 6.11 (s, 1H), 5.45 (s, 1H), 5.08 (s, 2H), 4.19 (m, 1H), 3.85 (d, <i>J</i> = 4.2 Hz, 2H), 3.22 (d, <i>J</i> = 8.7 Hz, 2H), 2.44 (s, 1H), 2.31 (d, <i>J</i> = 7.8 Hz, 2H), 2.09 (t, <i>J</i> = 7.8 Hz, 4H), 1.73 (br s, 2H), 1.65 (m, 3H), 1.43–1.38 (m, 2H), 1.17 (m, 1H), 0.89 (d, <i>J</i> = 4.8 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 545.28 [M + H]<sup>+</sup>.</div><div class="NLM_p last">To a solution of Cbz intermediate <b>36</b> (0.15 g, 0.308 mmol, 1.00 equiv) in 3.1 mL of absolute ethanol (0.10 M) was added 10% Pd/C (15.0 mg, 10 wt %), and then the reaction was fitted with a 3-way adapter containing a H<sub>2</sub> (g) balloon. The reaction atmosphere was purged and then backfilled with H<sub>2</sub> (g). This was repeated 3× total. The reaction was stirred at room temperature and monitored by TLC. After 4 h, TLC showed full consumption of the starting material. The reaction was poured over a pad of Celite, filtered, and the Celite was washed thoroughly with ethanol. The resulting filtrate was concentrated in vacuo, and the residue was purified by flash chromatography on silica gel, using 5:95:1 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq) to provide ethylated amine <b>37</b> as an oil (55.2 mg, 41% yield). <i>R<sub>f</sub></i> = 0.50 (10:90 MeOH/CH<sub>2</sub>Cl<sub>2</sub>/NH<sub>4</sub>OH (aq), UV, I<sub>2</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.59 (t, <i>J</i> = 7.8 Hz, 1H), 7.35 (d, <i>J</i> = 8.1 Hz, 1H), 7.20 (t, <i>J</i> = 4.8 Hz, 2H), 7.09 (t, <i>J</i> = 7.5 Hz, 1H), 5.31 (s, 1H), 4.60 (d, <i>J</i> = 5.4 Hz, 2H), 4.32 (br s, 1H), 3.38 (m, 4H), 2.71–2.44 (m, 9H), 2.11 (d, <i>J</i> = 11.7 Hz, 2H), 1.88–1.64 (m, 5H), 1.40 (dd, <i>J</i> = 10.2, 13.2 Hz, 2H), 1.28–1.20 (m, 1H), 1.07 (t, <i>J</i> = 6.9 Hz, 3H), 0.92 (d, <i>J</i> = 6.3 Hz, 6H). MS (ESI) <i>m</i>/<i>z</i>: 439.28 [M + H]<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>42</sub>N<sub>4</sub>O·0.50H<sub>2</sub>O·0.50CH<sub>2</sub>Cl<sub>2</sub>: C, 67.39; H, 9.05; N, 11.43. Found: C, 67.02; H, 9.01; N, 11.69.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> In Vitro Pharmacological Characterization</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Cells</h4><div class="NLM_p last">Human NOP, μ, δ, and κ opioid receptors were individually expressed in Chinese hamster ovary cells stably transfected with the human receptor cDNA, as we have described previously.<a onclick="showRef(event, 'ref24 ref32'); return false;" href="javascript:void(0);" class="ref ref24 ref32">(24,32)</a> κ-CN cells were used for KOP radioligand binding assays, while κ-FLG19 cells were used in KOP [<sup>35</sup>S]GTPγS functional assays. The cells were grown in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum, in the presence of 0.4 mg/mL G418 and 0.1% penicillin/streptomycin, in 100 mm plastic culture dishes.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Membrane Preparation</h4><div class="NLM_p last">The cell lines are grown to full confluency, then harvested for membrane preparation. The membranes are prepared in 50 mM Tris buffer (pH 7.4). Cells are scraped and centrifuged at 500<i>g</i> for 12 min. The cell pellet is homogenized in 50 mM Tris with a Fisher Scientific PowerGen 125 rotor-stator type homogenizer, centrifuged at 20 000<i>g</i> for 25 min, washed and recentrifuged once more, aliquoted at a concentration of 3 mg/mL protein per vial, and stored in a −80 °C freezer until further use.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Receptor Binding</h4><div class="NLM_p last">The assay is performed in a 96-well polystyrene plate using triplicates of six concentrations of each test compound and tritiated ligands [<sup>3</sup>H]DAMGO (48 Ci/mmol, <i>K</i><sub>d</sub> = 1.6 nM for MOP), [<sup>3</sup>H]DPDPE (46 Ci/mmol, <i>K</i><sub>d</sub> = 1.9 nM for DOP), [<sup>3</sup>H]U69593 (41.7 Ci/mmol, <i>K</i><sub>d</sub> = 2.1 nM for KOP), or [<sup>3</sup>H]N/OFQ (130 Ci/mmol, <i>K</i><sub>d</sub> = 0.2 nM for NOP). Nonspecific binding was determined by using 1.0 μM of the unlabeled nociceptin for NOP, 10 μM unlabeled DAMGO for MOP, 10 μM unlabeled DPDPE for DOP, and 10 μM unlabeled U69,593 for KOP. Assays were initiated by addition of membrane homogenates, and samples were incubated for 60 min at 25 °C in a total volume of 1.0 mL. In NOP receptor experiments, 1 mg/mL BSA is added to the assay buffer. The amount of protein in the binding assay was 15 μg. The incubation was terminated by rapid filtration through 0.5% PEI-soaked glass fiber Filtermats (GF/C Filtermat A, PerkinElmer) on a Tomtec Mach III cell harvester and washed 5 times with 0.5 mL of ice-cold 50 nM Tris-HCl, pH 7.4 buffer. The filters were dried overnight and soaked with scintillation cocktail before counting on a Wallac Beta plate 1205 liquid scintillation counter. Radioactivity was determined as counts per minutes (cpm). IC<sub>50</sub> values were determined by using at least six concentrations of each compound and calculated using GraphPad Prism 6. (ISI, San Diego, CA). <i>K</i><sub>i</sub> values were determined by the method of Cheng and Prusoff. Each compound data is from at least three independent experiments conducted in triplicate. Statistical analysis was conducted using GraphPad Prism.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> [<sup>35</sup>S]GTPγS Functional Assay</h4><div class="NLM_p last">The efficacy of the compounds was determined by the ability to stimulate [<sup>35</sup>S]GTPγS binding to cell membranes and compared to standard agonists. The functional assay was conducted in buffer A, containing 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 10 mM magnesium chloride (MgCl<sub>2</sub>), 100 mM sodium chloride (NaCl) at pH 7.4. Membrane prepared as described above was incubated with [<sup>35</sup>S]GTPγS (150 000 cpm/well), guanosine diphosphate (GDP) (10 mM), and the test compound, in a total volume of 1 mL for 60 min at 25 °C. Samples were filtered over Filtermat A and counted as described for the binding assays. A dose–response curve with a prototypical full agonist at the respective receptor was conducted in each experiment to identify full and partial agonist compounds. Typically, the standard full agonists (N/OFQ for NOP, DAMGO for MOP, U69593 for KOP, and DPDPE DOP) showed at least 2-fold to 5-fold stimulation over basal. The EC<sub>50</sub> values are calculated using GraphPad Prism 6 (ISI, San Diego, CA) The % stimulation by the test compound is calculated as the percentage of the standard full agonist stimulation taken as 100% (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Caco-2 Intestinal Permeability Assay and the MDR-MDCK Cell Permeability Assay</h3><div class="NLM_p last">The data shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> are from experiments performed by a commercial service and were determined by the standard Caco-2 two-way permeability analysis with monitoring of test compound by HPLC/MS/MS. Concentration of test compound on both apical side (A → B) and basolateral side (B → A) was determined as the apparent permeability <i>P</i><sub>app</sub> (10<sup>–6</sup> cm/s). The MDR-MDCK cell permeability was also measured using a two-way permeability measurement, with monitoring of test compound by HPLC/MS/MS.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Human and Rat/Mouse Liver Microsomal Stability Assays</h3><div class="NLM_p last">These assays were performed by a commercial service using a standard protocol. Briefly, 1 μM test compounds in 100 mM potassium phosphate, pH 7.4, and 5 mM magnesium chloride were incubated at 37 °C in a shaking water bath after initiation of reaction by the addition of 1 mM NADPH. Aliquots were taken at time points 30, 45, and 60 min. The reactions were terminated by addition of an equal volume of acetonitrile containing 0.1% formic acid, and samples were processed and analyzed by LC–MS to monitor loss of parent compound. Percent of remaining parent compound is calculated relative to <i>t</i> = 0 min, and assays were conducted in duplicate. The validation control (testosterone for human and rodent) was assayed by LC–MS/MS using electrospray ionization. The peak area response ratio to internal standard propranolol at each time point was compared to the response ratio at time 0 to determine the percent remaining. GraphPad (San Diego, CA) was used to calculate the half-life, and data were fit to a single-phase exponential decay equation.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> In Vivo Pharmacokinetics and Brain Penetration of Selected Compounds in Rats</h3><div class="NLM_p">Male Sprague-Dawley rats (250–300 g) were administered a single dose of the test compound in the formulated vehicle via subcutaneous (sc) injection. Dosing volume and dose were 2 mL/kg and 3 mg/kg, respectively, for all compounds tested. Compounds were formulated as a 1.5 mg/mL solution in 5% dimethylacetamide/95% of 30% SBECD (β-cyclodextrin sulfobutyl ether). The following sampling times were used (<i>n</i> = 3/time point): 0.5, 1, 2, 4, 8 h after dosing. Rats were lightly anesthetized with CO<sub>2</sub>, blood was collected via cardiac puncture, and brains were removed from the cranium. Blood samples were collected into vials containing K<sub>2</sub>-EDTA, and vials were capped and temporarily stored on ice. Brain samples were temporarily put on dry ice. Plasma was separated from blood by centrifugation and frozen at −80 °C until bioanalysis. Brains were rinsed with ice-cold phosphate buffered saline, blotted dry, weighed, and stored at −80 °C until bioanalysis.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Bioanalytical Method</h4><div class="NLM_p">Plasma samples were thawed on ice, and a 50 μL aliquot was transferred to a 1 mL plastic tube. 5 μL MeOH was added to the samples. 200 μL of 50 ng/mL internal standard (terfenadine) in MeOH/acetonitrile (1:1, v/v) was added to the plasma, vortexed, and centrifuged (15 min at 4000 rpm). The resultant supernatants were diluted 10× with MeOH/water (1:1, v/v, containing 0.1% formic acid) for injection and were analyzed. Brain samples were thawed on ice, placed into plastic tubes, and 4 volumes of purified water per gram of brain was added (1:4, w/v). Brains were homogenized using a mechanical high speed tissue homogenizer; 50 μL of brain homogenate was transferred to a 1 mL plastic tube. 5 μL of MeOH was added to the samples. 200 μL of 50 ng/mL internal standard (terfenadine) in MeOH/acetonitrile (1:1, v/v) was added, vortexed, and centrifuged (15 min at 4000 rpm). The resultant supernatants were diluted 10× with MeOH/water (1:1, v/v, containing 0.1% formic acid) for injection and were analyzed.</div><div class="NLM_p last">Processed plasma and brain samples were analyzed by liquid chromatography–tandem mass spectrometry (LC/MS/MS) on an AB Sciex API 4000 (Applied Biosystems, CA). The LC separation used a binary gradient and C18 reverse phase column [Kinetex C18 100A, 30 mm × 3 mm). The column was maintained at room temperature. Mobile phase A consisted of 0.05% formic acid in 5 mM aqueous NH<sub>4</sub>OAc, and mobile phase B consisted of 0.1% formic acid in acetonitrile. The flow rate was held constant at 0.7 mL/min. Detection was using electrospray ionization operating in positive ion mode.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Pharmacokinetic Data Analysis</h4><div class="NLM_p last">The noncompartmental plasma and brain pharmacokinetics were determined using the program WinNonlin version 4.0.1 (Pharsight, Mountain View, CA). The area under the curve plasma concentration–time profile was established by linear trapezoidal rule. The terminal phase half-life was calculated using at least three data points in the terminal phase excluding the <i>C</i><sub>max</sub>.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> In Vivo Efficacy in the 6-OHDA Hemilesioned Rat Model of Parkinson’s Disease</h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Animal Subjects</h4><div class="NLM_p last">Experiments were performed in accordance with the ARRIVE guidelines. Experimenters were blinded to treatments. Male Sprague-Dawley rats (150 g, 6 week old; Envigo, S. Pietro al Natisone, Italy) were housed in a standard facility with free access to food (4RF21 standard diet; Mucedola, Settimo Milanese, Milan, Italy) and water and kept under regular lighting conditions (12 h dark/light cycle). Animals were housed in groups of 5 in a 55 cm × 33 cm × 20 cm polycarbonate cage (Tecniplast, Buguggiate, Varese, Italy) with a Scobis Uno bedding (Mucedola, Settimo Milanese, Milan, Italy) and environmental enrichments. The experimental protocols were approved by the Italian Ministry of Health (license no. 170/2013-B). Adequate measures were taken to minimize animal pain and discomfort. At the end of the experiments, rats were sacrificed with an overdose of isoflurane.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Unilateral 6-OHDA Lesion</h4><div class="NLM_p last">The unilaterally 6-OHDA lesioned rat, the most popular and best validated model of PD,<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> was used to assess the ability of NOP partial agonists to improve parkinsonian-like motor deficits. Unilateral lesion of dopaminergic neurons was induced under isoflurane anesthesia as previously described.<a onclick="showRef(event, 'ref10 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref16">(10,16)</a> An amount of 8 μg of 6-OHDA freebase (dissolved in 0.9% saline solution containing 0.02% ascorbic acid) was stereotaxically injected in the medial forebrain bundle according to following coordinates from bregma: anteroposterior = −4.4 mm, mediolateral= −1.2, dorsoventral = −7.8 mm below dura.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Animals were pretreated with antibiotics (Synulox, 50 μL/kg, ip). The wound was sutured and infiltrated with 2% lidocaine solution (Esteve). In order to select rats that were successfully hemilesioned, 2 weeks after 6-OHDA injection, rats were injected with a test dose of <span class="smallcaps smallerCapital">d</span>-amphetamine (5 mg/kg, ip, dissolved in saline), and those performing >7 turns per minute in the direction ipsilateral to the lesion were enrolled in the study. In fact, this behavior has been associated with >95% loss of striatal dopaminergic terminals<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and extracellular dopaminergic levels.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Behavioral Tests</h4><div id="sec4_7_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Bar Test</h5><div class="NLM_p last">The bar test,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> also known as catalepsy test,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> measures the ability of the animal to react to an externally imposed position. The right and left forepaws were alternatively placed on three blocks of increasing heights (3, 6, 9 cm). The immobility time (in seconds) of each forepaw on the blocks was recorded (the cutoff for each step was set at 20 s).</div></div><div id="sec4_7_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Drag Test</h5><div class="NLM_p last">The drag test, modification of the “wheelbarrow test”,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> measures the ability of the animal to balance its body posture using the forelimbs in response to backward dragging. Each rat was gently lifted from the abdomen leaving the forepaws on the table and dragged backward at a constant speed of 20 cm/sec for a fixed distance of 1 m. Two different observers counted the number of touches made by each forepaw.</div></div><div id="sec4_7_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Rotarod Test</h5><div class="NLM_p last">This test measures the ability of the animal to run on a rotating cylinder and provides different information on a variety of motor parameters such as coordination, balance, muscle tone, gait, and motivation to run.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The fixed-speed rotarod test was employed using a previously validated protocol.<a onclick="showRef(event, 'ref10 ref31'); return false;" href="javascript:void(0);" class="ref ref10 ref31">(10,31)</a> Animals were tested starting from 5 rpm, speed was stepwise increased by 5 rpm every 180 s, and total time spent on the rod was calculated.</div></div></div></div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Experimental Protocols and Design. Motor Behavior in 6-OHDA Hemilesioned, L-DOPA Naive Rats</h3><div class="NLM_p last">Hemilesioned rats that met the selection criteria after amphetamine testing after 2 weeks were used in the behavioral tests. Ten days later, these rats were subjected to the bar, drag, and rotarod tests repeated in a fixed sequence as training. When motor performance was reproducible (usually after 7–10 days), rats were randomized and treated with the respective doses of the test partial agonist, L-DOPA, or vehicle. Rats were tested 3–4 times, and a 3-day washout was allowed between treatments. In the bar and drag tests, motor activity was assessed 20 and 90 min after compound administration at both the contralateral and ipsilateral paw and expressed as absolute values for the bar and drag tests and as percentage of the control session for the rotarod test. Since no motor changes were observed at the ipsilateral paw after compound administration, data for the ipsilateral paw were not shown.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Statistical Analysis</h3><div class="NLM_p last">Statistical analysis was performed using PRISM 6.0 (GraphPad Software Inc., San Diego, CA) with two-way ANOVA followed by the Bonferroni test. Rotarod performance was expressed as % of control time on rod and analyzed with two-way ANOVA followed by Bonferroni test. Statistical significance was set at <i>p</i> < 0.05.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02134" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02134?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02134</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES data (molecular formula strings) for all final compounds along with their in vitro pharmacological data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02134/suppl_file/jm9b02134_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02134/suppl_file/jm9b02134_si_001.csv">jm9b02134_si_001.csv (3.07 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02134" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74553" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74553" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nurulain T. Zaveri</span> - <span class="hlFld-Affiliation affiliation">Astraea
Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6b051e191e070a02052b0a181f190a0e0a1f030e190a1b0e1e1f02081845080406"><span class="__cf_email__" data-cfemail="bfd1cacdcad3ded6d1ffdecccbcddedadecbd7dacddecfdacacbd6dccc91dcd0d2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Uma Gayathri Kamakolanu</span> - <span class="hlFld-Affiliation affiliation">Astraea
Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4741-7164" title="Orcid link">http://orcid.org/0000-0003-4741-7164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael E. Meyer</span> - <span class="hlFld-Affiliation affiliation">Astraea
Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis Yasuda</span> - <span class="hlFld-Affiliation affiliation">Astraea
Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Willma E. Polgar</span> - <span class="hlFld-Affiliation affiliation">Astraea
Therapeutics, 320 Logue Avenue, Suite 142, Mountain View, California 94043, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matteo Marti</span> - <span class="hlFld-Affiliation affiliation">Department
of Morphology, Surgery and Experimental Medicine, Section of Legal
Medicine, University of Ferrara, Ferrara 44100, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Mercatelli</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clarissa Anna Pisanò</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alberto Brugnoli</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele Morari</span> - <span class="hlFld-Affiliation affiliation">Department
of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara 44100, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>U.G.K. and M.E.M. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50052" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50052" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Grants R01DA014026 (N.T.Z.), R01DA027811 (N.T.Z.), and R43NS070664 (N.T.Z.) from the National Institutes of Health.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">DOP</td><td class="NLM_def"><p class="first last">δ opioid receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">KOP</td><td class="NLM_def"><p class="first last">κ opioid receptor</p></td></tr><tr><td class="NLM_term">MOP</td><td class="NLM_def"><p class="first last">μ opioid receptor</p></td></tr><tr><td class="NLM_term">NOP</td><td class="NLM_def"><p class="first last">N/OFQ opioid peptide receptor</p></td></tr><tr><td class="NLM_term">N/OFQ</td><td class="NLM_def"><p class="first last">nociceptin/orphanin FQ</p></td></tr><tr><td class="NLM_term">L-DOPA</td><td class="NLM_def"><p class="first last">levodopa/<span class="smallcaps smallerCapital">l</span>-dihydroxyphenylalanine</p></td></tr><tr><td class="NLM_term">LID</td><td class="NLM_def"><p class="first last">levodopa-induced dyskinesia</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12546" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12546" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">GBD
2016 Parkinson’s Disease Collaborators.</span> <span> </span><span class="NLM_article-title">Global, regional, and national burden
of Parkinson’s disease, 1990–2016: a systematic analysis
for the Global Burden of Disease Study 2016</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(18)30295-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS1474-4422%2818%2930295-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=30287051" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=939-953&author=GBD%0A2016+Parkinson%E2%80%99s+Disease+Collaborators.&title=Global%2C+regional%2C+and+national+burden%0Aof+Parkinson%E2%80%99s+disease%2C+1990%E2%80%932016%3A+a+systematic+analysis%0Afor+the+Global+Burden+of+Disease+Study+2016&doi=10.1016%2FS1474-4422%2818%2930295-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2818%2930295-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252818%252930295-3%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520burden%250Aof%2520Parkinson%25E2%2580%2599s%2520disease%252C%25201990%25E2%2580%25932016%253A%2520a%2520systematic%2520analysis%250Afor%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202016%26jtitle%3DLancet%2520Neurol.%26date%3D2018%26volume%3D17%26spage%3D939%26epage%3D953%26doi%3D10.1016%2FS1474-4422%2818%2930295-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iourinets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, I. H.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease psychosis: presentation, diagnosis and management</span>. <i>Neurodegener Dis Manag</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.2217/nmt-2017-0028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.2217%2Fnmt-2017-0028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=29160144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC1M3jsVClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=365-376&author=R.+B.+Schneiderauthor=J.+Iourinetsauthor=I.+H.+Richard&title=Parkinson%E2%80%99s+disease+psychosis%3A+presentation%2C+diagnosis+and+management&doi=10.2217%2Fnmt-2017-0028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease psychosis: presentation, diagnosis and management</span></div><div class="casAuthors">Schneider Ruth B; Iourinets Julia; Richard Irene H</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative disease management</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">365-376</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms.  Psychosis is a common feature of Parkinson's disease.  Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions.  PDP is associated with reduced function and quality of life.  The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia.  Pimavanserin, quetiapine and clozapine may all be considered for use in PDP.  In this review, we discuss the presentation, diagnosis and management of PDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_NkDldPB5m2K_SFaaT9INfW6udTcc2eaV9lNFin1iXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3jsVClsQ%253D%253D&md5=9c891d9bdf2ff7c1b6a8ef03c00adfa9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2217%2Fnmt-2017-0028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnmt-2017-0028%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%2BB.%26aulast%3DIourinets%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DI.%2BH.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%2520psychosis%253A%2520presentation%252C%2520diagnosis%2520and%2520management%26jtitle%3DNeurodegener%2520Dis%2520Manag%26date%3D2017%26volume%3D7%26spage%3D365%26epage%3D376%26doi%3D10.2217%2Fnmt-2017-0028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obeso, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olanow, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, J. G.</span></span> <span> </span><span class="NLM_article-title">Levodopa motor complications in Parkinson’s disease</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">S2</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/S1471-1931(00)00031-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS1471-1931%2800%2900031-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=11052214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVGrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=S2-7&author=J.+A.+Obesoauthor=C.+W.+Olanowauthor=J.+G.+Nutt&title=Levodopa+motor+complications+in+Parkinson%E2%80%99s+disease&doi=10.1016%2FS1471-1931%2800%2900031-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa motor complications in Parkinson's disease</span></div><div class="casAuthors">Obeso, Jose A.; Olanow, C. Warren; Nutt, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10, Suppl.</span>),
    <span class="NLM_cas:pages">S2-S7</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 61 refs.  Parkinson's disease (PD) is an age-related neurodegenerative disorder with an av. onset age of 60 yr.  In the United States, approx. one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year.  The estd. cost of PD to society is $27 billion per yr.  Based on United States Census Bureau projections, it is estd. that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxzKLIFxaVJrVg90H21EOLACvtfcHk0liDqaU9kXhUmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVGrt7k%253D&md5=beb2a61b94436dbed0879bfe9ea0dc3a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1471-1931%2800%2900031-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-1931%252800%252900031-8%26sid%3Dliteratum%253Aachs%26aulast%3DObeso%26aufirst%3DJ.%2BA.%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DNutt%26aufirst%3DJ.%2BG.%26atitle%3DLevodopa%2520motor%2520complications%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2000%26volume%3D23%26spage%3DS2%26epage%3D7%26doi%3D10.1016%2FS1471-1931%2800%2900031-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koller, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Amantadine and other antiglutamate agents</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">S13</span>– <span class="NLM_lpage">S22</span>, <span class="refDoi"> DOI: 10.1002/mds.5557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1002%2Fmds.5557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=12211136" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=S13-S22&author=C.+G.+Goetzauthor=W.+C.+Kollerauthor=W.+Poewe&title=Amantadine+and+other+antiglutamate+agents&doi=10.1002%2Fmds.5557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fmds.5557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.5557%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DC.%2BG.%26aulast%3DKoller%26aufirst%3DW.%2BC.%26aulast%3DPoewe%26aufirst%3DW.%26atitle%3DAmantadine%2520and%2520other%2520antiglutamate%2520agents%26jtitle%3DMov.%2520Disord.%26date%3D2002%26volume%3D17%26spage%3DS13%26epage%3DS22%26doi%3D10.1002%2Fmds.5557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercatelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease: no NOP, new hope</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">8995</span>– <span class="NLM_lpage">8996</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.18632%2Foncotarget.13710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=28086211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ls1ajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=8995-8996&author=L.+Arcuriauthor=D.+Mercatelliauthor=M.+Morari&title=Parkinson%E2%80%99s+disease%3A+no+NOP%2C+new+hope&doi=10.18632%2Foncotarget.13710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease: no NOP, new hope</span></div><div class="casAuthors">Arcuri Ludovico; Mercatelli Daniela; Morari Michele</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">8995-8996</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQG5g7na5uZ_MAKB7Fa-xrUfW6udTcc2eZ462ZlBdfJS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ls1ajsg%253D%253D&md5=7efc409178109e1c6f6ef9db80f776ee</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13710%26sid%3Dliteratum%253Aachs%26aulast%3DArcuri%26aufirst%3DL.%26aulast%3DMercatelli%26aufirst%3DD.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%253A%2520no%2520NOP%252C%2520new%2520hope%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D8995%26epage%3D8996%26doi%3D10.18632%2Foncotarget.13710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mercatelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">NOP Receptor Ligands and Parkinson’s Disease</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1007/164_2018_199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1007%2F164_2018_199" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2018&pages=213-232&author=D.+Mercatelliauthor=C.+A.+Pisanoauthor=S.+Novelloauthor=M.+Morari&title=NOP+Receptor+Ligands+and+Parkinson%E2%80%99s+Disease&doi=10.1007%2F164_2018_199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2F164_2018_199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2018_199%26sid%3Dliteratum%253Aachs%26aulast%3DMercatelli%26aufirst%3DD.%26aulast%3DPisano%26aufirst%3DC.%2BA.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DNOP%2520Receptor%2520Ligands%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2018%26volume%3D254%26spage%3D213%26epage%3D232%26doi%3D10.1007%2F164_2018_199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailleux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butour, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moisand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caput, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J. C.</span></span> <span> </span><span class="NLM_article-title">ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)80235-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2F0014-5793%2894%2980235-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=8137918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaK2cXksFamurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1994&pages=33-38&author=C.+Mollereauauthor=M.+Parmentierauthor=P.+Mailleuxauthor=J.+L.+Butourauthor=C.+Moisandauthor=P.+Chalonauthor=D.+Caputauthor=G.+Vassartauthor=J.+C.+Meunier&title=ORL1%2C+a+novel+member+of+the+opioid+receptor+family.+Cloning%2C+functional+expression+and+localization&doi=10.1016%2F0014-5793%2894%2980235-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization</span></div><div class="casAuthors">Mollereau, Catherine; Parmentier, Marc; Mailleux, Pierre; Butour, Jean Luc; Moisand, Christiane; Chalon, Pascale; Caput, Daniel; Vassart, Gilbert; Meunier, Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-8</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">Selective PCR amplification of human and mouse genomic DNAs with oligonucleotides encoding highly conserved regions of the β-opioid and somatostatin receptors generated a human DNA probe (hOP01, 761 bp) and its murine counterpart (mOP86, 447 bp).  Probe hOP01 was used to screen a cDNA library from human brainstem.  A clone (named hORL1) was isolated, sequenced and found to encode a protein of 370 amino acids whose primary structure displays the seven putative membrane-spanning domains of a G protein-coupled membrane receptor.  The hORL1 receptor is most closely related to opioid receptors not only on structural (sequence) but also on functional grounds: hORL1 is 49-50% identical to the murine μ-, δ- and κ-opioid receptors and, in CHO-K1 cells stably transfected with a pRc/CMV:hORL1 construct, ORL1 mediates inhibition of adenylyl cyclase by etorphine, a universal (nonselective) opiate agonist.  Yet, hORL1 appears not to be a typical opioid receptor.  Neither is it a somatostatin or σ (N-allylnormetazocine) receptor.  The mRNAs hybridizing with synthetic oligonucleotides complementary to mOP86 are present in many regions of the mouse brain and spinal cord, particularly in limbic (amygdala, hippocampus, septum, habenula, ...) and hypothalamic structures.  The authors conclude that the hORL1 receptor is a new member of the opioid receptor family with a potential role in modulating a no. of brain functions, including instinctive behaviors and emotions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWFR7ExrwbJrVg90H21EOLACvtfcHk0lhMyfDBmDJ3xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFamurs%253D&md5=7a7190c4703811558b3ce3e60e9df7e8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2980235-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252980235-1%26sid%3Dliteratum%253Aachs%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DParmentier%26aufirst%3DM.%26aulast%3DMailleux%26aufirst%3DP.%26aulast%3DButour%26aufirst%3DJ.%2BL.%26aulast%3DMoisand%26aufirst%3DC.%26aulast%3DChalon%26aufirst%3DP.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DMeunier%26aufirst%3DJ.%2BC.%26atitle%3DORL1%252C%2520a%2520novel%2520member%2520of%2520the%2520opioid%2520receptor%2520family.%2520Cloning%252C%2520functional%2520expression%2520and%2520localization%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D341%26spage%3D33%26epage%3D38%26doi%3D10.1016%2F0014-5793%2894%2980235-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1124%2Fpr.114.009209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=26956246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC28josFaltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=419-457&author=L.+Tollauthor=M.+R.+Bruchasauthor=G.+Caloauthor=B.+M.+Coxauthor=N.+T.+Zaveri&title=Nociceptin%2FOrphanin+FQ+Receptor+Structure%2C+Signaling%2C+Ligands%2C+Functions%2C+and+Interactions+with+Opioid+Systems&doi=10.1124%2Fpr.114.009209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems</span></div><div class="casAuthors">Toll Lawrence; Bruchas Michael R; Calo' Girolamo; Cox Brian M; Zaveri Nurulain T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">419-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The NOP receptor (nociceptin/orphanin FQ opioid peptide receptor) is the most recently discovered member of the opioid receptor family and, together with its endogenous ligand, N/OFQ, make up the fourth members of the opioid receptor and opioid peptide family.  Because of its more recent discovery, an understanding of the cellular and behavioral actions induced by NOP receptor activation are less well developed than for the other members of the opioid receptor family.  All of these factors are important because NOP receptor activation has a clear modulatory role on mu opioid receptor-mediated actions and thereby affects opioid analgesia, tolerance development, and reward.  In addition to opioid modulatory actions, NOP receptor activation has important effects on motor function and other physiologic processes.  This review discusses how NOP pharmacology intersects, contrasts, and interacts with the mu opioid receptor in terms of tertiary structure and mechanism of receptor activation; location of receptors in the central nervous system; mechanisms of desensitization and downregulation; cellular actions; intracellular signal transduction pathways; and behavioral actions with respect to analgesia, tolerance, dependence, and reward.  This is followed by a discussion of the agonists and antagonists that have most contributed to our current knowledge.  Because NOP receptors are highly expressed in brain and spinal cord and NOP receptor activation sometimes synergizes with mu receptor-mediated actions and sometimes opposes them, an understanding of NOP receptor pharmacology in the context of these interactions with the opioid receptors will be crucial to the development of novel therapeutics that engage the NOP receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4KujB2a63gCEJCPKhJPuqfW6udTcc2eZ462ZlBdfJS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28josFaltw%253D%253D&md5=2a2c601fcd493fa3f67b0adee9259e02</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009209%26sid%3Dliteratum%253Aachs%26aulast%3DToll%26aufirst%3DL.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DCalo%26aufirst%3DG.%26aulast%3DCox%26aufirst%3DB.%2BM.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DNociceptin%252FOrphanin%2520FQ%2520Receptor%2520Structure%252C%2520Signaling%252C%2520Ligands%252C%2520Functions%252C%2520and%2520Interactions%2520with%2520Opioid%2520Systems%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D419%26epage%3D457%26doi%3D10.1124%2Fpr.114.009209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouledous, L.</span></span> <span> </span><span class="NLM_article-title">Tissue distribution of the opioid receptor-like (ORL1) receptor</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1016/S0196-9781(00)00227-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS0196-9781%2800%2900227-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10998524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1WrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=907-917&author=C.+Mollereauauthor=L.+Mouledous&title=Tissue+distribution+of+the+opioid+receptor-like+%28ORL1%29+receptor&doi=10.1016%2FS0196-9781%2800%2900227-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue distribution of the opioid receptor-like (ORL1) receptor</span></div><div class="casAuthors">Mollereau, C.; Mouledous, L.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-917</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review, with 92 refs.  The ORL1 receptor is a G protein-coupled receptor structurally related to the opioid receptors, whose endogenous ligand is the heptadecapeptide nociceptin/orphanin FQ.  In this review, data which have contributed to the mapping of the anat. distribution of the ORL1 receptor have been collated with an emphasis on their relation to physiol. functions.  The ORL1 receptor is widely expressed in the central nervous system, in particular in the forebrain (cortical areas, olfactory regions, limbic structures, thalamus), throughout the brainstem (central periaqueductal gray, substantia nigra, several sensory and motor nuclei), and in both the dorsal and ventral horns of the spinal cord.  Regions almost devoid of ORL1 receptors are the caudate-putamen and the cerebellum.  ORL1 mRNA and binding sites exhibit approx. the same distribution pattern, indicating that the ORL1 receptor is located on local neuronal circuits.  The ORL1 receptor is also expressed at the periphery in smooth muscles, peripheral ganglia, and the immune system.  The anat. distribution of ORL1 receptor suggests a broad spectrum of action for the nociceptin/orphanin FQ system (sensory perception, memory process, emotional behavior, etc.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppTa7glqyVR7Vg90H21EOLACvtfcHk0ljCpLMLnF4GbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1WrsLg%253D&md5=0887929cd793fa11c1fa6e0595841c5c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0196-9781%2800%2900227-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0196-9781%252800%252900227-8%26sid%3Dliteratum%253Aachs%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DMouledous%26aufirst%3DL.%26atitle%3DTissue%2520distribution%2520of%2520the%2520opioid%2520receptor-like%2520%2528ORL1%2529%2520receptor%26jtitle%3DPeptides%26date%3D2000%26volume%3D21%26spage%3D907%26epage%3D917%26doi%3D10.1016%2FS0196-9781%2800%2900227-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Benedetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinscheid, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romualdi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candeletti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">9591</span>– <span class="NLM_lpage">9601</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2546-05.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.2546-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=16237164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=9591-9601&author=M.+Martiauthor=F.+Melaauthor=M.+Fantinauthor=S.+Zucchiniauthor=J.+M.+Brownauthor=J.+Wittaauthor=M.+Di+Benedettoauthor=B.+Buzasauthor=R.+K.+Reinscheidauthor=S.+Salvadoriauthor=R.+Guerriniauthor=P.+Romualdiauthor=S.+Candelettiauthor=M.+Simonatoauthor=B.+M.+Coxauthor=M.+Morari&title=Blockade+of+nociceptin%2Forphanin+FQ+transmission+attenuates+symptoms+and+neurodegeneration+associated+with+Parkinson%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.2546-05.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease</span></div><div class="casAuthors">Marti, Matteo; Mela, Flora; Fantin, Martina; Zucchini, Silvia; Brown, Jeffrey M.; Witta, Jassir; Di Benedetto, Manuela; Buzas, Beata; Reinscheid, Rainer K.; Salvadori, Severo; Guerrini, Remo; Romualdi, Patrizia; Candeletti, Sanzio; Simonato, Michele; Cox, Brian M.; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">9591-9601</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The opioid-like neuropeptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are expressed in the substantia nigra (SN), a brain area contg. dopamine neurons that degenerate in Parkinson's disease.  Endogenous N/OFQ facilitates nigral glutamate release and inhibits nigrostriatal dopamine transmission and motor behavior.  Here, we present evidence suggesting that endogenous N/OFQ may contribute to Parkinson's disease.  Pharmacol. blockade of the SN N/OFQ-NOP receptor system attenuated parkinsonian-like akinesia/hypokinesia in 6-hydroxydopamine hemi-lesioned or haloperidol-treated rats, whereas deletion of the NOP receptor gene conferred mice partial protection from haloperidol-induced motor depression.  The antiparkinsonian action of NOP receptor antagonists was assocd. with redn. of glutamate release in the SN.  In 6-hydroxydopamine hemilesioned rats, enhancement of N/OFQ expression and release was detected in the lesioned compared with the unlesioned SN, indicating that parkinsonism may be assocd. with over-activation of the N/OFQ-NOP receptor system in the SN.  Finally, deletion of the N/OFQ gene conferred mice partial protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of SN dopamine neurons.  Based on these data, we propose that NOP receptor antagonists may represent a novel approach for combined (symptomatic and neuroprotective) therapy of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcXWmE9x6-rrVg90H21EOLACvtfcHk0ljCpLMLnF4GbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrjF&md5=893032d6983e5bc603cf446dd290b6b9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2546-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2546-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMela%26aufirst%3DF.%26aulast%3DFantin%26aufirst%3DM.%26aulast%3DZucchini%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DWitta%26aufirst%3DJ.%26aulast%3DDi%2BBenedetto%26aufirst%3DM.%26aulast%3DBuzas%26aufirst%3DB.%26aulast%3DReinscheid%26aufirst%3DR.%2BK.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DGuerrini%26aufirst%3DR.%26aulast%3DRomualdi%26aufirst%3DP.%26aulast%3DCandeletti%26aufirst%3DS.%26aulast%3DSimonato%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DB.%2BM.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520nociceptin%252Forphanin%2520FQ%2520transmission%2520attenuates%2520symptoms%2520and%2520neurodegeneration%2520associated%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D9591%26epage%3D9601%26doi%3D10.1523%2FJNEUROSCI.2546-05.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarubbo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biguzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quatrale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candeletti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romualdi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1002/mds.23271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1002%2Fmds.23271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=20589874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC3cjntlyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2010&pages=1723-1732&author=M.+Martiauthor=S.+Sarubboauthor=F.+Latiniauthor=M.+Cavalloauthor=R.+Eleopraauthor=S.+Biguzziauthor=C.+Lettieriauthor=C.+Contiauthor=M.+Simonatoauthor=S.+Zucchiniauthor=R.+Quatraleauthor=M.+Sensiauthor=S.+Candelettiauthor=P.+Romualdiauthor=M.+Morari&title=Brain+interstitial+nociceptin%2Forphanin+FQ+levels+are+elevated+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.23271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease</span></div><div class="casAuthors">Marti Matteo; Sarubbo Silvio; Latini Francesco; Cavallo Michele; Eleopra Roberto; Biguzzi Sara; Lettieri Christian; Conti Carlo; Simonato Michele; Zucchini Silvia; Quatrale Rocco; Sensi Mariachiara; Candeletti Sanzio; Romualdi Patrizia; Morari Michele</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Expression and release of nociceptin/orphanin FQ (N/OFQ) are elevated in the substantia nigra reticulata of 6-hydroxydopamine-hemilesioned rats, suggesting a pathogenic role for N/OFQ in Parkinson's disease.  In this study, we investigated whether elevation of N/OFQ expression in 6-hydroxydopamine-hemilesioned rats selectively occurs in substantia nigra and whether hypomotility following acute haloperidol administration is accompanied by a rise in nigral N/OFQ levels.  Moreover, to prove a link between N/OFQ and idiopathic Parkinson's disease in humans, we measured N/OFQ levels in the cerebrospinal fluid of parkinsonian patients undergoing surgery for deep brain stimulation.  In situ hybridization demonstrated that dopamine depletion was associated with increase of N/OFQ expression in substantia nigra (compacta +160%, reticulata +105%) and subthalamic nucleus (+45%), as well as reduction in caudate putamen (-20%).  No change was observed in globus pallidus, nucleus accumbens, thalamus, and motor cortex.  Microdialysis coupled to the bar test allowed to demonstrate that acute administration of haloperidol (0.8 and 3 mg/kg) increased nigral N/OFQ levels (maximally of +47% and +53%, respectively) in parallel with akinesia.  A correlation with preclinical studies was found by analyzing N/OFQ levels in humans.  Indeed, N/OFQ levels were found to be approximately 3.5-fold elevated in the cerebrospinal fluid of parkinsonian patients (148 fmol/ml) compared with nonparkinsonian neurologic controls (41 fmol/ml).  These data represent the first clinical evidence linking N/OFQ to idiopathic Parkinson's disease in humans.  They strengthen the pathogenic role of N/OFQ in the modulation of parkinsonism across species and provide a rationale for developing N/OFQ receptor antagonists as antiparkinsonian drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1HYQVGZGxJFWTCLT8lX9SfW6udTcc2ea0Ur2pHVr-97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjntlyhuw%253D%253D&md5=ca6bc5c0248c9c288061d9c7cb55e221</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fmds.23271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.23271%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DSarubbo%26aufirst%3DS.%26aulast%3DLatini%26aufirst%3DF.%26aulast%3DCavallo%26aufirst%3DM.%26aulast%3DEleopra%26aufirst%3DR.%26aulast%3DBiguzzi%26aufirst%3DS.%26aulast%3DLettieri%26aufirst%3DC.%26aulast%3DConti%26aufirst%3DC.%26aulast%3DSimonato%26aufirst%3DM.%26aulast%3DZucchini%26aufirst%3DS.%26aulast%3DQuatrale%26aufirst%3DR.%26aulast%3DSensi%26aufirst%3DM.%26aulast%3DCandeletti%26aufirst%3DS.%26aulast%3DRomualdi%26aufirst%3DP.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DBrain%2520interstitial%2520nociceptin%252Forphanin%2520FQ%2520levels%2520are%2520elevated%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2010%26volume%3D25%26spage%3D1723%26epage%3D1732%26doi%3D10.1002%2Fmds.23271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Pernaute, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2008.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.nbd.2008.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=18413287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlShs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=430-438&author=R.+Viaroauthor=R.+Sanchez-Pernauteauthor=M.+Martiauthor=C.+Trapellaauthor=O.+Isacsonauthor=M.+Morari&title=Nociceptin%2Forphanin+FQ+receptor+blockade+attenuates+MPTP-induced+parkinsonism&doi=10.1016%2Fj.nbd.2008.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism</span></div><div class="casAuthors">Viaro, Riccardo; Sanchez-Pernaute, Rosario; Marti, Matteo; Trapella, Claudio; Isacson, Ole; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Endogenous nociceptin/orphanin FQ (N/OFQ) inhibits the activity of dopamine neurons in the substantia nigra and affects motor behavior.  In this study we investigated whether a N/OFQ receptor (NOP) antagonist, J-113397, can modify movement in naive mice and nonhuman primates and attenuate motor deficits in MPTP-treated parkinsonian animals.  J-113397 facilitated motor activity in naive mice at low doses (0.1-1 mg/kg) and inhibited it at higher ones (10 mg/kg).  Likewise, in MPTP-treated mice, J-113397 reversed motor deficit at 0.01 mg/kg but worsened hypokinesia at higher doses (1 mg/kg).  In naive nonhuman primates, J-113397, ineffective up to 1 mg/kg, produced inconsistent motor improvements at 3 mg/kg.  Conversely, in parkinsonian primates J-113397 (0.01 mg/kg) reversed parkinsonism, being most effective against hypokinesia.  We conclude that endogenous N/OFQ modulates motor activity in mice and nonhuman primates and contributes to parkinsonian symptoms in MPTP-treated animals.  NOP receptor antagonists may represent a novel approach to Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW6b77UNWC3rVg90H21EOLACvtfcHk0liosfai3iavMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlShs7s%253D&md5=52c63df34902638af353e5de9146eb0d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2008.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2008.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DViaro%26aufirst%3DR.%26aulast%3DSanchez-Pernaute%26aufirst%3DR.%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DIsacson%26aufirst%3DO.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DNociceptin%252Forphanin%2520FQ%2520receptor%2520blockade%2520attenuates%2520MPTP-induced%2520parkinsonism%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2008%26volume%3D30%26spage%3D430%26epage%3D438%26doi%3D10.1016%2Fj.nbd.2008.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2010.07061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fj.1471-4159.2010.07061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=20950413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1aiurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=1543-1555&author=M.+Voltaauthor=O.+S.+Mabroukauthor=S.+Bidoauthor=M.+Martiauthor=M.+Morari&title=Further+evidence+for+an+involvement+of+nociceptin%2Forphanin+FQ+in+the+pathophysiology+of+Parkinson%E2%80%99s+disease%3A+a+behavioral+and+neurochemical+study+in+reserpinized+mice&doi=10.1111%2Fj.1471-4159.2010.07061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice</span></div><div class="casAuthors">Volta, Mattia; Mabrouk, Omar S.; Bido, Simone; Marti, Matteo; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1543-1555</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The contribution of nociceptin/orphanin FQ (N/OFQ) to reserpine-induced Parkinsonism was evaluated in mice.  A battery of motor tests revealed that reserpine caused dose-dependent and long-lasting motor impairment.  Endogenous N/OFQ sustained this response because N/OFQ peptide (NOP) receptor knockout (NOP-/-) mice were less susceptible to the hypokinetic action of reserpine than wild-type (NOP+/+) animals.  Microdialysis revealed that reserpine elevated glutamate and reduced GABA levels in substantia nigra reticulata, and that resistance to reserpine in NOP-/- mice was accompanied by a milder increase in glutamate and lack of inhibition of GABA levels.  To substantiate this genetic evidence, the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397) simultaneously reduced akinesia and nigral glutamate levels in reserpinized NOP+/+ mice, being ineffective in NOP-/- mice.  Moreover, repeated J-113397 administration in reserpinized mice resulted in faster recovery of baseline motor performance which was, however, accompanied by a loss of acute antiakinetic response.  The short-term beneficial effect of J-113397 was paralleled by normalization of nigral glutamate levels, whereas loss of acute response was paralleled by loss of the ability of J-113397 to inhibit glutamate levels.  We conclude that endogenous N/OFQ contributes to reserpine-induced Parkinsonism, and that sustained NOP receptor blockade produces short-term motor improvement accompanied by normalization of nigral glutamate release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-bDGcPmUmbVg90H21EOLACvtfcHk0liosfai3iavMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1aiurvO&md5=61432a975590486fcdf203b3c291480c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2010.07061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2010.07061.x%26sid%3Dliteratum%253Aachs%26aulast%3DVolta%26aufirst%3DM.%26aulast%3DMabrouk%26aufirst%3DO.%2BS.%26aulast%3DBido%26aufirst%3DS.%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DFurther%2520evidence%2520for%2520an%2520involvement%2520of%2520nociceptin%252Forphanin%2520FQ%2520in%2520the%2520pathophysiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520behavioral%2520and%2520neurochemical%2520study%2520in%2520reserpinized%2520mice%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D115%26spage%3D1543%26epage%3D1555%26doi%3D10.1111%2Fj.1471-4159.2010.07061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernagut, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson’s disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2016.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.nbd.2016.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=26804029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=55-64&author=L.+Arcuriauthor=R.+Viaroauthor=S.+Bidoauthor=F.+Longoauthor=M.+Calcagnoauthor=P.+O.+Fernagutauthor=N.+T.+Zaveriauthor=G.+Caloauthor=E.+Bezardauthor=M.+Morari&title=Genetic+and+pharmacological+evidence+that+endogenous+nociceptin%2Forphanin+FQ+contributes+to+dopamine+cell+loss+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2016.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease</span></div><div class="casAuthors">Arcuri, Ludovico; Viaro, Riccardo; Bido, Simone; Longo, Francesco; Calcagno, Mariangela; Fernagut, Pierre-Olivier; Zaveri, Nurulain T.; Calo, Girolamo; Bezard, Erwan; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-64</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To investigate whether the endogenous neuropeptide nociceptin/orphanin FQ N/OFQ contributes to the death of dopamine neurons in Parkinson's disease, we undertook a genetic and a pharmacol. approach using NOP receptor knockout NOP-/- mice, and the selective and potent small mol. NOP receptor antagonist - -cis-1-methyl-7-[[4-2,6-dichlorophenylpiperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol SB-612111.  Stereol. unbiased methods were used to est. the total no. of dopamine neurons in the substantia nigra of i) NOP-/- mice acutely treated with the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine MPTP, ii) naive mice subacutely treated with MPTP, alone or in combination with SB-612111, iii) rats injected with a recombinant adeno-assocd. viral AAV vector overexpressing human mutant p.  A53T α-synuclein, treated with vehicle or SB-612111.  NOP-/- mice showed a 50% greater amt. of nigral dopamine neurons spared in response to acute MPTP compared to controls, which was assocd. with a milder motor impairment.  SB-612111, given 4 days after MPTP treatment to mimic the clin. condition, prevented the loss of nigral dopamine neurons and striatal dopaminergic terminals caused by subacute MPTP.  SB-612111, administered a week after the AAV injections in a clin.-driven protocol, also increased by 50% both the no. of spared nigral dopamine neurons and striatal dopamine terminals, and prevented accompanying motor deficits induced by α-synuclein.  We conclude that endogenous N/OFQ contributes to dopamine neuron loss in pathogenic and etiol. models of Parkinson's disease through NOP receptor-mediated mechanisms.  NOP receptor antagonists might prove effective as disease-modifying agents in Parkinson's disease, through the rescue of degenerating nigral dopamine neurons and/or the protection of the healthy ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQC28OAfV4JLVg90H21EOLACvtfcHk0liosfai3iavMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOns74%253D&md5=afaf23fce49242261f565087b6201996</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DArcuri%26aufirst%3DL.%26aulast%3DViaro%26aufirst%3DR.%26aulast%3DBido%26aufirst%3DS.%26aulast%3DLongo%26aufirst%3DF.%26aulast%3DCalcagno%26aufirst%3DM.%26aulast%3DFernagut%26aufirst%3DP.%2BO.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DCalo%26aufirst%3DG.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DGenetic%2520and%2520pharmacological%2520evidence%2520that%2520endogenous%2520nociceptin%252Forphanin%2520FQ%2520contributes%2520to%2520dopamine%2520cell%2520loss%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2016%26volume%3D89%26spage%3D55%26epage%3D64%26doi%3D10.1016%2Fj.nbd.2016.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1683</span>– <span class="NLM_lpage">1696</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05735.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fj.1471-4159.2008.05735.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=19014386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1SrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2008&pages=1683-1696&author=M.+Martiauthor=C.+Trapellaauthor=M.+Morari&title=The+novel+nociceptin%2Forphanin+FQ+receptor+antagonist+Trap-101+alleviates+experimental+parkinsonism+through+inhibition+of+the+nigro-thalamic+pathway%3A+positive+interaction+with+L-DOPA&doi=10.1111%2Fj.1471-4159.2008.05735.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA</span></div><div class="casAuthors">Marti, Matteo; Trapella, Claudio; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1683-1696</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In this study we investigated whether the recently discovered antagonist of the nociceptin/orphanin FQ (N/OFQ) opioid peptide (NOP) receptor, 1-[1-(cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (Trap-101) changed motor activity in naive rats and mice, and alleviated parkinsonism in 6-hydroxydopamine hemilesioned rats.  In naive rats, Trap-101 stimulated motor activity at 10 mg/kg and inhibited it at 30 mg/Kg.  Such dual action was also obsd. in wild-type but not NOP receptor knockout mice suggesting specific involvement of NOP receptors.  Trap-101 alleviated akinesia/bradykinesia and improved overall gait ability in hemiparkinsonian rats, being effective starting at 1 mg/Kg and without worsening motor deficit at 30 mg/Kg.  To investigate the circuitry involved in the Trap-101 action, behavioral tests were performed in rats undergoing microdialysis.  The anti-akinetic/anti-bradykinetic effects of Trap-101, given systemically (10 mg/Kg) or perfused in substantia nigra reticulata (10 μM), were assocd. with reduced glutamate and enhanced GABA release in substantia nigra, and reduced GABA release in ipsilateral ventro-medial thalamus.  When combined with ineffective doses of L-DOPA (0.1 mg/Kg), Trap-101 evoked larger neurochem. and behavioral responses.  These data show that Trap-101 is an effective NOP receptor antagonist in vivo and confirm that NOP receptor antagonists alleviate parkinsonism through blockade of nigral NOP receptors and impairment of nigro-thalamic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn1My6a_g6WLVg90H21EOLACvtfcHk0lgkn-1RgZPtAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1SrtA%253D%253D&md5=5cc7eea58031e06842f19b8b7750dede</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05735.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05735.x%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DThe%2520novel%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520antagonist%2520Trap-101%2520alleviates%2520experimental%2520parkinsonism%2520through%2520inhibition%2520of%2520the%2520nigro-thalamic%2520pathway%253A%2520positive%2520interaction%2520with%2520L-DOPA%26jtitle%3DJ.%2520Neurochem.%26date%3D2008%26volume%3D107%26spage%3D1683%26epage%3D1696%26doi%3D10.1111%2Fj.1471-4159.2008.05735.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1297</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4346-06.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.4346-06.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=17287504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFCrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1297-1307&author=M.+Martiauthor=C.+Trapellaauthor=R.+Viaroauthor=M.+Morari&title=The+nociceptin%2Forphanin+FQ+receptor+antagonist+J-113397+and+L-DOPA+additively+attenuate+experimental+parkinsonism+through+overinhibition+of+the+nigrothalamic+pathway&doi=10.1523%2FJNEUROSCI.4346-06.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway</span></div><div class="casAuthors">Marti, Matteo; Trapella, Claudio; Viaro, Riccardo; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1297-1307</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">By using a battery of behavioral tests, we showed that nociceptin/orphanin FQ receptor (NOP receptor) antagonists attenuated parkinsonian-like symptoms in 6-hydroxydopamine hemilesioned rats.  We now present evidence that coadministration of the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397) and L-DOPA to 6-hydroxydopamine hemilesioned rats produced an additive attenuation of parkinsonism.  To investigate the neurobiol. substrates underlying this interaction, in vivo microdialysis was used in combination with behavioral measurements (bar test).  J-113397 and L-DOPA alone reduced the time on bars (i.e., attenuated akinesia) and elevated GABA release selectively in the lesioned substantia nigra reticulata.  J-113397 also reduced nigral glutamate levels, whereas L-DOPA was ineffective.  J-113397 and L-DOPA coadministration produced additive antiakinetic effect, which was assocd. with additive increase in nigral GABA release but no addnl. redns. in glutamate levels.  To investigate whether the increase in nigral GABA release could translate to changes in nigrothalamic transmission, GABA release was monitored in the ventromedial thalamus (one of the main target areas of the nigrothalamic projections).  J-113397 and L-DOPA decreased thalamic GABA release and attenuated akinesia, their combination resulting in a more profound effect.  These actions were prevented by perfusing the voltage-dependent Na+ channel blocker tetrodotoxin or the GABAA receptor antagonist bicuculline in the substantia nigra reticulata.  These data demonstrate that J-113397 and L-DOPA exert their antiparkinsonian action through overinhibition of nigrothalamic transmission and suggest that NOP receptor antagonists may be useful as an adjunct to L-DOPA therapy for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN4g43DttoNbVg90H21EOLACvtfcHk0lgkn-1RgZPtAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFCrtbo%253D&md5=6673bca29e2122f6d5e8c37db5bf014c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4346-06.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4346-06.2007%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DViaro%26aufirst%3DR.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DThe%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520antagonist%2520J-113397%2520and%2520L-DOPA%2520additively%2520attenuate%2520experimental%2520parkinsonism%2520through%2520overinhibition%2520of%2520the%2520nigrothalamic%2520pathway%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D1297%26epage%3D1307%26doi%3D10.1523%2FJNEUROSCI.4346-06.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morella, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Nociceptin/Orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">16106</span>– <span class="NLM_lpage">16119</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.6408-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.6408-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=23152595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslagur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=16106-16119&author=M.+Martiauthor=D.+Rodiauthor=Q.+Liauthor=R.+Guerriniauthor=S.+Fasanoauthor=I.+Morellaauthor=A.+Tozziauthor=R.+Brambillaauthor=P.+Calabresiauthor=M.+Simonatoauthor=E.+Bezardauthor=M.+Morari&title=Nociceptin%2FOrphanin+FQ+receptor+agonists+attenuate+L-DOPA-induced+dyskinesias&doi=10.1523%2FJNEUROSCI.6408-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias</span></div><div class="casAuthors">Marti, Matteo; Rodi, Donata; Li, Qin; Guerrini, Remo; Fasano, Stefania; Morella, Ilaria; Tozzi, Alessandro; Brambilla, Riccardo; Calabresi, Paolo; Simonato, Michele; Bezard, Erwan; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16106-16119</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">In the present study we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogenesis of Parkinson's disease, also affects L-DOPA-induced dyskinesia.  In striatal slices of naive rodents, N/OFQ (0.1-1 μM) prevented the increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist SKF38393 in spiny neurons.  In vivo, exogenous N/OFQ (0.03-1 nmol, i.c.v.) or a synthetic N/OFQ receptor agonist given systemically (0.01-1 mg/Kg) attenuated dyskinesias expression in 6-hydroxydopamine hemilesioned rats primed with L-DOPA, without causing primary hypolocomotive effects.  Conversely, N/OFQ receptor antagonists worsened dyskinesia expression.  In vivo microdialysis revealed that N/OFQ prevented dyskinesias simultaneously with its neurochem. correlates such as the surge of nigral GABA and glutamate, and the redn. of thalamic GABA.  Regional microinjections revealed that N/OFQ attenuated dyskinesias more potently and effectively when microinjected in striatum than substantia nigra (SN) reticulata, whereas N/OFQ receptor antagonists were ineffective in striatum but worsened dyskinesias when given in SN.  Quant. autoradiog. showed an increase in N/OFQ receptor binding in striatum and a redn. in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ transmission.  Finally, the N/OFQ receptor synthetic agonist also reduced dyskinesia expression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score.  We conclude that N/OFQ receptor agonists may represent a novel strategy to counteract L-DOPA-induced dyskinesias.  Their action is possibly mediated by upregulated striatal N/OFQ receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnovy4WPkPeLVg90H21EOLACvtfcHk0lgkn-1RgZPtAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslagur%252FK&md5=bb6549fe6190a16521bd73fbb4c95f57</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6408-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6408-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DRodi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DGuerrini%26aufirst%3DR.%26aulast%3DFasano%26aufirst%3DS.%26aulast%3DMorella%26aufirst%3DI.%26aulast%3DTozzi%26aufirst%3DA.%26aulast%3DBrambilla%26aufirst%3DR.%26aulast%3DCalabresi%26aufirst%3DP.%26aulast%3DSimonato%26aufirst%3DM.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DNociceptin%252FOrphanin%2520FQ%2520receptor%2520agonists%2520attenuate%2520L-DOPA-induced%2520dyskinesias%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26spage%3D16106%26epage%3D16119%26doi%3D10.1523%2FJNEUROSCI.6408-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frassineti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercatelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morella, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Journigan, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1111/bph.14123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fbph.14123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=29232769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=782-796&author=L.+Arcuriauthor=S.+Novelloauthor=M.+Frassinetiauthor=D.+Mercatelliauthor=C.+A.+Pisanoauthor=I.+Morellaauthor=S.+Fasanoauthor=B.+V.+Journiganauthor=M.+E.+Meyerauthor=W.+E.+Polgarauthor=R.+Brambillaauthor=N.+T.+Zaveriauthor=M.+Morari&title=Anti-Parkinsonian+and+anti-dyskinetic+profiles+of+two+novel+potent+and+selective+nociceptin%2Forphanin+FQ+receptor+agonists&doi=10.1111%2Fbph.14123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists</span></div><div class="casAuthors">Arcuri, Ludovico; Novello, Salvatore; Frassineti, Martina; Mercatelli, Daniela; Pisano, Clarissa Anna; Morella, Ilaria; Fasano, Stefania; Journigan, Blair V.; Meyer, Michael E.; Polgar, Willma E.; Brambilla, Riccardo; Zaveri, Nurulain T.; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">782-796</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : We previously showed that nociceptin/orphanin FQ opioid peptide (NOP) receptor agonists attenuate the expression of levodopa-induced dyskinesia in animal models of Parkinson's disease.  We now investigate the efficacy of two novel, potent and chem. distinct NOP receptor agonists, AT-390 and AT-403, to improve Parkinsonian disabilities and attenuate dyskinesia development and expression.  Exptl. Approach : Binding affinity and functional efficacy of AT-390 and AT-403 at the opioid receptors were detd. in radioligand displacement assays and in GTPγS binding assays resp., conducted in CHO cells.  Their anti-Parkinsonian activity was evaluated in 6-hydroxydopamine hemi-lesioned rats whereas the anti-dyskinetic properties were assessed in 6-hydroxydopamine hemi-lesioned rats chronically treated with levodopa.  The ability of AT-403 to inhibit the D1 receptor-induced phosphorylation of striatal ERK was investigated.  Key Results : AT-390 and AT-403 selectively improved akinesia at low doses and disrupted global motor activity at higher doses.  AT-403 palliated dyskinesia expression without causing sedation in a narrow therapeutic window, whereas AT-390 delayed the appearance of abnormal involuntary movements and increased their duration at doses causing sedation.  AT-403 did not prevent the priming to levodopa, although it significantly inhibited dyskinesia on the first day of administration.  AT-403 reduced the ERK phosphorylation induced by SKF38393 in vitro and by levodopa in vivo.  Conclusions and Implications : NOP receptor stimulation can provide significant albeit mild anti-dyskinetic effect at doses not causing sedation.  The therapeutic window, however, varies across compds.  AT-403 could be a potent and selective tool to investigate the role of NOP receptors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6ckNvBacmO7Vg90H21EOLACvtfcHk0lhKmtAW_m3vQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGisr8%253D&md5=1c0951920fee339d8765a8c63b836627</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fbph.14123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14123%26sid%3Dliteratum%253Aachs%26aulast%3DArcuri%26aufirst%3DL.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DFrassineti%26aufirst%3DM.%26aulast%3DMercatelli%26aufirst%3DD.%26aulast%3DPisano%26aufirst%3DC.%2BA.%26aulast%3DMorella%26aufirst%3DI.%26aulast%3DFasano%26aufirst%3DS.%26aulast%3DJournigan%26aufirst%3DB.%2BV.%26aulast%3DMeyer%26aufirst%3DM.%2BE.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DBrambilla%26aufirst%3DR.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DAnti-Parkinsonian%2520and%2520anti-dyskinetic%2520profiles%2520of%2520two%2520novel%2520potent%2520and%2520selective%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520agonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D782%26epage%3D796%26doi%3D10.1111%2Fbph.14123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2973</span>– <span class="NLM_lpage">2976</span>, <span class="refDoi"> DOI: 10.1021/jm034249d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034249d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Sjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2973-2976&author=N.+T.+Zaveriauthor=F.+Jiangauthor=C.+M.+Olsenauthor=J.+R.+Deschampsauthor=D.+Parrishauthor=W.+Polgarauthor=L.+Toll&title=A+novel+series+of+piperidin-4-yl-1%2C3-dihydroindol-2-ones+as+agonist+and+antagonist+ligands+at+the+nociceptin+receptor&doi=10.1021%2Fjm034249d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor</span></div><div class="casAuthors">Zaveri, Nurulain T.; Jiang, Faming; Olsen, Cris M.; Deschamps, Jeffrey R.; Parrish, Damon; Polgar, Willma; Toll, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2973-2976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-(4-piperidinyl)-2-indolinones were discovered as a new structural class of nociceptin receptor (NOP) ligands.  Unlike other previously reported classes of NOP receptor ligands, modifications of the piperidine N substituents afforded both potent agonists and antagonists, with modest selectivities over other opioid receptors.  The SAR revealed in this new series will provide important insights for the development of pharmacophores for agonist and antagonist actions at the NOP receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouCteePy22mbVg90H21EOLACvtfcHk0lhKmtAW_m3vQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Sjs7s%253D&md5=f7988bb47141c9055b43c47eadf06bba</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm034249d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034249d%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%2BM.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DParrish%26aufirst%3DD.%26aulast%3DPolgar%26aufirst%3DW.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DA%2520novel%2520series%2520of%2520piperidin-4-yl-1%252C3-dihydroindol-2-ones%2520as%2520agonist%2520and%2520antagonist%2520ligands%2520at%2520the%2520nociceptin%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2973%26epage%3D2976%26doi%3D10.1021%2Fjm034249d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">E345</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1208/aapsj070234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1208%2Faapsj070234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=16353914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ylt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=E345-352&author=N.+Zaveriauthor=F.+Jiangauthor=C.+Olsenauthor=W.+Polgarauthor=L.+Toll&title=Small-molecule+agonists+and+antagonists+of+the+opioid+receptor-like+receptor+%28ORL1%2C+NOP%29%3A+ligand-based+analysis+of+structural+factors+influencing+intrinsic+activity+at+NOP&doi=10.1208%2Faapsj070234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP</span></div><div class="casAuthors">Zaveri, Nurulain; Jiang, Faming; Olsen, Cris; Polgar, Willma; Toll, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E345-E352</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">American Association of Pharmaceutical Scientists</span>)
        </div><div class="casAbstract">A review.  The recently discovered fourth member of the opioid receptor family, the nociceptin receptor (NOP) and its endogenous ligand, the heptadecapeptide nociceptin, are involved in several central nervous system pathways, such as nociception, reward, tolerance, and feeding.  The discovery of small-mol. ligands for NOP is being actively pursued for several therapeutic applications.  This review presents a brief overview of the several recently reported NOP ligands, classified as NOP agonists and antagonists, with an emphasis on the anal. of the structural features that may be important for modulating the agonist/antagonist profile (intrinsic activity) of these ligands.  Structure-activity relationships in our own series of dihydroindolinone-based NOP ligands and those of the various reported ligands indicate that the lipophilic substituent on the common basic nitrogen present in all NOP ligands plays a role in detg. the agonist/antagonist profile of the NOP ligand.  This anal. provides a basis for the rational drug design of NOP ligands of desired intrinsic activity and provides a framework for developing pharmacophore models for high affinity binding and intrinsic activity at the NOP receptor.  Since NOP agonists and antagonists both have therapeutic value, rational approaches for obtaining both within a high-affinity binding class of compds. are very useful for designing potent and selective NOP ligands with the desired profile of intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4wQ41VBI3hrVg90H21EOLACvtfcHk0lg_ymzURkqcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ylt7bJ&md5=edfd4b8d20d0e33e6f64d970092d5604</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1208%2Faapsj070234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Faapsj070234%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%26aulast%3DPolgar%26aufirst%3DW.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DSmall-molecule%2520agonists%2520and%2520antagonists%2520of%2520the%2520opioid%2520receptor-like%2520receptor%2520%2528ORL1%252C%2520NOP%2529%253A%2520ligand-based%2520analysis%2520of%2520structural%2520factors%2520influencing%2520intrinsic%2520activity%2520at%2520NOP%26jtitle%3DAAPS%2520J.%26date%3D2005%26volume%3D7%26spage%3DE345%26epage%3D352%26doi%3D10.1208%2Faapsj070234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Journigan, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khroyan, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2508</span>– <span class="NLM_lpage">2516</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmc.2014.02.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=24657054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC2crmt1Ghtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2508-2516&author=V.+B.+Journiganauthor=W.+E.+Polgarauthor=T.+V.+Khroyanauthor=N.+T.+Zaveri&title=Designing+bifunctional+NOP+receptor-mu+opioid+receptor+ligands+from+NOP-receptor+selective+scaffolds.+Part+II&doi=10.1016%2Fj.bmc.2014.02.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II</span></div><div class="casAuthors">Journigan V Blair; Polgar Willma E; Khroyan Taline V; Zaveri Nurulain T</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2508-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The nociceptin opioid receptor (NOP) and its endogenous peptide ligand nociceptin/orphanin FQ have been shown to modulate the pharmacological effects of the classical opioid receptor system.  Suppression of opioid-induced reward associated with mu-opioid receptor (MOP)-mediated analgesia, without decreasing anti-nociceptive efficacy, can potentially be achieved with NOP agonists having bifunctional agonist activity at MOP, to afford 'non-addicting' analgesics.  In Part II of this series, we describe a continuing structure-activity relationship (SAR) study of the NOP-selective piperidin-4-yl-1,3-dihydroindol-2-one scaffold, to obtain bifunctional activity at MOP, and a suitable ratio of NOP/MOP agonist activity that produces a non-addicting analgesic profile.  The SAR reported here is focused on the influence of various piperidine nitrogen aromatic substituents on the ratio of binding affinity and intrinsic activity at both the NOP and MOP receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4csBsHOuCWtenUz0lpNqnfW6udTcc2eY70aswC6Fxcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmt1Ghtw%253D%253D&md5=64cd0c7b12508a4dfc24f4a875e32cc9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.047%26sid%3Dliteratum%253Aachs%26aulast%3DJournigan%26aufirst%3DV.%2BB.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DKhroyan%26aufirst%3DT.%2BV.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DDesigning%2520bifunctional%2520NOP%2520receptor-mu%2520opioid%2520receptor%2520ligands%2520from%2520NOP-receptor%2520selective%2520scaffolds.%2520Part%2520II%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2508%26epage%3D2516%26doi%3D10.1016%2Fj.bmc.2014.02.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larock, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yum, E. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6690</span>, <span class="refDoi"> DOI: 10.1021/ja00017a059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00017a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1991&pages=6689-6690&author=R.+C.+Larockauthor=E.+K.+Yum&title=Synthesis+of+indoles+via+palladium-catalyzed+heteroannulation+of+internal+alkynes&doi=10.1021%2Fja00017a059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes</span></div><div class="casAuthors">Larock, Richard C.; Yum, Eul Kgun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6689-90</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">2,3-Disubstituted indoles are formed in high yields by the Pd-catalyzed annulation of internal alkynes by o-IC6H4NH2 and its derivs.  The reaction is highly regioselective and tolerates alkynes bearing aryl, alc. and silyl groups, as well as C:C bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_hHxDmTHKLVg90H21EOLACvtfcHk0lg_ymzURkqcqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D&md5=498dd4febb8eba7e5903cd02b9258a16</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00017a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00017a059%26sid%3Dliteratum%253Aachs%26aulast%3DLarock%26aufirst%3DR.%2BC.%26aulast%3DYum%26aufirst%3DE.%2BK.%26atitle%3DSynthesis%2520of%2520indoles%2520via%2520palladium-catalyzed%2520heteroannulation%2520of%2520internal%2520alkynes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1991%26volume%3D113%26spage%3D6689%26epage%3D6690%26doi%3D10.1021%2Fja00017a059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2732</span>– <span class="NLM_lpage">2743</span>, <span class="refDoi"> DOI: 10.1021/ci500291a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500291a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=2732-2743&author=P.+R.+Dagaauthor=W.+E.+Polgarauthor=N.+T.+Zaveri&title=Structure-based+virtual+screening+of+the+nociceptin+receptor%3A+hybrid+docking+and+shape-based+approaches+for+improved+hit+identification&doi=10.1021%2Fci500291a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification</span></div><div class="casAuthors">Daga, Pankaj R.; Polgar, Willma E.; Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2732-2743</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antagonist-bound crystal structure of the nociceptin receptor (NOP), from the opioid receptor family, was recently reported along with those of the other opioid receptors bound to opioid antagonists.  We recently reported the first homol. model of the 'active-state' of the NOP receptor, which when docked with 'agonist' ligands showed differences in the TM helixes and residues, consistent with GPCR activation after agonist binding.  In this study, we explored the use of the active-state NOP homol. model for structure-based virtual screening to discover NOP ligands contg. new chem. scaffolds.  Several NOP agonist and antagonist ligands previously reported are based on a common piperidine scaffold.  Given the structure-activity relationships for known NOP ligands, we developed a hybrid method that combines a structure-based and ligand-based approach, utilizing the active-state NOP receptor as well as the pharmacophoric features of known NOP ligands, to identify novel NOP binding scaffolds by virtual screening.  Multiple conformations of the NOP active site including the flexible second extracellular loop (EL2) loop were generated by simulated annealing and ranked using enrichment factor (EF) anal. and a ligand-decoy dataset contg. known NOP agonist ligands.  The enrichment factors were further improved by combining shape-based screening of this ligand-decoy dataset and calcn. of consensus scores.  This combined structure-based and ligand-based EF anal. yielded higher enrichment factors than the individual methods, suggesting the effectiveness of the hybrid approach.  Virtual screening of the CNS Permeable subset of the ZINC database was carried out using the above-mentioned hybrid approach in a tiered fashion utilizing a ligand pharmacophore-based filtering step, followed by structure-based virtual screening using the refined NOP active-state models from the enrichment anal.  Detn. of the NOP receptor binding affinity of a selected set of top-scoring hits resulted in identification of several compds. with measurable binding affinity at the NOP receptor, one of which had a new chemotype for NOP receptor binding.  The hybrid ligand-based and structure-based methodol. demonstrates an effective approach for virtual screening that leverages existing SAR and receptor structure information for identifying novel hits for NOP receptor binding.  The refined active-state NOP homol. models obtained from the enrichment studies can be further used for structure-based optimization of these new chemotypes to obtain potent and selective NOP receptor ligands for therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXm5v3VfXyVbVg90H21EOLACvtfcHk0lj_2tLMwBCc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLbO&md5=ab818a07f155109601a2c16a819e5aba</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fci500291a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500291a%26sid%3Dliteratum%253Aachs%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DStructure-based%2520virtual%2520screening%2520of%2520the%2520nociceptin%2520receptor%253A%2520hybrid%2520docking%2520and%2520shape-based%2520approaches%2520for%2520improved%2520hit%2520identification%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D2732%26epage%3D2743%26doi%3D10.1021%2Fci500291a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khroyan, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.157446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1124%2Fjpet.109.157446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=19773529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=954-964&author=L.+Tollauthor=T.+V.+Khroyanauthor=W.+E.+Polgarauthor=F.+Jiangauthor=C.+Olsenauthor=N.+T.+Zaveri&title=Comparison+of+the+antinociceptive+and+antirewarding+profiles+of+novel+bifunctional+nociceptin+receptor%2Fmu-opioid+receptor+ligands%3A+implications+for+therapeutic+applications&doi=10.1124%2Fjpet.109.157446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/μ-opioid receptor ligands: implications for therapeutic applications</span></div><div class="casAuthors">Toll, Lawrence; Khroyan, Taline V.; Polgar, Willma E.; Jiang, Faming; Olsen, Cris; Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">954-964</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The nociceptin receptor (NOPr), a member of the opioid receptor family, is a target for the treatment of pain and drug abuse.  Nociceptin/orphanin FQ (N/OFQ), the endogenous peptide for NOPr, not only modulates opioid antinociception, but also blocks the rewarding effects of several abused drugs, such as morphine, cocaine, and amphetamine.  We hypothesized that NOPr agonists, with bifunctional activity at the μ-opioid receptor (MOPr), may function as nonaddicting analgesics or as drug abuse medications.  Bifunctional small-mol. NOPr agonists possessing different selectivities and efficacies at MOPr were evaluated in an acute thermal antinociception assay, and for their ability to induce conditioned place preference (CPP) and their effect on morphine-induced CPP.  1-(1-Cyclooctylpiperidin-4-yl)-indolin-2-one (SR14150), a high-affinity NOPr partial agonist, with low MOPr affinity and efficacy, produced analgesia that was naloxone-reversible.  SR14150 did not induce CPP alone, nor did it attenuate morphine-induced CPP.  3-Ethyl-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-indolin-2-one (SR16507), which has high affinity for both NOPr and MOPr, full agonist activity at NOPr, and partial agonist activity at MOPr, was also a potent analgesic and produced CPP alone, but also modestly attenuated morphine CPP.  1-(1-(2,3,3A,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl)-indolin-2-one (SR16835), a NOPr full agonist and low-affinity MOPr partial agonist, was not antinociceptive, did not produce CPP alone, but attenuated morphine CPP.  Our results suggest that NOPr full-agonist activity is required to modulate opioid-induced reward, whereas a bifunctional NOPr/MOPr partial agonist profile may be suitable as a nonaddicting analgesic.  The opioid-modulating effects of the NOPr ligands may be used effectively to produce better medications for treatment of drug abuse and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSq0nyX8esa7Vg90H21EOLACvtfcHk0lj_2tLMwBCc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsLrI&md5=d9386f73b81e02a7afddf8efe6cba83a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.157446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.157446%26sid%3Dliteratum%253Aachs%26aulast%3DToll%26aufirst%3DL.%26aulast%3DKhroyan%26aufirst%3DT.%2BV.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DComparison%2520of%2520the%2520antinociceptive%2520and%2520antirewarding%2520profiles%2520of%2520novel%2520bifunctional%2520nociceptin%2520receptor%252Fmu-opioid%2520receptor%2520ligands%253A%2520implications%2520for%2520therapeutic%2520applications%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D954%26epage%3D964%26doi%3D10.1124%2Fjpet.109.157446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7011</span>– <span class="NLM_lpage">7028</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7011-7028&author=N.+T.+Zaveri&title=Nociceptin+opioid+receptor+%28NOP%29+as+a+therapeutic+target%3A+progress+in+translation+from+preclinical+research+to+clinical+utility&doi=10.1021%2Facs.jmedchem.5b01499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility</span></div><div class="casAuthors">Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7011-7028</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in understanding the pharmacol. of this fourth opioid receptor/peptide system, aided by genetic and pharmacol. approaches.  This research spawned an explosion of small-mol. NOP receptor ligands from discovery programs in major pharmaceutical companies.  NOP agonists have been investigated for their efficacy in preclin. models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investigated for treatment of pain, depression, and motor symptoms in Parkinson's disease.  Translation of preclin. findings into the clinic is guided by PET and receptor occupancy studies, particularly for NOP antagonists.  Recent progress in preclin. NOP research suggests that NOP agonists may have clin. utility for pain treatment and substance abuse pharmacotherapy.  This review discusses the progress toward validating the NOP-N/OFQ system as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo51w0U-7QparVg90H21EOLACvtfcHk0lj_2tLMwBCc3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D&md5=b9746257e225a423dfa0539d8bf407c9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01499%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DNociceptin%2520opioid%2520receptor%2520%2528NOP%2529%2520as%2520a%2520therapeutic%2520target%253A%2520progress%2520in%2520translation%2520from%2520preclinical%2520research%2520to%2520clinical%2520utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7011%26epage%3D7028%26doi%3D10.1021%2Facs.jmedchem.5b01499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. E.</span></span> <span> </span><span class="NLM_article-title">NOP-targeted nonpeptide ligands</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1007/164_2019_213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1007%2F164_2019_213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=31119463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ovVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2019&pages=37-67&author=N.+T.+Zaveriauthor=M.+E.+Meyer&title=NOP-targeted+nonpeptide+ligands&doi=10.1007%2F164_2019_213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">NOP-Targeted Nonpeptide Ligands</span></div><div class="casAuthors">Zaveri Nurulain T; Meyer Michael E</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of experimental pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-67</span>
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    </div><div class="casAbstract">The development of nonpeptide systemically active small-molecule NOP-targeted ligands has contributed tremendously to validating the NOP receptor as a promising target for therapeutics.  Although a NOP-targeted compound is not yet approved for clinical use, a few NOP ligands are in clinical trials for various indications.  Both successful and failed human clinical trials with NOP ligands provide opportunities for rational development of new and improved NOP-targeted compounds.  A few years after the discovery of the NOP receptor in 1994, and its de-orphanization upon discovery of the endogenous peptide nociceptin/orphanin FQ (N/OFQ) in 1995, there was a significant effort in the pharmaceutical industry to discover nonpeptide NOP ligands from hits obtained from high-throughput screening campaigns of compound libraries.  Depending on the therapeutic indication to be pursued, NOP agonists and antagonists were discovered, and some were optimized as clinical candidates.  Advances such as G protein-coupled receptor (GPCR) structure elucidation, functional selectivity in ligand-driven GPCR activation, and multi-targeted ligands provide new scope for the rational design of novel NOP ligands fine-tuned for successful clinical translation.  This article reviews the field of nonpeptide NOP ligand drug design in the context of these exciting developments and highlights new optimized nonpeptide NOP ligands possessing interesting functional profiles, which are particularly attractive for several unmet clinical applications involving NOP receptor pharmacomodulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjfDkAYiAhzdHxxy173TfNfW6udTcc2eYDh4vVlj1Lr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ovVahuw%253D%253D&md5=5ac6ba1888a1758743b9f765c4697b95</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F164_2019_213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2019_213%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DMeyer%26aufirst%3DM.%2BE.%26atitle%3DNOP-targeted%2520nonpeptide%2520ligands%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2019%26volume%3D254%26spage%3D37%26epage%3D67%26doi%3D10.1007%2F164_2019_213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bignan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, A. B.</span></span> <span> </span><span class="NLM_article-title">3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-2,3-b pyridines as ligands for the ORL-1 receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3524</span>– <span class="NLM_lpage">3528</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmcl.2006.03.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=16632355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2isb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3524-3528&author=G.+C.+Bignanauthor=K.+Battistaauthor=P.+J.+Connollyauthor=M.+J.+Orsiniauthor=J.+Liuauthor=S.+A.+Middletonauthor=A.+B.+Reitz&title=3-%284-Piperidinyl%29indoles+and+3-%284-piperidinyl%29pyrrolo-2%2C3-b+pyridines+as+ligands+for+the+ORL-1+receptor&doi=10.1016%2Fj.bmcl.2006.03.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo[2,3-b]pyridines as ligands for the ORL-1 receptor</span></div><div class="casAuthors">Bignan, Gilles C.; Battista, Kathleen; Connolly, Peter J.; Orsini, Michael J.; Liu, Jingchun; Middleton, Steven A.; Reitz, Allen B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3524-3528</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of indole and 1H-pyrrolo[2,3-b]pyridine derivs. having a piperidine ring at the 3-position, e.g. I [R1 = 5-Cl, 5-F, 6-Cl, 6-F, 7-Cl; R2 = PhCH2, cyclooctylmethyl, 1-naphthylmethyl, acenaphthenyl; R3 = H, PhCH2, (R)-H2NCH2CH(OH)CH2; R4 = H, Me] were synthesized and found to bind with high affinity to the ORL-1 receptor.  Structure-activity relationships at the piperidine nitrogen were investigated in each series.  Substitution on the Ph ring and nitrogen atom of the indole and 1H-pyrrolo[2,3-b]pyridine cores generated several selective high-affinity ligands that were agonists of the ORL-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMqfT3bCUKLVg90H21EOLACvtfcHk0liVclS2lKJRig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2isb4%253D&md5=504194268e48b7f4177b64c21ff59815</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.094%26sid%3Dliteratum%253Aachs%26aulast%3DBignan%26aufirst%3DG.%2BC.%26aulast%3DBattista%26aufirst%3DK.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DOrsini%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26atitle%3D3-%25284-Piperidinyl%2529indoles%2520and%25203-%25284-piperidinyl%2529pyrrolo-2%252C3-b%2520pyridines%2520as%2520ligands%2520for%2520the%2520ORL-1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3524%26epage%3D3528%26doi%3D10.1016%2Fj.bmcl.2006.03.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. H.</span></span> <span> </span><span class="NLM_article-title">A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmcl.2014.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=25556095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=602-606&author=T.+M.+Rossauthor=K.+Battistaauthor=G.+C.+Bignanauthor=D.+E.+Brennemanauthor=P.+J.+Connollyauthor=J.+Liuauthor=S.+A.+Middletonauthor=M.+Orsiniauthor=A.+B.+Reitzauthor=D.+I.+Rosenthalauthor=M.+K.+Scottauthor=A.+H.+Vaidya&title=A+selective+small+molecule+NOP+%28ORL-1+receptor%29+partial+agonist+for+the+treatment+of+anxiety&doi=10.1016%2Fj.bmcl.2014.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety</span></div><div class="casAuthors">Ross, Tina Morgan; Battista, Kathleen; Bignan, Gilles C.; Brenneman, Doug E.; Connolly, Peter J.; Liu, Jingchun; Middleton, Steven A.; Orsini, Michael; Reitz, Allen B.; Rosenthal, Dan I.; Scott, Malcolm K.; Vaidya, Anil H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">602-606</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Small mol. (1) has been identified as a selective partial agonist of Opioid Receptor Like-1 (ORL-1) with potential utility for the treatment of anxiety and other disorders.  Nociceptin (orphanin FQ) is an endogenous peptide ligand that binds to ORL-1, however it does not bind the classical δ, μ and κ opioid receptors with high affinity.  The synthesis of 1 involved using a mol. diversity approach, to rapidly advance a library of compds. for biol. testing.  A lead selective potent partial agonist (35-fold ORL-1/Mu) progressed to ORL-1 (NOP or OP4) proof of concept testing in advanced studies.  The synthetic approach and biol. data for the related chem. series will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcRIu1rC3L0bVg90H21EOLACvtfcHk0liVclS2lKJRig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFOqsg%253D%253D&md5=f7e2c4a636a9631ee9a0d0cbf554b3e0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DT.%2BM.%26aulast%3DBattista%26aufirst%3DK.%26aulast%3DBignan%26aufirst%3DG.%2BC.%26aulast%3DBrenneman%26aufirst%3DD.%2BE.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DOrsini%26aufirst%3DM.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26aulast%3DRosenthal%26aufirst%3DD.%2BI.%26aulast%3DScott%26aufirst%3DM.%2BK.%26aulast%3DVaidya%26aufirst%3DA.%2BH.%26atitle%3DA%2520selective%2520small%2520molecule%2520NOP%2520%2528ORL-1%2520receptor%2529%2520partial%2520agonist%2520for%2520the%2520treatment%2520of%2520anxiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D602%26epage%3D606%26doi%3D10.1016%2Fj.bmcl.2014.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part 1</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3308</span>– <span class="NLM_lpage">3313</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmcl.2013.03.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=23623415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvV2ksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3308-3313&author=N.+T.+Zaveriauthor=F.+Jiangauthor=C.+Olsenauthor=W.+E.+Polgarauthor=L.+Toll&title=Designing+bifunctional+NOP+receptor-mu+opioid+receptor+ligands+from+NOP+receptor-selective+scaffolds.+Part+1&doi=10.1016%2Fj.bmcl.2013.03.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.</span></div><div class="casAuthors">Zaveri, Nurulain T.; Jiang, Faming; Olsen, Cris; Polgar, Willma E.; Toll, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3308-3313</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nociceptin receptor (NOP) and its endogenous agonist, nociceptin/orphanin FQ (N/OFQ), members of the opioid receptor and peptide families resp., modulate the pharmacol. effects of classical opioids, particularly opioid-induced reward and nociception.  We hypothesized that compds. contg. both NOP and opioid receptor activity in a single mol. may have useful pharmacol. profiles as non-addicting analgesics or as drug abuse medications.  We report here our forays into the structure-activity relationships for discovering 'bifunctional' NOP-mu opioid receptor (MOP) ligands, starting from our NOP-selective scaffolds.  This initial SAR suggests pharmacophoric elements that may be modified to modulate/increase opioid affinity, while maintaining high affinity for the NOP receptor, to result in potent bifunctional small-mol. NOP/MOP ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNMyjT_yppQrVg90H21EOLACvtfcHk0liVclS2lKJRig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvV2ksr0%253D&md5=22731f8e1bbe06a33145392214d4c908</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.101%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DDesigning%2520bifunctional%2520NOP%2520receptor-mu%2520opioid%2520receptor%2520ligands%2520from%2520NOP%2520receptor-selective%2520scaffolds.%2520Part%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3308%26epage%3D3313%26doi%3D10.1016%2Fj.bmcl.2013.03.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1948</span>– <span class="NLM_lpage">1961</span>, <span class="refDoi"> DOI: 10.1002/prot.24077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1002%2Fprot.24077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=22489047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFSkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2012&pages=1948-1961&author=P.+R.+Dagaauthor=N.+T.+Zaveri&title=Homology+modeling+and+molecular+dynamics+simulations+of+the+active+state+of+the+nociceptin+receptor+reveal+new+insights+into+agonist+binding+and+activation&doi=10.1002%2Fprot.24077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation</span></div><div class="casAuthors">Daga, Pankaj R.; Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1948-1961, S1948/1-S1948/8</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The opioid receptor-like receptor, also known as the nociceptin receptor (NOP), is a class A G protein-coupled receptor (GPCR) in the opioid receptor family.  Although NOP shares a significant homol. with the other opioid receptors, it does not bind known opioid ligands and has been shown to have a distinct mechanism of activation compared to the closely related opioid receptors mu, delta, and kappa.  Previously reported homol. models of the NOP receptor, based on the inactive-state GPCR crystal structures, give limited information on the activation and selectivity features of this fourth member of the opioid receptor family.  The authors report the first active-state homol. model of the NOP receptor based on the opsin GPCR crystal structure.  An inactive-state homol. model of NOP was also built using a multiple template approach.  Mol. dynamics simulation of the active-state NOP model and comparison to the inactive-state model suggest that NOP activation involves movements of transmembrane (TM)3 and TM6 and several activation microswitches, consistent with GPCR activation.  Docking of the selective nonpeptidic NOP agonist ligand Ro 64-6198 into the active-state model reveals active-site residues in NOP that play a role in the high selectivity of this ligand for NOP over the other opioid receptors.  Docking the shortest active fragment of endogenous agonist nociceptin/orphaninFQ (residues 1-13) shows that the NOP extracellular loop 2 (EL2) loop interacts with the pos. charged residues (8-13) of N/OFQ.  Both agonists show extensive polar interactions with residues at the extracellular end of the TM domain and EL2 loop, suggesting agonist-induced reorganization of polar networks, during receptor activation.  Proteins 2012; © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHyKNV6QUesbVg90H21EOLACvtfcHk0lgDqELor25mtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFSkur0%253D&md5=b239ff210a4b601c46401139c17f8fb5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fprot.24077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.24077%26sid%3Dliteratum%253Aachs%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DHomology%2520modeling%2520and%2520molecular%2520dynamics%2520simulations%2520of%2520the%2520active%2520state%2520of%2520the%2520nociceptin%2520receptor%2520reveal%2520new%2520insights%2520into%2520agonist%2520binding%2520and%2520activation%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2012%26volume%3D80%26spage%3D1948%26epage%3D1961%26doi%3D10.1002%2Fprot.24077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6659</span>– <span class="NLM_lpage">6666</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0987-04.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.0987-04.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=15282268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVCksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=6659-6666&author=M.+Martiauthor=F.+Melaauthor=C.+Veronesiauthor=R.+Guerriniauthor=S.+Salvadoriauthor=M.+Federiciauthor=N.+B.+Mercuriauthor=A.+Rizziauthor=G.+Franchiauthor=L.+Beaniauthor=C.+Bianchiauthor=M.+Morari&title=Blockade+of+nociceptin%2Forphanin+FQ+receptor+signaling+in+rat+substantia+nigra+pars+reticulata+stimulates+nigrostriatal+dopaminergic+transmission+and+motor+behavior&doi=10.1523%2FJNEUROSCI.0987-04.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior</span></div><div class="casAuthors">Marti, Matteo; Mela, Flora; Veronesi, Carlo; Guerrini, Remo; Salvadori, Severo; Federici, Mauro; Mercuri, Nicola B.; Rizzi, Anna; Franchi, Gianfranco; Beani, Lorenzo; Bianchi, Clementina; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">6659-6666</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">A multidisciplinary approach was followed to investigate whether the opioid-like peptide nociceptin/orphanin FQ (N/OFQ) regulates the nigrostriatal dopaminergic pathway and motor behavior.  Nigrostriatal dopaminergic cells, which express N/OFQ peptide (NOP) receptors, are located in the substantia nigra pars compacta and extend their dendrites in the substantia nigra pars reticulata, thereby modulating the basal ganglia output neurons.  In vitro electrophysiol. recordings demonstrated that N/OFQ hyperpolarized the dopaminergic cells of the substantia nigra pars compacta and inhibited their firing activity.  In vivo dual-probe microdialysis showed that N/OFQ perfused in the substantia nigra pars reticulata reduced dopamine release in the ipsilateral striatum, whereas UFP-101 ([Nphe1,Arg14,Lys15]N/OFQ(1-13)-NH2) (a selective NOP receptor peptide antagonist) stimulated it.  N/OFQ microinjected in the substantia nigra pars reticulata impaired rat performance on a rotarod app., whereas UFP-101 enhanced it.  Electromyog. revealed that N/OFQ and UFP-101 oppositely affected muscle tone, inducing relaxation and contraction of triceps, resp.  The selective NOP receptor nonpeptide antagonist J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one), either injected intranigrally or given systemically, also elevated striatal dopamine release and facilitated motor activity, confirming that these effects were caused by blockade of endogenous N/OFQ signaling.  The inhibitory role played by endogenous N/OFQ on motor activity was addnl. strengthened by the finding that mice lacking the NOP receptor gene outperformed wild-type mice on the rotarod.  The authors conclude that NOP receptors in the substantia nigra pars reticulata, activated by endogenous N/OFQ, drive a physiol. inhibitory control on motor behavior, possibly via modulation of the nigrostriatal dopaminergic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKEHVGKjAkn7Vg90H21EOLACvtfcHk0lgDqELor25mtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVCksLo%253D&md5=84f7e383d4b524170a75b3d581848903</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0987-04.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0987-04.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMela%26aufirst%3DF.%26aulast%3DVeronesi%26aufirst%3DC.%26aulast%3DGuerrini%26aufirst%3DR.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DFederici%26aufirst%3DM.%26aulast%3DMercuri%26aufirst%3DN.%2BB.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DFranchi%26aufirst%3DG.%26aulast%3DBeani%26aufirst%3DL.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520signaling%2520in%2520rat%2520substantia%2520nigra%2520pars%2520reticulata%2520stimulates%2520nigrostriatal%2520dopaminergic%2520transmission%2520and%2520motor%2520behavior%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D6659%26epage%3D6666%26doi%3D10.1523%2FJNEUROSCI.0987-04.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelson, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01282-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS0014-2999%2801%2901282-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=11779034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVSlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2001&pages=29-36&author=N.+Zaveriauthor=W.+E.+Polgarauthor=C.+M.+Olsenauthor=A.+B.+Kelsonauthor=P.+Grundtauthor=J.+W.+Lewisauthor=L.+Toll&title=Characterization+of+opiates%2C+neuroleptics%2C+and+synthetic+analogs+at+ORL1+and+opioid+receptors&doi=10.1016%2FS0014-2999%2801%2901282-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors</span></div><div class="casAuthors">Zaveri, N.; Polgar, W. E.; Olsen, C. M.; Kelson, A. B.; Grundt, P.; Lewis, J. W.; Toll, L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Nociceptin/orphanin FQ (N/OFQ) was recently identified as the endogenous ligand for the opioid-receptor like (ORL1) receptor.  Although the ORL1 receptor shows sequence homol. with the opioid receptors, the nociceptin/ORL1 ligand-receptor system has very distinct pharmacol. actions compared to the opioid receptor system.  Recently, several small-mol. ORL1 receptor ligands were reported by pharmaceutical companies.  Most of these ligands had close structural similarities with known neuroleptics and opiates.  In this study, we screened several available neuroleptics and opiates for their binding affinity and functional activity at ORL1 and the opioid receptors.  We also synthesized several analogs of known opiates with modified piperidine N-substituents in order to characterize the ORL1 receptor ligand binding pocket.  Substitution with the large, lipophilic cyclooctylmethyl moiety increased ORL1 receptor affinity and decreased μ receptor affinity and efficacy in the fentanyl series of ligands but had a different effect in the oripavine class of opiate ligands.  Our results indicate that opiates and neuroleptics may be good starting points for ORL1 receptor ligand design, and the selectivity may be modulated by appropriate structural modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDT6YZiwl5yLVg90H21EOLACvtfcHk0lgDqELor25mtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVSlur8%253D&md5=c5f45983b650c2afa47f8b58ce0314a0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901282-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901282-1%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DOlsen%26aufirst%3DC.%2BM.%26aulast%3DKelson%26aufirst%3DA.%2BB.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DCharacterization%2520of%2520opiates%252C%2520neuroleptics%252C%2520and%2520synthetic%2520analogs%2520at%2520ORL1%2520and%2520opioid%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D428%26spage%3D29%26epage%3D36%26doi%3D10.1016%2FS0014-2999%2801%2901282-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1391</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01426.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fj.1476-5381.2011.01426.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=21486284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1357-1391&author=S.+Dutyauthor=P.+Jenner&title=Animal+models+of+Parkinson%E2%80%99s+disease%3A+a+source+of+novel+treatments+and+clues+to+the+cause+of+the+disease&doi=10.1111%2Fj.1476-5381.2011.01426.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease</span></div><div class="casAuthors">Duty, Susan; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1391</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness.  Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression.  The array of available rodent models is large and ranges from acute pharmacol. models, such as the reserpine- or haloperidol-treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro-striatal pathway, such as the classical 6-hydroxydopamine (6-OHDA) rat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models.  All of these have provided test beds in which new mols. for treating the motor symptoms of PD can be assessed.  In addn., the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6-OHDA-lesioned rats with L-DOPA has allowed for examn. of the mechanisms responsible for treatment-related dyskinesia in PD, and the detection of mols. able to prevent or reverse their appearance.  Other toxin-based models of nigro-striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but while providing clues to disease pathogenesis, these are not so commonly used for drug development.  The MPTP-treated primate model of PD, which closely mimics the clin. features of PD and in which all currently used anti-parkinsonian medications have been shown to be effective, is undoubtedly the most clin.-relevant of all available models.  The MPTP-treated primate develops clear dyskinesia when repeatedly exposed to L-DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man.  Whether non-dopaminergic drugs show the same degree of predictability of response is a matter of debate.  As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed.  A further generation of models aimed at mimicking the genetic causes of PD has also sprung up.  While these newer models have provided further clues to the disease pathol., they have so far been less commonly used for drug development.  There is little doubt that the availability of exptl. animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug-related side effects that emerge with disease progression and chronic medication.  However, so far, we have made little progress in moving into other pharmacol. areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathol. and biochem. change.  Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression.  The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic.  This article aims to clarify the current position and highlight the strengths and weaknesses of available models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptecPrVBnv7Vg90H21EOLACvtfcHk0lgBoFGIlAollw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM&md5=587852b53e518988f9ab89436aa23326</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01426.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01426.x%26sid%3Dliteratum%253Aachs%26aulast%3DDuty%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520source%2520of%2520novel%2520treatments%2520and%2520clues%2520to%2520the%2520cause%2520of%2520the%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1357%26epage%3D1391%26doi%3D10.1111%2Fj.1476-5381.2011.01426.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwarting, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huston, J. P.</span></span> <span> </span><span class="NLM_article-title">The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/S0301-0082(96)00040-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS0301-0082%2896%2900040-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=8971983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaK2sXks12hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=275-331&author=R.+K.+Schwartingauthor=J.+P.+Huston&title=The+unilateral+6-hydroxydopamine+lesion+model+in+behavioral+brain+research.+Analysis+of+functional+deficits%2C+recovery+and+treatments&doi=10.1016%2FS0301-0082%2896%2900040-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments</span></div><div class="casAuthors">Schwarting, R. K. W.; Huston, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">275-331</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with over 400 refs.  Lesions with the neurotoxin 6-hydroxydopamine (6-OHDA) have provided an important tool to study dopamine neurons in the brain.  The most common version of such lesions is the unilateral one where the toxin is placed in the area of mesencephalic dopamine cell bodies or their ascending fibers.  This approach leads to a lateralized destruction of mesencephalic dopamine neurons and to a lateralized loss of striatal dopamine innervation.  Such lesions have contributed substantially to neuroscientific knowledge both, at the basic and clin. level.  Physiol., they have been used to clarify the neuroanatomy, neurochem., and electrophysiol. of mesencephalic DA neurons and their relationships with the basal ganglia; the relevant findings have been summarized in a previous review (Schwarting, R.K.W. and Huston, J.P. (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiol. sequelae, Progress in Neurobiol. 49, 215-266).  Furthermore, 6-OHDA lesions have been used extensively to investigate the role of these dopamine neurons with respect to behavior, to examine the brain's capacity to recover from or compensate for specific neurochem. depletions, and to investigate the promotive effects of exptl. and clin. approaches which are relevant for the treatment of Parkinson's disease.  These findings are summarized here, including the spectrum of behavioral deficits (turning, sensory neglect, etc.), functional recovery and its possible mechanisms, the behavioral effects of widely used pharmacol. challenges (amphetamines, apomorphine, selective receptor agonists, L-DOPA), and the effects of treatments which can promote recovery (like neuropeptides, neurotrophins, and grafts).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqYnX6Nw15Y7Vg90H21EOLACvtfcHk0lgBoFGIlAollw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks12hsQ%253D%253D&md5=80337b55ade69356ae4b7e4e802ef246</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2896%2900040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252896%252900040-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchwarting%26aufirst%3DR.%2BK.%26aulast%3DHuston%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520unilateral%25206-hydroxydopamine%2520lesion%2520model%2520in%2520behavioral%2520brain%2520research.%2520Analysis%2520of%2520functional%2520deficits%252C%2520recovery%2520and%2520treatments%26jtitle%3DProg.%2520Neurobiol.%26date%3D1996%26volume%3D50%26spage%3D275%26epage%3D331%26doi%3D10.1016%2FS0301-0082%2896%2900040-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paxinos, G.</span>; <span class="NLM_string-name">Watson, C.</span></span> <i>The Rat Brain in Stereotaxic Coordinates</i>; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">1986</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=G.+Paxinos&author=C.+Watson&title=The+Rat+Brain+in+Stereotaxic+Coordinates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPaxinos%26aufirst%3DG.%26btitle%3DThe%2520Rat%2520Brain%2520in%2520Stereotaxic%2520Coordinates%26pub%3DAcademic%2520Press%26date%3D1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2002.01169.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1046%2Fj.1471-4159.2002.01169.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=12390525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1Sjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2002&pages=635-644&author=M.+Martiauthor=F.+Melaauthor=C.+Bianchiauthor=L.+Beaniauthor=M.+Morari&title=Striatal+dopamine-NMDA+receptor+interactions+in+the+modulation+of+glutamate+release+in+the+substantia+nigra+pars+reticulata+in+vivo%3A+opposite+role+for+D1+and+D2+receptors&doi=10.1046%2Fj.1471-4159.2002.01169.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: Opposite role for D1 and D2 receptors</span></div><div class="casAuthors">Marti, Matteo; Mela, Flora; Bianchi, Clementina; Beani, Lorenzo; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">635-644</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Dual probe microdialysis was employed in conscious rats to investigate whether endogenous dopamine is involved in the stimulation of glutamate release in the substantia nigra pars reticulata following striatal NMDA receptor activation.  Intrastriatal perfusion with NMDA (1 and 10 μM) facilitated nigral glutamate release (dizocilpine- and tetrodotoxin-sensitive).  The D2 dopamine receptor antagonist raclopride increased spontaneous nigral glutamate release and caused a leftward shift in the NMDA sensitivity, lowering NMDA effective concns. to submicromolar levels.  Conversely, the D1 antagonist SCH23390 prevented the effect of NMDA (1 μM) and caused a rightward shift in the NMDA sensitivity.  It was tested whether the antagonist effects were due to dopamine receptor blockade or increased tone on D1/D2 receptors.  SCH23390 prevented the raclopride-induced enhancement of spontaneous but not NMDA-evoked glutamate release while raclopride left unchanged the SCH23390-induced inhibition.  The physiopathol. relevance of the dopaminergic modulation was strengthened by perfusing NMDA in the dopamine-depleted striatum of hemiparkinsonian rats.  Nigral glutamate responsiveness to NMDA was enhanced as with raclopride.  The authors conclude that endogenous striatal dopamine regulates both spontaneous and NMDA-induced nigral glutamate release via an opposite control mediated by D1 facilitatory and D2 inhibitory receptors.  Alterations of this control may subserve the motor symptoms of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEwtOgDnqWbVg90H21EOLACvtfcHk0lgBoFGIlAollw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1Sjur8%253D&md5=480c12d44c517b1e271658108361c9dc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2002.01169.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2002.01169.x%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMela%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DBeani%26aufirst%3DL.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DStriatal%2520dopamine-NMDA%2520receptor%2520interactions%2520in%2520the%2520modulation%2520of%2520glutamate%2520release%2520in%2520the%2520substantia%2520nigra%2520pars%2520reticulata%2520in%2520vivo%253A%2520opposite%2520role%2520for%2520D1%2520and%2520D2%2520receptors%26jtitle%3DJ.%2520Neurochem.%26date%3D2002%26volume%3D83%26spage%3D635%26epage%3D644%26doi%3D10.1046%2Fj.1471-4159.2002.01169.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanberg, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunsey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, A. B.</span></span> <span> </span><span class="NLM_article-title">The catalepsy test: its ups and downs</span>. <i>Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1037/0735-7044.102.5.748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1037%2F0735-7044.102.5.748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=2904271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADyaL1M%252FmtF2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1988&pages=748-759&author=P.+R.+Sanbergauthor=M.+D.+Bunseyauthor=M.+Giordanoauthor=A.+B.+Norman&title=The+catalepsy+test%3A+its+ups+and+downs&doi=10.1037%2F0735-7044.102.5.748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The catalepsy test: its ups and downs</span></div><div class="casAuthors">Sanberg P R; Bunsey M D; Giordano M; Norman A B</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral neuroscience</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">748-59</span>
        ISSN:<span class="NLM_cas:issn">0735-7044</span>.
    </div><div class="casAbstract">The typical catalepsy test consists of placing an animal into an unusual posture and recording the time taken to correct this posture.  This time is regarded as an index of the intensity of catalepsy.  Catalepsy is a robust behavior, and the lack of standardization does not usually hinder its actual detection.  However, the intensity of the cataleptic effect is influenced by minor methodological differences, and thus interpretation and comparison of results across laboratories are difficult.  The behavioral catalepsy test can use any of several different apparatus, including wire grids, parallel bars, platforms, or pegs, to situate the animals in unusual positions.  The most common, however, is the "bar test," and despite its wide use in psychopharmacological research, even parameters of this test are not standardized.  The present article reviews the wide variety of parameters chosen by investigators that measure catalepsy.  The methodological issues of repeated testing, scaling of scores, apparatus, animal weight, maximal test duration, behavioral criteria, and other influences are discussed.  In addition, a brief review of the neuropharmacological basis of catalepsy is also included.  Finally, it is argued that a universal, standardized bar test be adopted by researchers.  New data on a novel automated bar test in the Digiscan Activity Monitoring System is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQ0Z7nr9lnp9LIORRPd5lbfW6udTcc2eYzuaZnBmUmP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M%252FmtF2jsw%253D%253D&md5=222a8efe37eab467024bcc1f70b39203</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1037%2F0735-7044.102.5.748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0735-7044.102.5.748%26sid%3Dliteratum%253Aachs%26aulast%3DSanberg%26aufirst%3DP.%2BR.%26aulast%3DBunsey%26aufirst%3DM.%2BD.%26aulast%3DGiordano%26aufirst%3DM.%26aulast%3DNorman%26aufirst%3DA.%2BB.%26atitle%3DThe%2520catalepsy%2520test%253A%2520its%2520ups%2520and%2520downs%26jtitle%3DBehav.%2520Neurosci.%26date%3D1988%26volume%3D102%26spage%3D748%26epage%3D759%26doi%3D10.1037%2F0735-7044.102.5.748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schallert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ryck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whishaw, I. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitelbaum, P.</span></span> <span> </span><span class="NLM_article-title">Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/0014-4886(79)90003-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2F0014-4886%2879%2990003-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=428497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaE1MXktlaqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1979&pages=33-43&author=T.+Schallertauthor=M.+De+Ryckauthor=I.+Q.+Whishawauthor=V.+D.+Ramirezauthor=P.+Teitelbaum&title=Excessive+bracing+reactions+and+their+control+by+atropine+and+L-DOPA+in+an+animal+analog+of+Parkinsonism&doi=10.1016%2F0014-4886%2879%2990003-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism</span></div><div class="casAuthors">Schallert, Timothy; De Ryck, Marc; Whishaw, Ian Q.; Ramirez, Victor D.; Teitelbaum, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-43</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    </div><div class="casAbstract">Atropine sulfate (I sulfate)  [55-48-1], an anticholinergic drug, administered to rats made akinetic by intraventricular application of 6-hydroxydopamine to induce a parkinsonian symptom, improved the bracing reaction and locomotor activity.  The effect of I was increased by simultaneous administration with L-dopa  [59-92-7].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCvaE443vaLVg90H21EOLACvtfcHk0lj1I_mjOVwxCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXktlaqs7s%253D&md5=b976867418534361c030bb559f766434</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0014-4886%2879%2990003-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4886%252879%252990003-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchallert%26aufirst%3DT.%26aulast%3DDe%2BRyck%26aufirst%3DM.%26aulast%3DWhishaw%26aufirst%3DI.%2BQ.%26aulast%3DRamirez%26aufirst%3DV.%2BD.%26aulast%3DTeitelbaum%26aufirst%3DP.%26atitle%3DExcessive%2520bracing%2520reactions%2520and%2520their%2520control%2520by%2520atropine%2520and%2520L-DOPA%2520in%2520an%2520animal%2520analog%2520of%2520Parkinsonism%26jtitle%3DExp.%2520Neurol.%26date%3D1979%26volume%3D64%26spage%3D33%26epage%3D43%26doi%3D10.1016%2F0014-4886%2879%2990003-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labandeira-Garcia, J. L.</span></span> <span> </span><span class="NLM_article-title">An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism</span>. <i>Brain Res. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/S1385-299X(97)00034-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS1385-299X%2897%2900034-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=9438075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADyaK1c7gtV2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1997&pages=75-84&author=G.+Rozasauthor=M.+J.+Guerraauthor=J.+L.+Labandeira-Garcia&title=An+automated+rotarod+method+for+quantitative+drug-free+evaluation+of+overall+motor+deficits+in+rat+models+of+parkinsonism&doi=10.1016%2FS1385-299X%2897%2900034-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism</span></div><div class="casAuthors">Rozas G; Guerra M J; Labandeira-Garcia J L</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research protocols</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-84</span>
        ISSN:<span class="NLM_cas:issn">1385-299X</span>.
    </div><div class="casAbstract">A variety of tests have been proposed for evaluation of motor deficits in rat models of hemiparkinsonism.  The most widely used test, the "rotational behaviour" test, is based upon motor asymmetry induced by drug administration, leading to problems of sensitization, conditioning and priming.  In addition, lesion-induced rotational behaviour is sometimes overcompensated by treatments (grafts) while other deficits are unaffected.  However, rotational behaviour is reproducible and easy to quantify.  On the contrary, most drug-free tests have proved of limited applicability because of subjective scaling, excessive interaction between the experimenter and animals, motivational effects, excessively complex tasks, etc., making it difficult to compare results from different laboratories.  In this paper, we present a rotarod based method for automated drug-free evaluation of overall motor deficits in the rat model of hemiparkinsonism, and for identifying treatment-induced changes.  Animals are pre-trained on the rotarod and then tested at a series of increasing rod speeds; from this set of values a unique score for each animal is computed (the overall rotarod performance, ORP) summarizing its performance at different speeds.  This value is easy to compute and greatly simplifies statistical comparisons.  Major advantages of the test are: (i) it does not require drugs, but is nevertheless highly objective, reproducible and easy to quantify; and (ii) falling of animals from rotating rod seems to depend on a combination of lesion-induced deficits which become more evident when rats are forced to move at faster speeds.  Since the test is not based exclusively on motor asymmetry, it may also be useful for characterization of bilaterally lesioned animals, for which drug-induced rotational behaviour tests cannot be used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEF4B2MWhtvJcXNb62YGmbfW6udTcc2eYzuaZnBmUmP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7gtV2gug%253D%253D&md5=ecf3ab7c32d8ee8c53b5e1b1c00f09e0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1385-299X%2897%2900034-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1385-299X%252897%252900034-2%26sid%3Dliteratum%253Aachs%26aulast%3DRozas%26aufirst%3DG.%26aulast%3DGuerra%26aufirst%3DM.%2BJ.%26aulast%3DLabandeira-Garcia%26aufirst%3DJ.%2BL.%26atitle%3DAn%2520automated%2520rotarod%2520method%2520for%2520quantitative%2520drug-free%2520evaluation%2520of%2520overall%2520motor%2520deficits%2520in%2520rat%2520models%2520of%2520parkinsonism%26jtitle%3DBrain%2520Res.%2520Protoc.%26date%3D1997%26volume%3D2%26spage%3D75%26epage%3D84%26doi%3D10.1016%2FS1385-299X%2897%2900034-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James J.  Lu</span>, <span class="hlFld-ContribAuthor ">Willma E.  Polgar</span>, <span class="hlFld-ContribAuthor ">Anika  Mann</span>, <span class="hlFld-ContribAuthor ">Pooja  Dasgupta</span>, <span class="hlFld-ContribAuthor ">Stefan  Schulz</span>, <span class="hlFld-ContribAuthor ">Nurulain T.  Zaveri</span>. </span><span class="cited-content_cbyCitation_article-title">Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmacology</span><span> <strong>2021,</strong> <em>100 </em>
                                    (1)
                                     , 7-18. <a href="https://doi.org/10.1124/molpharm.120.000076" title="DOI URL">https://doi.org/10.1124/molpharm.120.000076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/molpharm.120.000076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fmolpharm.120.000076%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmacology%26atitle%3DDifferential%252BIn%252BVitro%252BPharmacological%252BProfiles%252Bof%252BStructurally%252BDiverse%252BNociceptin%252BReceptor%252BAgonists%252Bin%252BActivating%252BG%252BProtein%252Band%252BBeta-Arrestin%252BSignaling%252Bat%252Bthe%252BHuman%252BNociceptin%252BOpioid%252BReceptor%26aulast%3DLu%26aufirst%3DJames%2BJ.%26date%3D2021%26date%3D2021%26volume%3D100%26issue%3D1%26spage%3D7%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Da-Yun  Luo</span>, <span class="hlFld-ContribAuthor ">Xing-Mei  Hu</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Shi-Sheng  Cui</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Base-promoted relay reaction of heterocyclic ketene aminals with o-difluorobenzene derivatives for the highly site-selective synthesis of functionalized indoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132275. <a href="https://doi.org/10.1016/j.tet.2021.132275" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132275%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DBase-promoted%252Brelay%252Breaction%252Bof%252Bheterocyclic%252Bketene%252Baminals%252Bwith%252Bo-difluorobenzene%252Bderivatives%252Bfor%252Bthe%252Bhighly%252Bsite-selective%252Bsynthesis%252Bof%252Bfunctionalized%252Bindoles%26aulast%3DLuo%26aufirst%3DDa-Yun%26date%3D2021%26volume%3D92%26spage%3D132275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oliwia  Koszła</span>, <span class="hlFld-ContribAuthor ">Piotr  Stępnicki</span>, <span class="hlFld-ContribAuthor ">Agata  Zięba</span>, <span class="hlFld-ContribAuthor ">Angelika  Grudzińska</span>, <span class="hlFld-ContribAuthor ">Dariusz  Matosiuk</span>, <span class="hlFld-ContribAuthor ">Agnieszka A.  Kaczor</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches and Tools Used in Drug Development against Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2021,</strong> <em>11 </em>
                                    (6)
                                     , 897. <a href="https://doi.org/10.3390/biom11060897" title="DOI URL">https://doi.org/10.3390/biom11060897</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom11060897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom11060897%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DCurrent%252BApproaches%252Band%252BTools%252BUsed%252Bin%252BDrug%252BDevelopment%252Bagainst%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DKosz%25C5%2582a%26aufirst%3DOliwia%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D6%26spage%3D897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael E.  Meyer</span>, <span class="hlFld-ContribAuthor ">Arpit  Doshi</span>, <span class="hlFld-ContribAuthor ">Dennis  Yasuda</span>, <span class="hlFld-ContribAuthor ">Nurulain T.  Zaveri</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     <a href="https://doi.org/10.1208/s12248-021-00589-7" title="DOI URL">https://doi.org/10.1208/s12248-021-00589-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-021-00589-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-021-00589-7%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DStructure-Based%252BSAR%252Bin%252Bthe%252BDesign%252Bof%252BSelective%252Bor%252BBifunctional%252BNociceptin%252B%252528NOP%252529%252BReceptor%252BAgonists%26aulast%3DMeyer%26aufirst%3DMichael%2BE.%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="schI" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0002.jpeg" id="rightTab-GRAPHIC-d7e456-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schI"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AcOH, STAB, DCE, rt, 16 h, 96%; (b) (i) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 1 h, (ii) 4-<i>i</i>Pr-cyclohexanone, STAB, AcOH, DCE, rt, 1–2 days, 28% over 2 steps; (c) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 79%; (d) ClSO<sub>2</sub>NCO, MeCN, 0 °C, 30 min, 37%; (e) POCl<sub>3</sub>, DMF, 0 °C, 1 h, 74%; (f) NH<sub>2</sub>OH·HCl, NaOAc·3H<sub>2</sub>O, EtOH:H<sub>2</sub>O (2:1), 110 °C, 20 min, 96%; (g) H<sub>2</sub>(g) (55 psi), 100 wt % Ra-Ni, MeOH, 16 h, 78% for <b>9</b>, 10–15% for <b>10</b>; (h) (i) BzNCS, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 58%; (i) NaBH<sub>4</sub>, EtOH, rt, 2 h, 86%.</p></p></figure><figure data-id="schII" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0003.jpeg" id="rightTab-GRAPHIC-d7e632-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TsCl, TEA, cat. DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, 93–99%; (b) phthalimide, K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 6 h, 67–94%; (c) NH<sub>2</sub>NH<sub>2</sub>, MeOH, rt, 16 h, 59–70%; (d) (Boc)<sub>2</sub>O, cat. DMAP, THF, rt, 85–88%; (e) AcOH, STAB, DCE, rt, 16 h; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 1 h; (g) 4-<i>i</i>Pr-cyclohexanone, AcOH, STAB, DCE, rt, 1–2 days, 39% over 3 steps; (h) alkyne <b>15</b> or <b>16</b>, cat. Pd(OAc)<sub>2</sub>, LiCl, K<sub>2</sub>CO<sub>3</sub>, DMF, 102 °C, 2.5 h, 65–76%; (i) AcCl, MeOH, 0 °C to rt, then EtOAc, 78–80%; (j) (i) BzNCS, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, (ii) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 47–50%.</p></p></figure><figure data-id="schIII" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0004.jpeg" id="rightTab-GRAPHIC-d7e797-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schIII"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) amine, AcOH, STAB, DCE or MeOH, rt, 1–2 days, 22–98%; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 20 min, 78%.</p></p></figure><figure data-id="schIV" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0005.jpeg" id="rightTab-GRAPHIC-d7e848-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=schIV"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HOBT, EDCI, TEA, <i>N</i>-Cbz acid, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 67–88%; (b) H<sub>2</sub> balloon, 10 wt % Pd/C (10%), THF or EtOH, 3 h, 39–87%.</p></p></figure><figure data-id="fig1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/medium/jm9b02134_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Effect of NOP partial agonists <b>4</b> (AT-001), <b>5</b> (AT-004), and <b>9</b> (AT-035) on parkinsonian disabilities in the 6-OHDA hemilesioned rat model of PD. Acute systemic administration of <b>4</b>, <b>5</b>, and <b>9</b> in a range of doses (panels A–C, <b>4</b>, AT-001, 0.001–3 mg/kg, ip) (panels D–F, <b>5</b>, AT-004, 0.1–3 mg/kg, ip) or (panels G–I, <b>9</b>, AT-035, 0.01–3 mg/kg, ip) attenuated motor deficits in three behavioral measures, (A) the bar test (left graphs), (B) the drag test (middle graphs), and (C) rotarod test (right graphs). AT-001 data (panels A–C) are the mean ± SEM values of 17–23 mice per group. AT-004 data (panels D–F) are the mean ± SEM values of 6–12 mice per group, and AT-035 data (G–I) are the mean ± SEM values of 6–7 mice per group. Essential statistical values: treatment effect panels A–C (<i>F</i><sub>5,2</sub> = 4.60, <i>p</i> = 0.0007, <i>F</i><sub>5,2</sub> = 4.52, <i>p</i> = 0.0008, <i>F</i><sub>5,1</sub> = 13.72, <i>p</i> < 0.0001, respectively), panels D–F (<i>F</i><sub>3,2</sub> = 4.39, <i>p</i> = 0.0051, <i>F</i><sub>3,2</sub> = 8.45, <i>p</i> < 0.0001, F<sub>3,1</sub> = 7.59, <i>p</i> < 0.0001, respectively), panels G–I (<i>F</i><sub>4,2</sub> = 14.31, <i>p</i> < 0.0001, <i>F</i><sub>4,2</sub> = 3.79, <i>p</i> = 0.0071, <i>F</i><sub>4,1</sub> = 11.51, <i>p</i> < 0.0001, respectively); *<i>P</i> < 0.05, **<i>P</i> < 0.01 different from vehicle (saline + 5% Tween 80 and 1% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b02134/20200306/images/large/jm9b02134_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02134&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10730" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10730" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">GBD
2016 Parkinson’s Disease Collaborators.</span> <span> </span><span class="NLM_article-title">Global, regional, and national burden
of Parkinson’s disease, 1990–2016: a systematic analysis
for the Global Burden of Disease Study 2016</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(18)30295-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS1474-4422%2818%2930295-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=30287051" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=939-953&author=GBD%0A2016+Parkinson%E2%80%99s+Disease+Collaborators.&title=Global%2C+regional%2C+and+national+burden%0Aof+Parkinson%E2%80%99s+disease%2C+1990%E2%80%932016%3A+a+systematic+analysis%0Afor+the+Global+Burden+of+Disease+Study+2016&doi=10.1016%2FS1474-4422%2818%2930295-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2818%2930295-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252818%252930295-3%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520burden%250Aof%2520Parkinson%25E2%2580%2599s%2520disease%252C%25201990%25E2%2580%25932016%253A%2520a%2520systematic%2520analysis%250Afor%2520the%2520Global%2520Burden%2520of%2520Disease%2520Study%25202016%26jtitle%3DLancet%2520Neurol.%26date%3D2018%26volume%3D17%26spage%3D939%26epage%3D953%26doi%3D10.1016%2FS1474-4422%2818%2930295-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iourinets, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, I. H.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease psychosis: presentation, diagnosis and management</span>. <i>Neurodegener Dis Manag</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.2217/nmt-2017-0028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.2217%2Fnmt-2017-0028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=29160144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC1M3jsVClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=365-376&author=R.+B.+Schneiderauthor=J.+Iourinetsauthor=I.+H.+Richard&title=Parkinson%E2%80%99s+disease+psychosis%3A+presentation%2C+diagnosis+and+management&doi=10.2217%2Fnmt-2017-0028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease psychosis: presentation, diagnosis and management</span></div><div class="casAuthors">Schneider Ruth B; Iourinets Julia; Richard Irene H</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative disease management</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">365-376</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Parkinson's disease is a neurodegenerative disorder characterized by motor and nonmotor symptoms.  Psychosis is a common feature of Parkinson's disease.  Parkinson's disease psychosis (PDP) encompasses minor phenomena (illusions, passage hallucinations and presence hallucinations), visual and nonvisual hallucinations and delusions.  PDP is associated with reduced function and quality of life.  The initial management approach should focus on identification and treatment of any contributory medical factors, reduction or discontinuation of medications with potential to induce or worsen psychosis, nonpharmacological strategies and consideration of acetylcholinesterase inhibitor treatment in the setting of dementia.  Pimavanserin, quetiapine and clozapine may all be considered for use in PDP.  In this review, we discuss the presentation, diagnosis and management of PDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_NkDldPB5m2K_SFaaT9INfW6udTcc2eYcm_Mz1r4Q8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3jsVClsQ%253D%253D&md5=9c891d9bdf2ff7c1b6a8ef03c00adfa9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2217%2Fnmt-2017-0028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnmt-2017-0028%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DR.%2BB.%26aulast%3DIourinets%26aufirst%3DJ.%26aulast%3DRichard%26aufirst%3DI.%2BH.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%2520psychosis%253A%2520presentation%252C%2520diagnosis%2520and%2520management%26jtitle%3DNeurodegener%2520Dis%2520Manag%26date%3D2017%26volume%3D7%26spage%3D365%26epage%3D376%26doi%3D10.2217%2Fnmt-2017-0028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obeso, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olanow, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutt, J. G.</span></span> <span> </span><span class="NLM_article-title">Levodopa motor complications in Parkinson’s disease</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">S2</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/S1471-1931(00)00031-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS1471-1931%2800%2900031-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=11052214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotVGrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2000&pages=S2-7&author=J.+A.+Obesoauthor=C.+W.+Olanowauthor=J.+G.+Nutt&title=Levodopa+motor+complications+in+Parkinson%E2%80%99s+disease&doi=10.1016%2FS1471-1931%2800%2900031-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Levodopa motor complications in Parkinson's disease</span></div><div class="casAuthors">Obeso, Jose A.; Olanow, C. Warren; Nutt, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10, Suppl.</span>),
    <span class="NLM_cas:pages">S2-S7</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 61 refs.  Parkinson's disease (PD) is an age-related neurodegenerative disorder with an av. onset age of 60 yr.  In the United States, approx. one million persons suffer from PD, and there are 60 000 newly diagnosed cases every year.  The estd. cost of PD to society is $27 billion per yr.  Based on United States Census Bureau projections, it is estd. that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxzKLIFxaVJrVg90H21EOLACvtfcHk0lhIEDstAEpZqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotVGrt7k%253D&md5=beb2a61b94436dbed0879bfe9ea0dc3a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1471-1931%2800%2900031-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-1931%252800%252900031-8%26sid%3Dliteratum%253Aachs%26aulast%3DObeso%26aufirst%3DJ.%2BA.%26aulast%3DOlanow%26aufirst%3DC.%2BW.%26aulast%3DNutt%26aufirst%3DJ.%2BG.%26atitle%3DLevodopa%2520motor%2520complications%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2000%26volume%3D23%26spage%3DS2%26epage%3D7%26doi%3D10.1016%2FS1471-1931%2800%2900031-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goetz, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koller, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poewe, W.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Amantadine and other antiglutamate agents</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">S13</span>– <span class="NLM_lpage">S22</span>, <span class="refDoi"> DOI: 10.1002/mds.5557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1002%2Fmds.5557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=12211136" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2002&pages=S13-S22&author=C.+G.+Goetzauthor=W.+C.+Kollerauthor=W.+Poewe&title=Amantadine+and+other+antiglutamate+agents&doi=10.1002%2Fmds.5557"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fmds.5557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.5557%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DC.%2BG.%26aulast%3DKoller%26aufirst%3DW.%2BC.%26aulast%3DPoewe%26aufirst%3DW.%26atitle%3DAmantadine%2520and%2520other%2520antiglutamate%2520agents%26jtitle%3DMov.%2520Disord.%26date%3D2002%26volume%3D17%26spage%3DS13%26epage%3DS22%26doi%3D10.1002%2Fmds.5557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercatelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Parkinson’s disease: no NOP, new hope</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">8995</span>– <span class="NLM_lpage">8996</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.18632%2Foncotarget.13710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=28086211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ls1ajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=8995-8996&author=L.+Arcuriauthor=D.+Mercatelliauthor=M.+Morari&title=Parkinson%E2%80%99s+disease%3A+no+NOP%2C+new+hope&doi=10.18632%2Foncotarget.13710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Parkinson's disease: no NOP, new hope</span></div><div class="casAuthors">Arcuri Ludovico; Mercatelli Daniela; Morari Michele</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">8995-8996</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQG5g7na5uZ_MAKB7Fa-xrUfW6udTcc2eYcm_Mz1r4Q8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ls1ajsg%253D%253D&md5=7efc409178109e1c6f6ef9db80f776ee</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13710%26sid%3Dliteratum%253Aachs%26aulast%3DArcuri%26aufirst%3DL.%26aulast%3DMercatelli%26aufirst%3DD.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%253A%2520no%2520NOP%252C%2520new%2520hope%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D8995%26epage%3D8996%26doi%3D10.18632%2Foncotarget.13710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mercatelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">NOP Receptor Ligands and Parkinson’s Disease</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1007/164_2018_199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1007%2F164_2018_199" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2018&pages=213-232&author=D.+Mercatelliauthor=C.+A.+Pisanoauthor=S.+Novelloauthor=M.+Morari&title=NOP+Receptor+Ligands+and+Parkinson%E2%80%99s+Disease&doi=10.1007%2F164_2018_199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2F164_2018_199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2018_199%26sid%3Dliteratum%253Aachs%26aulast%3DMercatelli%26aufirst%3DD.%26aulast%3DPisano%26aufirst%3DC.%2BA.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DNOP%2520Receptor%2520Ligands%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2018%26volume%3D254%26spage%3D213%26epage%3D232%26doi%3D10.1007%2F164_2018_199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailleux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butour, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moisand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caput, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J. C.</span></span> <span> </span><span class="NLM_article-title">ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/0014-5793(94)80235-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2F0014-5793%2894%2980235-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=8137918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaK2cXksFamurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1994&pages=33-38&author=C.+Mollereauauthor=M.+Parmentierauthor=P.+Mailleuxauthor=J.+L.+Butourauthor=C.+Moisandauthor=P.+Chalonauthor=D.+Caputauthor=G.+Vassartauthor=J.+C.+Meunier&title=ORL1%2C+a+novel+member+of+the+opioid+receptor+family.+Cloning%2C+functional+expression+and+localization&doi=10.1016%2F0014-5793%2894%2980235-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization</span></div><div class="casAuthors">Mollereau, Catherine; Parmentier, Marc; Mailleux, Pierre; Butour, Jean Luc; Moisand, Christiane; Chalon, Pascale; Caput, Daniel; Vassart, Gilbert; Meunier, Jean Claude</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-8</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">Selective PCR amplification of human and mouse genomic DNAs with oligonucleotides encoding highly conserved regions of the β-opioid and somatostatin receptors generated a human DNA probe (hOP01, 761 bp) and its murine counterpart (mOP86, 447 bp).  Probe hOP01 was used to screen a cDNA library from human brainstem.  A clone (named hORL1) was isolated, sequenced and found to encode a protein of 370 amino acids whose primary structure displays the seven putative membrane-spanning domains of a G protein-coupled membrane receptor.  The hORL1 receptor is most closely related to opioid receptors not only on structural (sequence) but also on functional grounds: hORL1 is 49-50% identical to the murine μ-, δ- and κ-opioid receptors and, in CHO-K1 cells stably transfected with a pRc/CMV:hORL1 construct, ORL1 mediates inhibition of adenylyl cyclase by etorphine, a universal (nonselective) opiate agonist.  Yet, hORL1 appears not to be a typical opioid receptor.  Neither is it a somatostatin or σ (N-allylnormetazocine) receptor.  The mRNAs hybridizing with synthetic oligonucleotides complementary to mOP86 are present in many regions of the mouse brain and spinal cord, particularly in limbic (amygdala, hippocampus, septum, habenula, ...) and hypothalamic structures.  The authors conclude that the hORL1 receptor is a new member of the opioid receptor family with a potential role in modulating a no. of brain functions, including instinctive behaviors and emotions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWFR7ExrwbJrVg90H21EOLACvtfcHk0lj5tauGXIugFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksFamurs%253D&md5=7a7190c4703811558b3ce3e60e9df7e8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2980235-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252980235-1%26sid%3Dliteratum%253Aachs%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DParmentier%26aufirst%3DM.%26aulast%3DMailleux%26aufirst%3DP.%26aulast%3DButour%26aufirst%3DJ.%2BL.%26aulast%3DMoisand%26aufirst%3DC.%26aulast%3DChalon%26aufirst%3DP.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DVassart%26aufirst%3DG.%26aulast%3DMeunier%26aufirst%3DJ.%2BC.%26atitle%3DORL1%252C%2520a%2520novel%2520member%2520of%2520the%2520opioid%2520receptor%2520family.%2520Cloning%252C%2520functional%2520expression%2520and%2520localization%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D341%26spage%3D33%26epage%3D38%26doi%3D10.1016%2F0014-5793%2894%2980235-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">457</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1124%2Fpr.114.009209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=26956246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC28josFaltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=419-457&author=L.+Tollauthor=M.+R.+Bruchasauthor=G.+Caloauthor=B.+M.+Coxauthor=N.+T.+Zaveri&title=Nociceptin%2FOrphanin+FQ+Receptor+Structure%2C+Signaling%2C+Ligands%2C+Functions%2C+and+Interactions+with+Opioid+Systems&doi=10.1124%2Fpr.114.009209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems</span></div><div class="casAuthors">Toll Lawrence; Bruchas Michael R; Calo' Girolamo; Cox Brian M; Zaveri Nurulain T</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">419-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The NOP receptor (nociceptin/orphanin FQ opioid peptide receptor) is the most recently discovered member of the opioid receptor family and, together with its endogenous ligand, N/OFQ, make up the fourth members of the opioid receptor and opioid peptide family.  Because of its more recent discovery, an understanding of the cellular and behavioral actions induced by NOP receptor activation are less well developed than for the other members of the opioid receptor family.  All of these factors are important because NOP receptor activation has a clear modulatory role on mu opioid receptor-mediated actions and thereby affects opioid analgesia, tolerance development, and reward.  In addition to opioid modulatory actions, NOP receptor activation has important effects on motor function and other physiologic processes.  This review discusses how NOP pharmacology intersects, contrasts, and interacts with the mu opioid receptor in terms of tertiary structure and mechanism of receptor activation; location of receptors in the central nervous system; mechanisms of desensitization and downregulation; cellular actions; intracellular signal transduction pathways; and behavioral actions with respect to analgesia, tolerance, dependence, and reward.  This is followed by a discussion of the agonists and antagonists that have most contributed to our current knowledge.  Because NOP receptors are highly expressed in brain and spinal cord and NOP receptor activation sometimes synergizes with mu receptor-mediated actions and sometimes opposes them, an understanding of NOP receptor pharmacology in the context of these interactions with the opioid receptors will be crucial to the development of novel therapeutics that engage the NOP receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4KujB2a63gCEJCPKhJPuqfW6udTcc2eaE2g4FgUgdVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28josFaltw%253D%253D&md5=2a2c601fcd493fa3f67b0adee9259e02</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009209%26sid%3Dliteratum%253Aachs%26aulast%3DToll%26aufirst%3DL.%26aulast%3DBruchas%26aufirst%3DM.%2BR.%26aulast%3DCalo%26aufirst%3DG.%26aulast%3DCox%26aufirst%3DB.%2BM.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DNociceptin%252FOrphanin%2520FQ%2520Receptor%2520Structure%252C%2520Signaling%252C%2520Ligands%252C%2520Functions%252C%2520and%2520Interactions%2520with%2520Opioid%2520Systems%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D419%26epage%3D457%26doi%3D10.1124%2Fpr.114.009209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouledous, L.</span></span> <span> </span><span class="NLM_article-title">Tissue distribution of the opioid receptor-like (ORL1) receptor</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1016/S0196-9781(00)00227-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS0196-9781%2800%2900227-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10998524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1WrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=907-917&author=C.+Mollereauauthor=L.+Mouledous&title=Tissue+distribution+of+the+opioid+receptor-like+%28ORL1%29+receptor&doi=10.1016%2FS0196-9781%2800%2900227-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tissue distribution of the opioid receptor-like (ORL1) receptor</span></div><div class="casAuthors">Mollereau, C.; Mouledous, L.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-917</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review, with 92 refs.  The ORL1 receptor is a G protein-coupled receptor structurally related to the opioid receptors, whose endogenous ligand is the heptadecapeptide nociceptin/orphanin FQ.  In this review, data which have contributed to the mapping of the anat. distribution of the ORL1 receptor have been collated with an emphasis on their relation to physiol. functions.  The ORL1 receptor is widely expressed in the central nervous system, in particular in the forebrain (cortical areas, olfactory regions, limbic structures, thalamus), throughout the brainstem (central periaqueductal gray, substantia nigra, several sensory and motor nuclei), and in both the dorsal and ventral horns of the spinal cord.  Regions almost devoid of ORL1 receptors are the caudate-putamen and the cerebellum.  ORL1 mRNA and binding sites exhibit approx. the same distribution pattern, indicating that the ORL1 receptor is located on local neuronal circuits.  The ORL1 receptor is also expressed at the periphery in smooth muscles, peripheral ganglia, and the immune system.  The anat. distribution of ORL1 receptor suggests a broad spectrum of action for the nociceptin/orphanin FQ system (sensory perception, memory process, emotional behavior, etc.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppTa7glqyVR7Vg90H21EOLACvtfcHk0lj5tauGXIugFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1WrsLg%253D&md5=0887929cd793fa11c1fa6e0595841c5c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0196-9781%2800%2900227-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0196-9781%252800%252900227-8%26sid%3Dliteratum%253Aachs%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DMouledous%26aufirst%3DL.%26atitle%3DTissue%2520distribution%2520of%2520the%2520opioid%2520receptor-like%2520%2528ORL1%2529%2520receptor%26jtitle%3DPeptides%26date%3D2000%26volume%3D21%26spage%3D907%26epage%3D917%26doi%3D10.1016%2FS0196-9781%2800%2900227-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fantin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Benedetto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinscheid, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romualdi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candeletti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">9591</span>– <span class="NLM_lpage">9601</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2546-05.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.2546-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=16237164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=9591-9601&author=M.+Martiauthor=F.+Melaauthor=M.+Fantinauthor=S.+Zucchiniauthor=J.+M.+Brownauthor=J.+Wittaauthor=M.+Di+Benedettoauthor=B.+Buzasauthor=R.+K.+Reinscheidauthor=S.+Salvadoriauthor=R.+Guerriniauthor=P.+Romualdiauthor=S.+Candelettiauthor=M.+Simonatoauthor=B.+M.+Coxauthor=M.+Morari&title=Blockade+of+nociceptin%2Forphanin+FQ+transmission+attenuates+symptoms+and+neurodegeneration+associated+with+Parkinson%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.2546-05.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease</span></div><div class="casAuthors">Marti, Matteo; Mela, Flora; Fantin, Martina; Zucchini, Silvia; Brown, Jeffrey M.; Witta, Jassir; Di Benedetto, Manuela; Buzas, Beata; Reinscheid, Rainer K.; Salvadori, Severo; Guerrini, Remo; Romualdi, Patrizia; Candeletti, Sanzio; Simonato, Michele; Cox, Brian M.; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">9591-9601</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The opioid-like neuropeptide nociceptin/orphanin FQ (N/OFQ) and its receptor (NOP) are expressed in the substantia nigra (SN), a brain area contg. dopamine neurons that degenerate in Parkinson's disease.  Endogenous N/OFQ facilitates nigral glutamate release and inhibits nigrostriatal dopamine transmission and motor behavior.  Here, we present evidence suggesting that endogenous N/OFQ may contribute to Parkinson's disease.  Pharmacol. blockade of the SN N/OFQ-NOP receptor system attenuated parkinsonian-like akinesia/hypokinesia in 6-hydroxydopamine hemi-lesioned or haloperidol-treated rats, whereas deletion of the NOP receptor gene conferred mice partial protection from haloperidol-induced motor depression.  The antiparkinsonian action of NOP receptor antagonists was assocd. with redn. of glutamate release in the SN.  In 6-hydroxydopamine hemilesioned rats, enhancement of N/OFQ expression and release was detected in the lesioned compared with the unlesioned SN, indicating that parkinsonism may be assocd. with over-activation of the N/OFQ-NOP receptor system in the SN.  Finally, deletion of the N/OFQ gene conferred mice partial protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of SN dopamine neurons.  Based on these data, we propose that NOP receptor antagonists may represent a novel approach for combined (symptomatic and neuroprotective) therapy of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcXWmE9x6-rrVg90H21EOLACvtfcHk0lhAWcy1fFLWsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WqsrjF&md5=893032d6983e5bc603cf446dd290b6b9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2546-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2546-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMela%26aufirst%3DF.%26aulast%3DFantin%26aufirst%3DM.%26aulast%3DZucchini%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DWitta%26aufirst%3DJ.%26aulast%3DDi%2BBenedetto%26aufirst%3DM.%26aulast%3DBuzas%26aufirst%3DB.%26aulast%3DReinscheid%26aufirst%3DR.%2BK.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DGuerrini%26aufirst%3DR.%26aulast%3DRomualdi%26aufirst%3DP.%26aulast%3DCandeletti%26aufirst%3DS.%26aulast%3DSimonato%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DB.%2BM.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520nociceptin%252Forphanin%2520FQ%2520transmission%2520attenuates%2520symptoms%2520and%2520neurodegeneration%2520associated%2520with%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D9591%26epage%3D9601%26doi%3D10.1523%2FJNEUROSCI.2546-05.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarubbo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eleopra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biguzzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quatrale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candeletti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romualdi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson’s disease</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1732</span>, <span class="refDoi"> DOI: 10.1002/mds.23271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1002%2Fmds.23271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=20589874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC3cjntlyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2010&pages=1723-1732&author=M.+Martiauthor=S.+Sarubboauthor=F.+Latiniauthor=M.+Cavalloauthor=R.+Eleopraauthor=S.+Biguzziauthor=C.+Lettieriauthor=C.+Contiauthor=M.+Simonatoauthor=S.+Zucchiniauthor=R.+Quatraleauthor=M.+Sensiauthor=S.+Candelettiauthor=P.+Romualdiauthor=M.+Morari&title=Brain+interstitial+nociceptin%2Forphanin+FQ+levels+are+elevated+in+Parkinson%E2%80%99s+disease&doi=10.1002%2Fmds.23271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease</span></div><div class="casAuthors">Marti Matteo; Sarubbo Silvio; Latini Francesco; Cavallo Michele; Eleopra Roberto; Biguzzi Sara; Lettieri Christian; Conti Carlo; Simonato Michele; Zucchini Silvia; Quatrale Rocco; Sensi Mariachiara; Candeletti Sanzio; Romualdi Patrizia; Morari Michele</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1723-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Expression and release of nociceptin/orphanin FQ (N/OFQ) are elevated in the substantia nigra reticulata of 6-hydroxydopamine-hemilesioned rats, suggesting a pathogenic role for N/OFQ in Parkinson's disease.  In this study, we investigated whether elevation of N/OFQ expression in 6-hydroxydopamine-hemilesioned rats selectively occurs in substantia nigra and whether hypomotility following acute haloperidol administration is accompanied by a rise in nigral N/OFQ levels.  Moreover, to prove a link between N/OFQ and idiopathic Parkinson's disease in humans, we measured N/OFQ levels in the cerebrospinal fluid of parkinsonian patients undergoing surgery for deep brain stimulation.  In situ hybridization demonstrated that dopamine depletion was associated with increase of N/OFQ expression in substantia nigra (compacta +160%, reticulata +105%) and subthalamic nucleus (+45%), as well as reduction in caudate putamen (-20%).  No change was observed in globus pallidus, nucleus accumbens, thalamus, and motor cortex.  Microdialysis coupled to the bar test allowed to demonstrate that acute administration of haloperidol (0.8 and 3 mg/kg) increased nigral N/OFQ levels (maximally of +47% and +53%, respectively) in parallel with akinesia.  A correlation with preclinical studies was found by analyzing N/OFQ levels in humans.  Indeed, N/OFQ levels were found to be approximately 3.5-fold elevated in the cerebrospinal fluid of parkinsonian patients (148 fmol/ml) compared with nonparkinsonian neurologic controls (41 fmol/ml).  These data represent the first clinical evidence linking N/OFQ to idiopathic Parkinson's disease in humans.  They strengthen the pathogenic role of N/OFQ in the modulation of parkinsonism across species and provide a rationale for developing N/OFQ receptor antagonists as antiparkinsonian drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1HYQVGZGxJFWTCLT8lX9SfW6udTcc2ebTDFxF2YThTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjntlyhuw%253D%253D&md5=ca6bc5c0248c9c288061d9c7cb55e221</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fmds.23271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.23271%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DSarubbo%26aufirst%3DS.%26aulast%3DLatini%26aufirst%3DF.%26aulast%3DCavallo%26aufirst%3DM.%26aulast%3DEleopra%26aufirst%3DR.%26aulast%3DBiguzzi%26aufirst%3DS.%26aulast%3DLettieri%26aufirst%3DC.%26aulast%3DConti%26aufirst%3DC.%26aulast%3DSimonato%26aufirst%3DM.%26aulast%3DZucchini%26aufirst%3DS.%26aulast%3DQuatrale%26aufirst%3DR.%26aulast%3DSensi%26aufirst%3DM.%26aulast%3DCandeletti%26aufirst%3DS.%26aulast%3DRomualdi%26aufirst%3DP.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DBrain%2520interstitial%2520nociceptin%252Forphanin%2520FQ%2520levels%2520are%2520elevated%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DMov.%2520Disord.%26date%3D2010%26volume%3D25%26spage%3D1723%26epage%3D1732%26doi%3D10.1002%2Fmds.23271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Pernaute, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">430</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2008.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.nbd.2008.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=18413287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtlShs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=430-438&author=R.+Viaroauthor=R.+Sanchez-Pernauteauthor=M.+Martiauthor=C.+Trapellaauthor=O.+Isacsonauthor=M.+Morari&title=Nociceptin%2Forphanin+FQ+receptor+blockade+attenuates+MPTP-induced+parkinsonism&doi=10.1016%2Fj.nbd.2008.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism</span></div><div class="casAuthors">Viaro, Riccardo; Sanchez-Pernaute, Rosario; Marti, Matteo; Trapella, Claudio; Isacson, Ole; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">430-438</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Endogenous nociceptin/orphanin FQ (N/OFQ) inhibits the activity of dopamine neurons in the substantia nigra and affects motor behavior.  In this study we investigated whether a N/OFQ receptor (NOP) antagonist, J-113397, can modify movement in naive mice and nonhuman primates and attenuate motor deficits in MPTP-treated parkinsonian animals.  J-113397 facilitated motor activity in naive mice at low doses (0.1-1 mg/kg) and inhibited it at higher ones (10 mg/kg).  Likewise, in MPTP-treated mice, J-113397 reversed motor deficit at 0.01 mg/kg but worsened hypokinesia at higher doses (1 mg/kg).  In naive nonhuman primates, J-113397, ineffective up to 1 mg/kg, produced inconsistent motor improvements at 3 mg/kg.  Conversely, in parkinsonian primates J-113397 (0.01 mg/kg) reversed parkinsonism, being most effective against hypokinesia.  We conclude that endogenous N/OFQ modulates motor activity in mice and nonhuman primates and contributes to parkinsonian symptoms in MPTP-treated animals.  NOP receptor antagonists may represent a novel approach to Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW6b77UNWC3rVg90H21EOLACvtfcHk0lhAWcy1fFLWsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtlShs7s%253D&md5=52c63df34902638af353e5de9146eb0d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2008.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2008.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DViaro%26aufirst%3DR.%26aulast%3DSanchez-Pernaute%26aufirst%3DR.%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DIsacson%26aufirst%3DO.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DNociceptin%252Forphanin%2520FQ%2520receptor%2520blockade%2520attenuates%2520MPTP-induced%2520parkinsonism%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2008%26volume%3D30%26spage%3D430%26epage%3D438%26doi%3D10.1016%2Fj.nbd.2008.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Volta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabrouk, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson’s disease: a behavioral and neurochemical study in reserpinized mice</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2010.07061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fj.1471-4159.2010.07061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=20950413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1aiurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=1543-1555&author=M.+Voltaauthor=O.+S.+Mabroukauthor=S.+Bidoauthor=M.+Martiauthor=M.+Morari&title=Further+evidence+for+an+involvement+of+nociceptin%2Forphanin+FQ+in+the+pathophysiology+of+Parkinson%E2%80%99s+disease%3A+a+behavioral+and+neurochemical+study+in+reserpinized+mice&doi=10.1111%2Fj.1471-4159.2010.07061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice</span></div><div class="casAuthors">Volta, Mattia; Mabrouk, Omar S.; Bido, Simone; Marti, Matteo; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1543-1555</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The contribution of nociceptin/orphanin FQ (N/OFQ) to reserpine-induced Parkinsonism was evaluated in mice.  A battery of motor tests revealed that reserpine caused dose-dependent and long-lasting motor impairment.  Endogenous N/OFQ sustained this response because N/OFQ peptide (NOP) receptor knockout (NOP-/-) mice were less susceptible to the hypokinetic action of reserpine than wild-type (NOP+/+) animals.  Microdialysis revealed that reserpine elevated glutamate and reduced GABA levels in substantia nigra reticulata, and that resistance to reserpine in NOP-/- mice was accompanied by a milder increase in glutamate and lack of inhibition of GABA levels.  To substantiate this genetic evidence, the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397) simultaneously reduced akinesia and nigral glutamate levels in reserpinized NOP+/+ mice, being ineffective in NOP-/- mice.  Moreover, repeated J-113397 administration in reserpinized mice resulted in faster recovery of baseline motor performance which was, however, accompanied by a loss of acute antiakinetic response.  The short-term beneficial effect of J-113397 was paralleled by normalization of nigral glutamate levels, whereas loss of acute response was paralleled by loss of the ability of J-113397 to inhibit glutamate levels.  We conclude that endogenous N/OFQ contributes to reserpine-induced Parkinsonism, and that sustained NOP receptor blockade produces short-term motor improvement accompanied by normalization of nigral glutamate release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC-bDGcPmUmbVg90H21EOLACvtfcHk0ljPgmWbNUeFCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1aiurvO&md5=61432a975590486fcdf203b3c291480c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2010.07061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2010.07061.x%26sid%3Dliteratum%253Aachs%26aulast%3DVolta%26aufirst%3DM.%26aulast%3DMabrouk%26aufirst%3DO.%2BS.%26aulast%3DBido%26aufirst%3DS.%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DFurther%2520evidence%2520for%2520an%2520involvement%2520of%2520nociceptin%252Forphanin%2520FQ%2520in%2520the%2520pathophysiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520behavioral%2520and%2520neurochemical%2520study%2520in%2520reserpinized%2520mice%26jtitle%3DJ.%2520Neurochem.%26date%3D2010%26volume%3D115%26spage%3D1543%26epage%3D1555%26doi%3D10.1111%2Fj.1471-4159.2010.07061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bido, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernagut, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson’s disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2016.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.nbd.2016.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=26804029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVOns74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=55-64&author=L.+Arcuriauthor=R.+Viaroauthor=S.+Bidoauthor=F.+Longoauthor=M.+Calcagnoauthor=P.+O.+Fernagutauthor=N.+T.+Zaveriauthor=G.+Caloauthor=E.+Bezardauthor=M.+Morari&title=Genetic+and+pharmacological+evidence+that+endogenous+nociceptin%2Forphanin+FQ+contributes+to+dopamine+cell+loss+in+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.nbd.2016.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease</span></div><div class="casAuthors">Arcuri, Ludovico; Viaro, Riccardo; Bido, Simone; Longo, Francesco; Calcagno, Mariangela; Fernagut, Pierre-Olivier; Zaveri, Nurulain T.; Calo, Girolamo; Bezard, Erwan; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-64</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">To investigate whether the endogenous neuropeptide nociceptin/orphanin FQ N/OFQ contributes to the death of dopamine neurons in Parkinson's disease, we undertook a genetic and a pharmacol. approach using NOP receptor knockout NOP-/- mice, and the selective and potent small mol. NOP receptor antagonist - -cis-1-methyl-7-[[4-2,6-dichlorophenylpiperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol SB-612111.  Stereol. unbiased methods were used to est. the total no. of dopamine neurons in the substantia nigra of i) NOP-/- mice acutely treated with the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine MPTP, ii) naive mice subacutely treated with MPTP, alone or in combination with SB-612111, iii) rats injected with a recombinant adeno-assocd. viral AAV vector overexpressing human mutant p.  A53T α-synuclein, treated with vehicle or SB-612111.  NOP-/- mice showed a 50% greater amt. of nigral dopamine neurons spared in response to acute MPTP compared to controls, which was assocd. with a milder motor impairment.  SB-612111, given 4 days after MPTP treatment to mimic the clin. condition, prevented the loss of nigral dopamine neurons and striatal dopaminergic terminals caused by subacute MPTP.  SB-612111, administered a week after the AAV injections in a clin.-driven protocol, also increased by 50% both the no. of spared nigral dopamine neurons and striatal dopamine terminals, and prevented accompanying motor deficits induced by α-synuclein.  We conclude that endogenous N/OFQ contributes to dopamine neuron loss in pathogenic and etiol. models of Parkinson's disease through NOP receptor-mediated mechanisms.  NOP receptor antagonists might prove effective as disease-modifying agents in Parkinson's disease, through the rescue of degenerating nigral dopamine neurons and/or the protection of the healthy ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQC28OAfV4JLVg90H21EOLACvtfcHk0ljPgmWbNUeFCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVOns74%253D&md5=afaf23fce49242261f565087b6201996</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DArcuri%26aufirst%3DL.%26aulast%3DViaro%26aufirst%3DR.%26aulast%3DBido%26aufirst%3DS.%26aulast%3DLongo%26aufirst%3DF.%26aulast%3DCalcagno%26aufirst%3DM.%26aulast%3DFernagut%26aufirst%3DP.%2BO.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DCalo%26aufirst%3DG.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DGenetic%2520and%2520pharmacological%2520evidence%2520that%2520endogenous%2520nociceptin%252Forphanin%2520FQ%2520contributes%2520to%2520dopamine%2520cell%2520loss%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2016%26volume%3D89%26spage%3D55%26epage%3D64%26doi%3D10.1016%2Fj.nbd.2016.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1683</span>– <span class="NLM_lpage">1696</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05735.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fj.1471-4159.2008.05735.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=19014386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1SrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2008&pages=1683-1696&author=M.+Martiauthor=C.+Trapellaauthor=M.+Morari&title=The+novel+nociceptin%2Forphanin+FQ+receptor+antagonist+Trap-101+alleviates+experimental+parkinsonism+through+inhibition+of+the+nigro-thalamic+pathway%3A+positive+interaction+with+L-DOPA&doi=10.1111%2Fj.1471-4159.2008.05735.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA</span></div><div class="casAuthors">Marti, Matteo; Trapella, Claudio; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1683-1696</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In this study we investigated whether the recently discovered antagonist of the nociceptin/orphanin FQ (N/OFQ) opioid peptide (NOP) receptor, 1-[1-(cyclooctylmethyl)-1,2,3,6-tetrahydro-5-(hydroxymethyl)-4-pyridinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (Trap-101) changed motor activity in naive rats and mice, and alleviated parkinsonism in 6-hydroxydopamine hemilesioned rats.  In naive rats, Trap-101 stimulated motor activity at 10 mg/kg and inhibited it at 30 mg/Kg.  Such dual action was also obsd. in wild-type but not NOP receptor knockout mice suggesting specific involvement of NOP receptors.  Trap-101 alleviated akinesia/bradykinesia and improved overall gait ability in hemiparkinsonian rats, being effective starting at 1 mg/Kg and without worsening motor deficit at 30 mg/Kg.  To investigate the circuitry involved in the Trap-101 action, behavioral tests were performed in rats undergoing microdialysis.  The anti-akinetic/anti-bradykinetic effects of Trap-101, given systemically (10 mg/Kg) or perfused in substantia nigra reticulata (10 μM), were assocd. with reduced glutamate and enhanced GABA release in substantia nigra, and reduced GABA release in ipsilateral ventro-medial thalamus.  When combined with ineffective doses of L-DOPA (0.1 mg/Kg), Trap-101 evoked larger neurochem. and behavioral responses.  These data show that Trap-101 is an effective NOP receptor antagonist in vivo and confirm that NOP receptor antagonists alleviate parkinsonism through blockade of nigral NOP receptors and impairment of nigro-thalamic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn1My6a_g6WLVg90H21EOLACvtfcHk0lizVaSDVxWWKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1SrtA%253D%253D&md5=5cc7eea58031e06842f19b8b7750dede</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05735.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05735.x%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DThe%2520novel%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520antagonist%2520Trap-101%2520alleviates%2520experimental%2520parkinsonism%2520through%2520inhibition%2520of%2520the%2520nigro-thalamic%2520pathway%253A%2520positive%2520interaction%2520with%2520L-DOPA%26jtitle%3DJ.%2520Neurochem.%26date%3D2008%26volume%3D107%26spage%3D1683%26epage%3D1696%26doi%3D10.1111%2Fj.1471-4159.2008.05735.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1297</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4346-06.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.4346-06.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=17287504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFCrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=1297-1307&author=M.+Martiauthor=C.+Trapellaauthor=R.+Viaroauthor=M.+Morari&title=The+nociceptin%2Forphanin+FQ+receptor+antagonist+J-113397+and+L-DOPA+additively+attenuate+experimental+parkinsonism+through+overinhibition+of+the+nigrothalamic+pathway&doi=10.1523%2FJNEUROSCI.4346-06.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway</span></div><div class="casAuthors">Marti, Matteo; Trapella, Claudio; Viaro, Riccardo; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1297-1307</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">By using a battery of behavioral tests, we showed that nociceptin/orphanin FQ receptor (NOP receptor) antagonists attenuated parkinsonian-like symptoms in 6-hydroxydopamine hemilesioned rats.  We now present evidence that coadministration of the NOP receptor antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397) and L-DOPA to 6-hydroxydopamine hemilesioned rats produced an additive attenuation of parkinsonism.  To investigate the neurobiol. substrates underlying this interaction, in vivo microdialysis was used in combination with behavioral measurements (bar test).  J-113397 and L-DOPA alone reduced the time on bars (i.e., attenuated akinesia) and elevated GABA release selectively in the lesioned substantia nigra reticulata.  J-113397 also reduced nigral glutamate levels, whereas L-DOPA was ineffective.  J-113397 and L-DOPA coadministration produced additive antiakinetic effect, which was assocd. with additive increase in nigral GABA release but no addnl. redns. in glutamate levels.  To investigate whether the increase in nigral GABA release could translate to changes in nigrothalamic transmission, GABA release was monitored in the ventromedial thalamus (one of the main target areas of the nigrothalamic projections).  J-113397 and L-DOPA decreased thalamic GABA release and attenuated akinesia, their combination resulting in a more profound effect.  These actions were prevented by perfusing the voltage-dependent Na+ channel blocker tetrodotoxin or the GABAA receptor antagonist bicuculline in the substantia nigra reticulata.  These data demonstrate that J-113397 and L-DOPA exert their antiparkinsonian action through overinhibition of nigrothalamic transmission and suggest that NOP receptor antagonists may be useful as an adjunct to L-DOPA therapy for Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN4g43DttoNbVg90H21EOLACvtfcHk0lizVaSDVxWWKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFCrtbo%253D&md5=6673bca29e2122f6d5e8c37db5bf014c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4346-06.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4346-06.2007%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DTrapella%26aufirst%3DC.%26aulast%3DViaro%26aufirst%3DR.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DThe%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520antagonist%2520J-113397%2520and%2520L-DOPA%2520additively%2520attenuate%2520experimental%2520parkinsonism%2520through%2520overinhibition%2520of%2520the%2520nigrothalamic%2520pathway%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D1297%26epage%3D1307%26doi%3D10.1523%2FJNEUROSCI.4346-06.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morella, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calabresi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Nociceptin/Orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">16106</span>– <span class="NLM_lpage">16119</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.6408-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.6408-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=23152595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslagur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=16106-16119&author=M.+Martiauthor=D.+Rodiauthor=Q.+Liauthor=R.+Guerriniauthor=S.+Fasanoauthor=I.+Morellaauthor=A.+Tozziauthor=R.+Brambillaauthor=P.+Calabresiauthor=M.+Simonatoauthor=E.+Bezardauthor=M.+Morari&title=Nociceptin%2FOrphanin+FQ+receptor+agonists+attenuate+L-DOPA-induced+dyskinesias&doi=10.1523%2FJNEUROSCI.6408-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias</span></div><div class="casAuthors">Marti, Matteo; Rodi, Donata; Li, Qin; Guerrini, Remo; Fasano, Stefania; Morella, Ilaria; Tozzi, Alessandro; Brambilla, Riccardo; Calabresi, Paolo; Simonato, Michele; Bezard, Erwan; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">16106-16119</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">In the present study we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogenesis of Parkinson's disease, also affects L-DOPA-induced dyskinesia.  In striatal slices of naive rodents, N/OFQ (0.1-1 μM) prevented the increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist SKF38393 in spiny neurons.  In vivo, exogenous N/OFQ (0.03-1 nmol, i.c.v.) or a synthetic N/OFQ receptor agonist given systemically (0.01-1 mg/Kg) attenuated dyskinesias expression in 6-hydroxydopamine hemilesioned rats primed with L-DOPA, without causing primary hypolocomotive effects.  Conversely, N/OFQ receptor antagonists worsened dyskinesia expression.  In vivo microdialysis revealed that N/OFQ prevented dyskinesias simultaneously with its neurochem. correlates such as the surge of nigral GABA and glutamate, and the redn. of thalamic GABA.  Regional microinjections revealed that N/OFQ attenuated dyskinesias more potently and effectively when microinjected in striatum than substantia nigra (SN) reticulata, whereas N/OFQ receptor antagonists were ineffective in striatum but worsened dyskinesias when given in SN.  Quant. autoradiog. showed an increase in N/OFQ receptor binding in striatum and a redn. in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ transmission.  Finally, the N/OFQ receptor synthetic agonist also reduced dyskinesia expression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score.  We conclude that N/OFQ receptor agonists may represent a novel strategy to counteract L-DOPA-induced dyskinesias.  Their action is possibly mediated by upregulated striatal N/OFQ receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnovy4WPkPeLVg90H21EOLACvtfcHk0lizVaSDVxWWKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslagur%252FK&md5=bb6549fe6190a16521bd73fbb4c95f57</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.6408-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.6408-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DRodi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DGuerrini%26aufirst%3DR.%26aulast%3DFasano%26aufirst%3DS.%26aulast%3DMorella%26aufirst%3DI.%26aulast%3DTozzi%26aufirst%3DA.%26aulast%3DBrambilla%26aufirst%3DR.%26aulast%3DCalabresi%26aufirst%3DP.%26aulast%3DSimonato%26aufirst%3DM.%26aulast%3DBezard%26aufirst%3DE.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DNociceptin%252FOrphanin%2520FQ%2520receptor%2520agonists%2520attenuate%2520L-DOPA-induced%2520dyskinesias%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26spage%3D16106%26epage%3D16119%26doi%3D10.1523%2FJNEUROSCI.6408-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcuri, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frassineti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercatelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morella, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Journigan, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1111/bph.14123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fbph.14123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=29232769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=782-796&author=L.+Arcuriauthor=S.+Novelloauthor=M.+Frassinetiauthor=D.+Mercatelliauthor=C.+A.+Pisanoauthor=I.+Morellaauthor=S.+Fasanoauthor=B.+V.+Journiganauthor=M.+E.+Meyerauthor=W.+E.+Polgarauthor=R.+Brambillaauthor=N.+T.+Zaveriauthor=M.+Morari&title=Anti-Parkinsonian+and+anti-dyskinetic+profiles+of+two+novel+potent+and+selective+nociceptin%2Forphanin+FQ+receptor+agonists&doi=10.1111%2Fbph.14123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists</span></div><div class="casAuthors">Arcuri, Ludovico; Novello, Salvatore; Frassineti, Martina; Mercatelli, Daniela; Pisano, Clarissa Anna; Morella, Ilaria; Fasano, Stefania; Journigan, Blair V.; Meyer, Michael E.; Polgar, Willma E.; Brambilla, Riccardo; Zaveri, Nurulain T.; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">782-796</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : We previously showed that nociceptin/orphanin FQ opioid peptide (NOP) receptor agonists attenuate the expression of levodopa-induced dyskinesia in animal models of Parkinson's disease.  We now investigate the efficacy of two novel, potent and chem. distinct NOP receptor agonists, AT-390 and AT-403, to improve Parkinsonian disabilities and attenuate dyskinesia development and expression.  Exptl. Approach : Binding affinity and functional efficacy of AT-390 and AT-403 at the opioid receptors were detd. in radioligand displacement assays and in GTPγS binding assays resp., conducted in CHO cells.  Their anti-Parkinsonian activity was evaluated in 6-hydroxydopamine hemi-lesioned rats whereas the anti-dyskinetic properties were assessed in 6-hydroxydopamine hemi-lesioned rats chronically treated with levodopa.  The ability of AT-403 to inhibit the D1 receptor-induced phosphorylation of striatal ERK was investigated.  Key Results : AT-390 and AT-403 selectively improved akinesia at low doses and disrupted global motor activity at higher doses.  AT-403 palliated dyskinesia expression without causing sedation in a narrow therapeutic window, whereas AT-390 delayed the appearance of abnormal involuntary movements and increased their duration at doses causing sedation.  AT-403 did not prevent the priming to levodopa, although it significantly inhibited dyskinesia on the first day of administration.  AT-403 reduced the ERK phosphorylation induced by SKF38393 in vitro and by levodopa in vivo.  Conclusions and Implications : NOP receptor stimulation can provide significant albeit mild anti-dyskinetic effect at doses not causing sedation.  The therapeutic window, however, varies across compds.  AT-403 could be a potent and selective tool to investigate the role of NOP receptors in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6ckNvBacmO7Vg90H21EOLACvtfcHk0livkOgxJ7XYyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGisr8%253D&md5=1c0951920fee339d8765a8c63b836627</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fbph.14123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14123%26sid%3Dliteratum%253Aachs%26aulast%3DArcuri%26aufirst%3DL.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DFrassineti%26aufirst%3DM.%26aulast%3DMercatelli%26aufirst%3DD.%26aulast%3DPisano%26aufirst%3DC.%2BA.%26aulast%3DMorella%26aufirst%3DI.%26aulast%3DFasano%26aufirst%3DS.%26aulast%3DJournigan%26aufirst%3DB.%2BV.%26aulast%3DMeyer%26aufirst%3DM.%2BE.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DBrambilla%26aufirst%3DR.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DAnti-Parkinsonian%2520and%2520anti-dyskinetic%2520profiles%2520of%2520two%2520novel%2520potent%2520and%2520selective%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520agonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D782%26epage%3D796%26doi%3D10.1111%2Fbph.14123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2973</span>– <span class="NLM_lpage">2976</span>, <span class="refDoi"> DOI: 10.1021/jm034249d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm034249d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Sjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2973-2976&author=N.+T.+Zaveriauthor=F.+Jiangauthor=C.+M.+Olsenauthor=J.+R.+Deschampsauthor=D.+Parrishauthor=W.+Polgarauthor=L.+Toll&title=A+novel+series+of+piperidin-4-yl-1%2C3-dihydroindol-2-ones+as+agonist+and+antagonist+ligands+at+the+nociceptin+receptor&doi=10.1021%2Fjm034249d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor</span></div><div class="casAuthors">Zaveri, Nurulain T.; Jiang, Faming; Olsen, Cris M.; Deschamps, Jeffrey R.; Parrish, Damon; Polgar, Willma; Toll, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2973-2976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-(4-piperidinyl)-2-indolinones were discovered as a new structural class of nociceptin receptor (NOP) ligands.  Unlike other previously reported classes of NOP receptor ligands, modifications of the piperidine N substituents afforded both potent agonists and antagonists, with modest selectivities over other opioid receptors.  The SAR revealed in this new series will provide important insights for the development of pharmacophores for agonist and antagonist actions at the NOP receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouCteePy22mbVg90H21EOLACvtfcHk0livkOgxJ7XYyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Sjs7s%253D&md5=f7988bb47141c9055b43c47eadf06bba</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm034249d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm034249d%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%2BM.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DParrish%26aufirst%3DD.%26aulast%3DPolgar%26aufirst%3DW.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DA%2520novel%2520series%2520of%2520piperidin-4-yl-1%252C3-dihydroindol-2-ones%2520as%2520agonist%2520and%2520antagonist%2520ligands%2520at%2520the%2520nociceptin%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2973%26epage%3D2976%26doi%3D10.1021%2Fjm034249d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">E345</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1208/aapsj070234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1208%2Faapsj070234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=16353914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ylt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=E345-352&author=N.+Zaveriauthor=F.+Jiangauthor=C.+Olsenauthor=W.+Polgarauthor=L.+Toll&title=Small-molecule+agonists+and+antagonists+of+the+opioid+receptor-like+receptor+%28ORL1%2C+NOP%29%3A+ligand-based+analysis+of+structural+factors+influencing+intrinsic+activity+at+NOP&doi=10.1208%2Faapsj070234"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP</span></div><div class="casAuthors">Zaveri, Nurulain; Jiang, Faming; Olsen, Cris; Polgar, Willma; Toll, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E345-E352</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">American Association of Pharmaceutical Scientists</span>)
        </div><div class="casAbstract">A review.  The recently discovered fourth member of the opioid receptor family, the nociceptin receptor (NOP) and its endogenous ligand, the heptadecapeptide nociceptin, are involved in several central nervous system pathways, such as nociception, reward, tolerance, and feeding.  The discovery of small-mol. ligands for NOP is being actively pursued for several therapeutic applications.  This review presents a brief overview of the several recently reported NOP ligands, classified as NOP agonists and antagonists, with an emphasis on the anal. of the structural features that may be important for modulating the agonist/antagonist profile (intrinsic activity) of these ligands.  Structure-activity relationships in our own series of dihydroindolinone-based NOP ligands and those of the various reported ligands indicate that the lipophilic substituent on the common basic nitrogen present in all NOP ligands plays a role in detg. the agonist/antagonist profile of the NOP ligand.  This anal. provides a basis for the rational drug design of NOP ligands of desired intrinsic activity and provides a framework for developing pharmacophore models for high affinity binding and intrinsic activity at the NOP receptor.  Since NOP agonists and antagonists both have therapeutic value, rational approaches for obtaining both within a high-affinity binding class of compds. are very useful for designing potent and selective NOP ligands with the desired profile of intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4wQ41VBI3hrVg90H21EOLACvtfcHk0livkOgxJ7XYyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ylt7bJ&md5=edfd4b8d20d0e33e6f64d970092d5604</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1208%2Faapsj070234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Faapsj070234%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%26aulast%3DPolgar%26aufirst%3DW.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DSmall-molecule%2520agonists%2520and%2520antagonists%2520of%2520the%2520opioid%2520receptor-like%2520receptor%2520%2528ORL1%252C%2520NOP%2529%253A%2520ligand-based%2520analysis%2520of%2520structural%2520factors%2520influencing%2520intrinsic%2520activity%2520at%2520NOP%26jtitle%3DAAPS%2520J.%26date%3D2005%26volume%3D7%26spage%3DE345%26epage%3D352%26doi%3D10.1208%2Faapsj070234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Journigan, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khroyan, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2508</span>– <span class="NLM_lpage">2516</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmc.2014.02.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=24657054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BC2crmt1Ghtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2508-2516&author=V.+B.+Journiganauthor=W.+E.+Polgarauthor=T.+V.+Khroyanauthor=N.+T.+Zaveri&title=Designing+bifunctional+NOP+receptor-mu+opioid+receptor+ligands+from+NOP-receptor+selective+scaffolds.+Part+II&doi=10.1016%2Fj.bmc.2014.02.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II</span></div><div class="casAuthors">Journigan V Blair; Polgar Willma E; Khroyan Taline V; Zaveri Nurulain T</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2508-16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The nociceptin opioid receptor (NOP) and its endogenous peptide ligand nociceptin/orphanin FQ have been shown to modulate the pharmacological effects of the classical opioid receptor system.  Suppression of opioid-induced reward associated with mu-opioid receptor (MOP)-mediated analgesia, without decreasing anti-nociceptive efficacy, can potentially be achieved with NOP agonists having bifunctional agonist activity at MOP, to afford 'non-addicting' analgesics.  In Part II of this series, we describe a continuing structure-activity relationship (SAR) study of the NOP-selective piperidin-4-yl-1,3-dihydroindol-2-one scaffold, to obtain bifunctional activity at MOP, and a suitable ratio of NOP/MOP agonist activity that produces a non-addicting analgesic profile.  The SAR reported here is focused on the influence of various piperidine nitrogen aromatic substituents on the ratio of binding affinity and intrinsic activity at both the NOP and MOP receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4csBsHOuCWtenUz0lpNqnfW6udTcc2eYdr0LiXFjsVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmt1Ghtw%253D%253D&md5=64cd0c7b12508a4dfc24f4a875e32cc9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.047%26sid%3Dliteratum%253Aachs%26aulast%3DJournigan%26aufirst%3DV.%2BB.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DKhroyan%26aufirst%3DT.%2BV.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DDesigning%2520bifunctional%2520NOP%2520receptor-mu%2520opioid%2520receptor%2520ligands%2520from%2520NOP-receptor%2520selective%2520scaffolds.%2520Part%2520II%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2508%26epage%3D2516%26doi%3D10.1016%2Fj.bmc.2014.02.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larock, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yum, E. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6690</span>, <span class="refDoi"> DOI: 10.1021/ja00017a059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00017a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1991&pages=6689-6690&author=R.+C.+Larockauthor=E.+K.+Yum&title=Synthesis+of+indoles+via+palladium-catalyzed+heteroannulation+of+internal+alkynes&doi=10.1021%2Fja00017a059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes</span></div><div class="casAuthors">Larock, Richard C.; Yum, Eul Kgun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6689-90</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">2,3-Disubstituted indoles are formed in high yields by the Pd-catalyzed annulation of internal alkynes by o-IC6H4NH2 and its derivs.  The reaction is highly regioselective and tolerates alkynes bearing aryl, alc. and silyl groups, as well as C:C bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_hHxDmTHKLVg90H21EOLACvtfcHk0liKxbzVyF0ZpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D&md5=498dd4febb8eba7e5903cd02b9258a16</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fja00017a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00017a059%26sid%3Dliteratum%253Aachs%26aulast%3DLarock%26aufirst%3DR.%2BC.%26aulast%3DYum%26aufirst%3DE.%2BK.%26atitle%3DSynthesis%2520of%2520indoles%2520via%2520palladium-catalyzed%2520heteroannulation%2520of%2520internal%2520alkynes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1991%26volume%3D113%26spage%3D6689%26epage%3D6690%26doi%3D10.1021%2Fja00017a059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2732</span>– <span class="NLM_lpage">2743</span>, <span class="refDoi"> DOI: 10.1021/ci500291a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci500291a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2014&pages=2732-2743&author=P.+R.+Dagaauthor=W.+E.+Polgarauthor=N.+T.+Zaveri&title=Structure-based+virtual+screening+of+the+nociceptin+receptor%3A+hybrid+docking+and+shape-based+approaches+for+improved+hit+identification&doi=10.1021%2Fci500291a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification</span></div><div class="casAuthors">Daga, Pankaj R.; Polgar, Willma E.; Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2732-2743</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antagonist-bound crystal structure of the nociceptin receptor (NOP), from the opioid receptor family, was recently reported along with those of the other opioid receptors bound to opioid antagonists.  We recently reported the first homol. model of the 'active-state' of the NOP receptor, which when docked with 'agonist' ligands showed differences in the TM helixes and residues, consistent with GPCR activation after agonist binding.  In this study, we explored the use of the active-state NOP homol. model for structure-based virtual screening to discover NOP ligands contg. new chem. scaffolds.  Several NOP agonist and antagonist ligands previously reported are based on a common piperidine scaffold.  Given the structure-activity relationships for known NOP ligands, we developed a hybrid method that combines a structure-based and ligand-based approach, utilizing the active-state NOP receptor as well as the pharmacophoric features of known NOP ligands, to identify novel NOP binding scaffolds by virtual screening.  Multiple conformations of the NOP active site including the flexible second extracellular loop (EL2) loop were generated by simulated annealing and ranked using enrichment factor (EF) anal. and a ligand-decoy dataset contg. known NOP agonist ligands.  The enrichment factors were further improved by combining shape-based screening of this ligand-decoy dataset and calcn. of consensus scores.  This combined structure-based and ligand-based EF anal. yielded higher enrichment factors than the individual methods, suggesting the effectiveness of the hybrid approach.  Virtual screening of the CNS Permeable subset of the ZINC database was carried out using the above-mentioned hybrid approach in a tiered fashion utilizing a ligand pharmacophore-based filtering step, followed by structure-based virtual screening using the refined NOP active-state models from the enrichment anal.  Detn. of the NOP receptor binding affinity of a selected set of top-scoring hits resulted in identification of several compds. with measurable binding affinity at the NOP receptor, one of which had a new chemotype for NOP receptor binding.  The hybrid ligand-based and structure-based methodol. demonstrates an effective approach for virtual screening that leverages existing SAR and receptor structure information for identifying novel hits for NOP receptor binding.  The refined active-state NOP homol. models obtained from the enrichment studies can be further used for structure-based optimization of these new chemotypes to obtain potent and selective NOP receptor ligands for therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXm5v3VfXyVbVg90H21EOLACvtfcHk0liKxbzVyF0ZpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLbO&md5=ab818a07f155109601a2c16a819e5aba</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fci500291a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci500291a%26sid%3Dliteratum%253Aachs%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DStructure-based%2520virtual%2520screening%2520of%2520the%2520nociceptin%2520receptor%253A%2520hybrid%2520docking%2520and%2520shape-based%2520approaches%2520for%2520improved%2520hit%2520identification%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2014%26volume%3D54%26spage%3D2732%26epage%3D2743%26doi%3D10.1021%2Fci500291a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khroyan, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.157446</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1124%2Fjpet.109.157446" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=19773529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2009&pages=954-964&author=L.+Tollauthor=T.+V.+Khroyanauthor=W.+E.+Polgarauthor=F.+Jiangauthor=C.+Olsenauthor=N.+T.+Zaveri&title=Comparison+of+the+antinociceptive+and+antirewarding+profiles+of+novel+bifunctional+nociceptin+receptor%2Fmu-opioid+receptor+ligands%3A+implications+for+therapeutic+applications&doi=10.1124%2Fjpet.109.157446"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/μ-opioid receptor ligands: implications for therapeutic applications</span></div><div class="casAuthors">Toll, Lawrence; Khroyan, Taline V.; Polgar, Willma E.; Jiang, Faming; Olsen, Cris; Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">954-964</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The nociceptin receptor (NOPr), a member of the opioid receptor family, is a target for the treatment of pain and drug abuse.  Nociceptin/orphanin FQ (N/OFQ), the endogenous peptide for NOPr, not only modulates opioid antinociception, but also blocks the rewarding effects of several abused drugs, such as morphine, cocaine, and amphetamine.  We hypothesized that NOPr agonists, with bifunctional activity at the μ-opioid receptor (MOPr), may function as nonaddicting analgesics or as drug abuse medications.  Bifunctional small-mol. NOPr agonists possessing different selectivities and efficacies at MOPr were evaluated in an acute thermal antinociception assay, and for their ability to induce conditioned place preference (CPP) and their effect on morphine-induced CPP.  1-(1-Cyclooctylpiperidin-4-yl)-indolin-2-one (SR14150), a high-affinity NOPr partial agonist, with low MOPr affinity and efficacy, produced analgesia that was naloxone-reversible.  SR14150 did not induce CPP alone, nor did it attenuate morphine-induced CPP.  3-Ethyl-1-(1-(4-isopropylcyclohexyl)piperidin-4-yl)-indolin-2-one (SR16507), which has high affinity for both NOPr and MOPr, full agonist activity at NOPr, and partial agonist activity at MOPr, was also a potent analgesic and produced CPP alone, but also modestly attenuated morphine CPP.  1-(1-(2,3,3A,4,5,6-hexahydro-1H-phenalen-1-yl)piperidin-4-yl)-indolin-2-one (SR16835), a NOPr full agonist and low-affinity MOPr partial agonist, was not antinociceptive, did not produce CPP alone, but attenuated morphine CPP.  Our results suggest that NOPr full-agonist activity is required to modulate opioid-induced reward, whereas a bifunctional NOPr/MOPr partial agonist profile may be suitable as a nonaddicting analgesic.  The opioid-modulating effects of the NOPr ligands may be used effectively to produce better medications for treatment of drug abuse and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSq0nyX8esa7Vg90H21EOLACvtfcHk0ljwO-MCYSDZrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFaqsLrI&md5=d9386f73b81e02a7afddf8efe6cba83a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.157446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.157446%26sid%3Dliteratum%253Aachs%26aulast%3DToll%26aufirst%3DL.%26aulast%3DKhroyan%26aufirst%3DT.%2BV.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DComparison%2520of%2520the%2520antinociceptive%2520and%2520antirewarding%2520profiles%2520of%2520novel%2520bifunctional%2520nociceptin%2520receptor%252Fmu-opioid%2520receptor%2520ligands%253A%2520implications%2520for%2520therapeutic%2520applications%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D331%26spage%3D954%26epage%3D964%26doi%3D10.1124%2Fjpet.109.157446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7011</span>– <span class="NLM_lpage">7028</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7011-7028&author=N.+T.+Zaveri&title=Nociceptin+opioid+receptor+%28NOP%29+as+a+therapeutic+target%3A+progress+in+translation+from+preclinical+research+to+clinical+utility&doi=10.1021%2Facs.jmedchem.5b01499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility</span></div><div class="casAuthors">Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7011-7028</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the two decades since the discovery of the nociceptin opioid receptor (NOP) and its ligand, nociceptin/orphaninFQ (N/OFQ), steady progress has been achieved in understanding the pharmacol. of this fourth opioid receptor/peptide system, aided by genetic and pharmacol. approaches.  This research spawned an explosion of small-mol. NOP receptor ligands from discovery programs in major pharmaceutical companies.  NOP agonists have been investigated for their efficacy in preclin. models of anxiety, cough, substance abuse, pain (spinal and peripheral), and urinary incontinence, whereas NOP antagonists have been investigated for treatment of pain, depression, and motor symptoms in Parkinson's disease.  Translation of preclin. findings into the clinic is guided by PET and receptor occupancy studies, particularly for NOP antagonists.  Recent progress in preclin. NOP research suggests that NOP agonists may have clin. utility for pain treatment and substance abuse pharmacotherapy.  This review discusses the progress toward validating the NOP-N/OFQ system as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo51w0U-7QparVg90H21EOLACvtfcHk0ljwO-MCYSDZrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyitb8%253D&md5=b9746257e225a423dfa0539d8bf407c9</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01499%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DNociceptin%2520opioid%2520receptor%2520%2528NOP%2529%2520as%2520a%2520therapeutic%2520target%253A%2520progress%2520in%2520translation%2520from%2520preclinical%2520research%2520to%2520clinical%2520utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7011%26epage%3D7028%26doi%3D10.1021%2Facs.jmedchem.5b01499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. E.</span></span> <span> </span><span class="NLM_article-title">NOP-targeted nonpeptide ligands</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1007/164_2019_213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1007%2F164_2019_213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=31119463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ovVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2019&pages=37-67&author=N.+T.+Zaveriauthor=M.+E.+Meyer&title=NOP-targeted+nonpeptide+ligands&doi=10.1007%2F164_2019_213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">NOP-Targeted Nonpeptide Ligands</span></div><div class="casAuthors">Zaveri Nurulain T; Meyer Michael E</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of experimental pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-67</span>
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    </div><div class="casAbstract">The development of nonpeptide systemically active small-molecule NOP-targeted ligands has contributed tremendously to validating the NOP receptor as a promising target for therapeutics.  Although a NOP-targeted compound is not yet approved for clinical use, a few NOP ligands are in clinical trials for various indications.  Both successful and failed human clinical trials with NOP ligands provide opportunities for rational development of new and improved NOP-targeted compounds.  A few years after the discovery of the NOP receptor in 1994, and its de-orphanization upon discovery of the endogenous peptide nociceptin/orphanin FQ (N/OFQ) in 1995, there was a significant effort in the pharmaceutical industry to discover nonpeptide NOP ligands from hits obtained from high-throughput screening campaigns of compound libraries.  Depending on the therapeutic indication to be pursued, NOP agonists and antagonists were discovered, and some were optimized as clinical candidates.  Advances such as G protein-coupled receptor (GPCR) structure elucidation, functional selectivity in ligand-driven GPCR activation, and multi-targeted ligands provide new scope for the rational design of novel NOP ligands fine-tuned for successful clinical translation.  This article reviews the field of nonpeptide NOP ligand drug design in the context of these exciting developments and highlights new optimized nonpeptide NOP ligands possessing interesting functional profiles, which are particularly attractive for several unmet clinical applications involving NOP receptor pharmacomodulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSjfDkAYiAhzdHxxy173TfNfW6udTcc2eZqB1om-YEahLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ovVahuw%253D%253D&md5=5ac6ba1888a1758743b9f765c4697b95</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F164_2019_213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2019_213%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DMeyer%26aufirst%3DM.%2BE.%26atitle%3DNOP-targeted%2520nonpeptide%2520ligands%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2019%26volume%3D254%26spage%3D37%26epage%3D67%26doi%3D10.1007%2F164_2019_213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bignan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, A. B.</span></span> <span> </span><span class="NLM_article-title">3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-2,3-b pyridines as ligands for the ORL-1 receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3524</span>– <span class="NLM_lpage">3528</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmcl.2006.03.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=16632355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2isb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=3524-3528&author=G.+C.+Bignanauthor=K.+Battistaauthor=P.+J.+Connollyauthor=M.+J.+Orsiniauthor=J.+Liuauthor=S.+A.+Middletonauthor=A.+B.+Reitz&title=3-%284-Piperidinyl%29indoles+and+3-%284-piperidinyl%29pyrrolo-2%2C3-b+pyridines+as+ligands+for+the+ORL-1+receptor&doi=10.1016%2Fj.bmcl.2006.03.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo[2,3-b]pyridines as ligands for the ORL-1 receptor</span></div><div class="casAuthors">Bignan, Gilles C.; Battista, Kathleen; Connolly, Peter J.; Orsini, Michael J.; Liu, Jingchun; Middleton, Steven A.; Reitz, Allen B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3524-3528</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of indole and 1H-pyrrolo[2,3-b]pyridine derivs. having a piperidine ring at the 3-position, e.g. I [R1 = 5-Cl, 5-F, 6-Cl, 6-F, 7-Cl; R2 = PhCH2, cyclooctylmethyl, 1-naphthylmethyl, acenaphthenyl; R3 = H, PhCH2, (R)-H2NCH2CH(OH)CH2; R4 = H, Me] were synthesized and found to bind with high affinity to the ORL-1 receptor.  Structure-activity relationships at the piperidine nitrogen were investigated in each series.  Substitution on the Ph ring and nitrogen atom of the indole and 1H-pyrrolo[2,3-b]pyridine cores generated several selective high-affinity ligands that were agonists of the ORL-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMqfT3bCUKLVg90H21EOLACvtfcHk0ljUggG1wABtkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2isb4%253D&md5=504194268e48b7f4177b64c21ff59815</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.094%26sid%3Dliteratum%253Aachs%26aulast%3DBignan%26aufirst%3DG.%2BC.%26aulast%3DBattista%26aufirst%3DK.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DOrsini%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26atitle%3D3-%25284-Piperidinyl%2529indoles%2520and%25203-%25284-piperidinyl%2529pyrrolo-2%252C3-b%2520pyridines%2520as%2520ligands%2520for%2520the%2520ORL-1%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D3524%26epage%3D3528%26doi%3D10.1016%2Fj.bmcl.2006.03.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battista, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A. H.</span></span> <span> </span><span class="NLM_article-title">A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmcl.2014.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=25556095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFOqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=602-606&author=T.+M.+Rossauthor=K.+Battistaauthor=G.+C.+Bignanauthor=D.+E.+Brennemanauthor=P.+J.+Connollyauthor=J.+Liuauthor=S.+A.+Middletonauthor=M.+Orsiniauthor=A.+B.+Reitzauthor=D.+I.+Rosenthalauthor=M.+K.+Scottauthor=A.+H.+Vaidya&title=A+selective+small+molecule+NOP+%28ORL-1+receptor%29+partial+agonist+for+the+treatment+of+anxiety&doi=10.1016%2Fj.bmcl.2014.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety</span></div><div class="casAuthors">Ross, Tina Morgan; Battista, Kathleen; Bignan, Gilles C.; Brenneman, Doug E.; Connolly, Peter J.; Liu, Jingchun; Middleton, Steven A.; Orsini, Michael; Reitz, Allen B.; Rosenthal, Dan I.; Scott, Malcolm K.; Vaidya, Anil H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">602-606</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Small mol. (1) has been identified as a selective partial agonist of Opioid Receptor Like-1 (ORL-1) with potential utility for the treatment of anxiety and other disorders.  Nociceptin (orphanin FQ) is an endogenous peptide ligand that binds to ORL-1, however it does not bind the classical δ, μ and κ opioid receptors with high affinity.  The synthesis of 1 involved using a mol. diversity approach, to rapidly advance a library of compds. for biol. testing.  A lead selective potent partial agonist (35-fold ORL-1/Mu) progressed to ORL-1 (NOP or OP4) proof of concept testing in advanced studies.  The synthetic approach and biol. data for the related chem. series will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcRIu1rC3L0bVg90H21EOLACvtfcHk0liBCdodXUyTuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFOqsg%253D%253D&md5=f7e2c4a636a9631ee9a0d0cbf554b3e0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DT.%2BM.%26aulast%3DBattista%26aufirst%3DK.%26aulast%3DBignan%26aufirst%3DG.%2BC.%26aulast%3DBrenneman%26aufirst%3DD.%2BE.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DOrsini%26aufirst%3DM.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26aulast%3DRosenthal%26aufirst%3DD.%2BI.%26aulast%3DScott%26aufirst%3DM.%2BK.%26aulast%3DVaidya%26aufirst%3DA.%2BH.%26atitle%3DA%2520selective%2520small%2520molecule%2520NOP%2520%2528ORL-1%2520receptor%2529%2520partial%2520agonist%2520for%2520the%2520treatment%2520of%2520anxiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D602%26epage%3D606%26doi%3D10.1016%2Fj.bmcl.2014.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part 1</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3308</span>– <span class="NLM_lpage">3313</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2Fj.bmcl.2013.03.101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=23623415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvV2ksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3308-3313&author=N.+T.+Zaveriauthor=F.+Jiangauthor=C.+Olsenauthor=W.+E.+Polgarauthor=L.+Toll&title=Designing+bifunctional+NOP+receptor-mu+opioid+receptor+ligands+from+NOP+receptor-selective+scaffolds.+Part+1&doi=10.1016%2Fj.bmcl.2013.03.101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.</span></div><div class="casAuthors">Zaveri, Nurulain T.; Jiang, Faming; Olsen, Cris; Polgar, Willma E.; Toll, Lawrence</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3308-3313</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The nociceptin receptor (NOP) and its endogenous agonist, nociceptin/orphanin FQ (N/OFQ), members of the opioid receptor and peptide families resp., modulate the pharmacol. effects of classical opioids, particularly opioid-induced reward and nociception.  We hypothesized that compds. contg. both NOP and opioid receptor activity in a single mol. may have useful pharmacol. profiles as non-addicting analgesics or as drug abuse medications.  We report here our forays into the structure-activity relationships for discovering 'bifunctional' NOP-mu opioid receptor (MOP) ligands, starting from our NOP-selective scaffolds.  This initial SAR suggests pharmacophoric elements that may be modified to modulate/increase opioid affinity, while maintaining high affinity for the NOP receptor, to result in potent bifunctional small-mol. NOP/MOP ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNMyjT_yppQrVg90H21EOLACvtfcHk0liBCdodXUyTuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvV2ksr0%253D&md5=22731f8e1bbe06a33145392214d4c908</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.101%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DOlsen%26aufirst%3DC.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DDesigning%2520bifunctional%2520NOP%2520receptor-mu%2520opioid%2520receptor%2520ligands%2520from%2520NOP%2520receptor-selective%2520scaffolds.%2520Part%25201%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3308%26epage%3D3313%26doi%3D10.1016%2Fj.bmcl.2013.03.101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span> <span> </span><span class="NLM_article-title">Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1948</span>– <span class="NLM_lpage">1961</span>, <span class="refDoi"> DOI: 10.1002/prot.24077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1002%2Fprot.24077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=22489047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFSkur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2012&pages=1948-1961&author=P.+R.+Dagaauthor=N.+T.+Zaveri&title=Homology+modeling+and+molecular+dynamics+simulations+of+the+active+state+of+the+nociceptin+receptor+reveal+new+insights+into+agonist+binding+and+activation&doi=10.1002%2Fprot.24077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation</span></div><div class="casAuthors">Daga, Pankaj R.; Zaveri, Nurulain T.</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1948-1961, S1948/1-S1948/8</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The opioid receptor-like receptor, also known as the nociceptin receptor (NOP), is a class A G protein-coupled receptor (GPCR) in the opioid receptor family.  Although NOP shares a significant homol. with the other opioid receptors, it does not bind known opioid ligands and has been shown to have a distinct mechanism of activation compared to the closely related opioid receptors mu, delta, and kappa.  Previously reported homol. models of the NOP receptor, based on the inactive-state GPCR crystal structures, give limited information on the activation and selectivity features of this fourth member of the opioid receptor family.  The authors report the first active-state homol. model of the NOP receptor based on the opsin GPCR crystal structure.  An inactive-state homol. model of NOP was also built using a multiple template approach.  Mol. dynamics simulation of the active-state NOP model and comparison to the inactive-state model suggest that NOP activation involves movements of transmembrane (TM)3 and TM6 and several activation microswitches, consistent with GPCR activation.  Docking of the selective nonpeptidic NOP agonist ligand Ro 64-6198 into the active-state model reveals active-site residues in NOP that play a role in the high selectivity of this ligand for NOP over the other opioid receptors.  Docking the shortest active fragment of endogenous agonist nociceptin/orphaninFQ (residues 1-13) shows that the NOP extracellular loop 2 (EL2) loop interacts with the pos. charged residues (8-13) of N/OFQ.  Both agonists show extensive polar interactions with residues at the extracellular end of the TM domain and EL2 loop, suggesting agonist-induced reorganization of polar networks, during receptor activation.  Proteins 2012; © 2012 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHyKNV6QUesbVg90H21EOLACvtfcHk0liBCdodXUyTuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFSkur0%253D&md5=b239ff210a4b601c46401139c17f8fb5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fprot.24077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.24077%26sid%3Dliteratum%253Aachs%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26atitle%3DHomology%2520modeling%2520and%2520molecular%2520dynamics%2520simulations%2520of%2520the%2520active%2520state%2520of%2520the%2520nociceptin%2520receptor%2520reveal%2520new%2520insights%2520into%2520agonist%2520binding%2520and%2520activation%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2012%26volume%3D80%26spage%3D1948%26epage%3D1961%26doi%3D10.1002%2Fprot.24077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veronesi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6659</span>– <span class="NLM_lpage">6666</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0987-04.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1523%2FJNEUROSCI.0987-04.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=15282268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVCksLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=6659-6666&author=M.+Martiauthor=F.+Melaauthor=C.+Veronesiauthor=R.+Guerriniauthor=S.+Salvadoriauthor=M.+Federiciauthor=N.+B.+Mercuriauthor=A.+Rizziauthor=G.+Franchiauthor=L.+Beaniauthor=C.+Bianchiauthor=M.+Morari&title=Blockade+of+nociceptin%2Forphanin+FQ+receptor+signaling+in+rat+substantia+nigra+pars+reticulata+stimulates+nigrostriatal+dopaminergic+transmission+and+motor+behavior&doi=10.1523%2FJNEUROSCI.0987-04.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior</span></div><div class="casAuthors">Marti, Matteo; Mela, Flora; Veronesi, Carlo; Guerrini, Remo; Salvadori, Severo; Federici, Mauro; Mercuri, Nicola B.; Rizzi, Anna; Franchi, Gianfranco; Beani, Lorenzo; Bianchi, Clementina; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">6659-6666</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">A multidisciplinary approach was followed to investigate whether the opioid-like peptide nociceptin/orphanin FQ (N/OFQ) regulates the nigrostriatal dopaminergic pathway and motor behavior.  Nigrostriatal dopaminergic cells, which express N/OFQ peptide (NOP) receptors, are located in the substantia nigra pars compacta and extend their dendrites in the substantia nigra pars reticulata, thereby modulating the basal ganglia output neurons.  In vitro electrophysiol. recordings demonstrated that N/OFQ hyperpolarized the dopaminergic cells of the substantia nigra pars compacta and inhibited their firing activity.  In vivo dual-probe microdialysis showed that N/OFQ perfused in the substantia nigra pars reticulata reduced dopamine release in the ipsilateral striatum, whereas UFP-101 ([Nphe1,Arg14,Lys15]N/OFQ(1-13)-NH2) (a selective NOP receptor peptide antagonist) stimulated it.  N/OFQ microinjected in the substantia nigra pars reticulata impaired rat performance on a rotarod app., whereas UFP-101 enhanced it.  Electromyog. revealed that N/OFQ and UFP-101 oppositely affected muscle tone, inducing relaxation and contraction of triceps, resp.  The selective NOP receptor nonpeptide antagonist J-113397 (1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one), either injected intranigrally or given systemically, also elevated striatal dopamine release and facilitated motor activity, confirming that these effects were caused by blockade of endogenous N/OFQ signaling.  The inhibitory role played by endogenous N/OFQ on motor activity was addnl. strengthened by the finding that mice lacking the NOP receptor gene outperformed wild-type mice on the rotarod.  The authors conclude that NOP receptors in the substantia nigra pars reticulata, activated by endogenous N/OFQ, drive a physiol. inhibitory control on motor behavior, possibly via modulation of the nigrostriatal dopaminergic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKEHVGKjAkn7Vg90H21EOLACvtfcHk0lhl0ip2NheIOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVCksLo%253D&md5=84f7e383d4b524170a75b3d581848903</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0987-04.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0987-04.2004%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMela%26aufirst%3DF.%26aulast%3DVeronesi%26aufirst%3DC.%26aulast%3DGuerrini%26aufirst%3DR.%26aulast%3DSalvadori%26aufirst%3DS.%26aulast%3DFederici%26aufirst%3DM.%26aulast%3DMercuri%26aufirst%3DN.%2BB.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DFranchi%26aufirst%3DG.%26aulast%3DBeani%26aufirst%3DL.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520nociceptin%252Forphanin%2520FQ%2520receptor%2520signaling%2520in%2520rat%2520substantia%2520nigra%2520pars%2520reticulata%2520stimulates%2520nigrostriatal%2520dopaminergic%2520transmission%2520and%2520motor%2520behavior%26jtitle%3DJ.%2520Neurosci.%26date%3D2004%26volume%3D24%26spage%3D6659%26epage%3D6666%26doi%3D10.1523%2FJNEUROSCI.0987-04.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelson, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span> <span> </span><span class="NLM_article-title">Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>428</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01282-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS0014-2999%2801%2901282-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=11779034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVSlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=428&publication_year=2001&pages=29-36&author=N.+Zaveriauthor=W.+E.+Polgarauthor=C.+M.+Olsenauthor=A.+B.+Kelsonauthor=P.+Grundtauthor=J.+W.+Lewisauthor=L.+Toll&title=Characterization+of+opiates%2C+neuroleptics%2C+and+synthetic+analogs+at+ORL1+and+opioid+receptors&doi=10.1016%2FS0014-2999%2801%2901282-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors</span></div><div class="casAuthors">Zaveri, N.; Polgar, W. E.; Olsen, C. M.; Kelson, A. B.; Grundt, P.; Lewis, J. W.; Toll, L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">428</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Nociceptin/orphanin FQ (N/OFQ) was recently identified as the endogenous ligand for the opioid-receptor like (ORL1) receptor.  Although the ORL1 receptor shows sequence homol. with the opioid receptors, the nociceptin/ORL1 ligand-receptor system has very distinct pharmacol. actions compared to the opioid receptor system.  Recently, several small-mol. ORL1 receptor ligands were reported by pharmaceutical companies.  Most of these ligands had close structural similarities with known neuroleptics and opiates.  In this study, we screened several available neuroleptics and opiates for their binding affinity and functional activity at ORL1 and the opioid receptors.  We also synthesized several analogs of known opiates with modified piperidine N-substituents in order to characterize the ORL1 receptor ligand binding pocket.  Substitution with the large, lipophilic cyclooctylmethyl moiety increased ORL1 receptor affinity and decreased μ receptor affinity and efficacy in the fentanyl series of ligands but had a different effect in the oripavine class of opiate ligands.  Our results indicate that opiates and neuroleptics may be good starting points for ORL1 receptor ligand design, and the selectivity may be modulated by appropriate structural modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDT6YZiwl5yLVg90H21EOLACvtfcHk0lhl0ip2NheIOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVSlur8%253D&md5=c5f45983b650c2afa47f8b58ce0314a0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901282-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901282-1%26sid%3Dliteratum%253Aachs%26aulast%3DZaveri%26aufirst%3DN.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DOlsen%26aufirst%3DC.%2BM.%26aulast%3DKelson%26aufirst%3DA.%2BB.%26aulast%3DGrundt%26aufirst%3DP.%26aulast%3DLewis%26aufirst%3DJ.%2BW.%26aulast%3DToll%26aufirst%3DL.%26atitle%3DCharacterization%2520of%2520opiates%252C%2520neuroleptics%252C%2520and%2520synthetic%2520analogs%2520at%2520ORL1%2520and%2520opioid%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D428%26spage%3D29%26epage%3D36%26doi%3D10.1016%2FS0014-2999%2801%2901282-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenner, P.</span></span> <span> </span><span class="NLM_article-title">Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1391</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01426.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1111%2Fj.1476-5381.2011.01426.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=21486284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=1357-1391&author=S.+Dutyauthor=P.+Jenner&title=Animal+models+of+Parkinson%E2%80%99s+disease%3A+a+source+of+novel+treatments+and+clues+to+the+cause+of+the+disease&doi=10.1111%2Fj.1476-5381.2011.01426.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease</span></div><div class="casAuthors">Duty, Susan; Jenner, Peter</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1357-1391</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness.  Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression.  The array of available rodent models is large and ranges from acute pharmacol. models, such as the reserpine- or haloperidol-treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro-striatal pathway, such as the classical 6-hydroxydopamine (6-OHDA) rat and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse models.  All of these have provided test beds in which new mols. for treating the motor symptoms of PD can be assessed.  In addn., the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6-OHDA-lesioned rats with L-DOPA has allowed for examn. of the mechanisms responsible for treatment-related dyskinesia in PD, and the detection of mols. able to prevent or reverse their appearance.  Other toxin-based models of nigro-striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but while providing clues to disease pathogenesis, these are not so commonly used for drug development.  The MPTP-treated primate model of PD, which closely mimics the clin. features of PD and in which all currently used anti-parkinsonian medications have been shown to be effective, is undoubtedly the most clin.-relevant of all available models.  The MPTP-treated primate develops clear dyskinesia when repeatedly exposed to L-DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man.  Whether non-dopaminergic drugs show the same degree of predictability of response is a matter of debate.  As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed.  A further generation of models aimed at mimicking the genetic causes of PD has also sprung up.  While these newer models have provided further clues to the disease pathol., they have so far been less commonly used for drug development.  There is little doubt that the availability of exptl. animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug-related side effects that emerge with disease progression and chronic medication.  However, so far, we have made little progress in moving into other pharmacol. areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathol. and biochem. change.  Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression.  The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic.  This article aims to clarify the current position and highlight the strengths and weaknesses of available models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoptecPrVBnv7Vg90H21EOLACvtfcHk0lhl0ip2NheIOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlShtrbM&md5=587852b53e518988f9ab89436aa23326</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01426.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01426.x%26sid%3Dliteratum%253Aachs%26aulast%3DDuty%26aufirst%3DS.%26aulast%3DJenner%26aufirst%3DP.%26atitle%3DAnimal%2520models%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520source%2520of%2520novel%2520treatments%2520and%2520clues%2520to%2520the%2520cause%2520of%2520the%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D1357%26epage%3D1391%26doi%3D10.1111%2Fj.1476-5381.2011.01426.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwarting, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huston, J. P.</span></span> <span> </span><span class="NLM_article-title">The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">331</span>, <span class="refDoi"> DOI: 10.1016/S0301-0082(96)00040-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS0301-0082%2896%2900040-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=8971983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaK2sXks12hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=275-331&author=R.+K.+Schwartingauthor=J.+P.+Huston&title=The+unilateral+6-hydroxydopamine+lesion+model+in+behavioral+brain+research.+Analysis+of+functional+deficits%2C+recovery+and+treatments&doi=10.1016%2FS0301-0082%2896%2900040-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments</span></div><div class="casAuthors">Schwarting, R. K. W.; Huston, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">275-331</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with over 400 refs.  Lesions with the neurotoxin 6-hydroxydopamine (6-OHDA) have provided an important tool to study dopamine neurons in the brain.  The most common version of such lesions is the unilateral one where the toxin is placed in the area of mesencephalic dopamine cell bodies or their ascending fibers.  This approach leads to a lateralized destruction of mesencephalic dopamine neurons and to a lateralized loss of striatal dopamine innervation.  Such lesions have contributed substantially to neuroscientific knowledge both, at the basic and clin. level.  Physiol., they have been used to clarify the neuroanatomy, neurochem., and electrophysiol. of mesencephalic DA neurons and their relationships with the basal ganglia; the relevant findings have been summarized in a previous review (Schwarting, R.K.W. and Huston, J.P. (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiol. sequelae, Progress in Neurobiol. 49, 215-266).  Furthermore, 6-OHDA lesions have been used extensively to investigate the role of these dopamine neurons with respect to behavior, to examine the brain's capacity to recover from or compensate for specific neurochem. depletions, and to investigate the promotive effects of exptl. and clin. approaches which are relevant for the treatment of Parkinson's disease.  These findings are summarized here, including the spectrum of behavioral deficits (turning, sensory neglect, etc.), functional recovery and its possible mechanisms, the behavioral effects of widely used pharmacol. challenges (amphetamines, apomorphine, selective receptor agonists, L-DOPA), and the effects of treatments which can promote recovery (like neuropeptides, neurotrophins, and grafts).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqYnX6Nw15Y7Vg90H21EOLACvtfcHk0lgs6BxjjY2KTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXks12hsQ%253D%253D&md5=80337b55ade69356ae4b7e4e802ef246</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2896%2900040-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252896%252900040-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchwarting%26aufirst%3DR.%2BK.%26aulast%3DHuston%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520unilateral%25206-hydroxydopamine%2520lesion%2520model%2520in%2520behavioral%2520brain%2520research.%2520Analysis%2520of%2520functional%2520deficits%252C%2520recovery%2520and%2520treatments%26jtitle%3DProg.%2520Neurobiol.%26date%3D1996%26volume%3D50%26spage%3D275%26epage%3D331%26doi%3D10.1016%2FS0301-0082%2896%2900040-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paxinos, G.</span>; <span class="NLM_string-name">Watson, C.</span></span> <i>The Rat Brain in Stereotaxic Coordinates</i>; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">1986</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&author=G.+Paxinos&author=C.+Watson&title=The+Rat+Brain+in+Stereotaxic+Coordinates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPaxinos%26aufirst%3DG.%26btitle%3DThe%2520Rat%2520Brain%2520in%2520Stereotaxic%2520Coordinates%26pub%3DAcademic%2520Press%26date%3D1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morari, M.</span></span> <span> </span><span class="NLM_article-title">Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2002.01169.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1046%2Fj.1471-4159.2002.01169.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=12390525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADC%252BD38Xos1Sjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2002&pages=635-644&author=M.+Martiauthor=F.+Melaauthor=C.+Bianchiauthor=L.+Beaniauthor=M.+Morari&title=Striatal+dopamine-NMDA+receptor+interactions+in+the+modulation+of+glutamate+release+in+the+substantia+nigra+pars+reticulata+in+vivo%3A+opposite+role+for+D1+and+D2+receptors&doi=10.1046%2Fj.1471-4159.2002.01169.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: Opposite role for D1 and D2 receptors</span></div><div class="casAuthors">Marti, Matteo; Mela, Flora; Bianchi, Clementina; Beani, Lorenzo; Morari, Michele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">635-644</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">Dual probe microdialysis was employed in conscious rats to investigate whether endogenous dopamine is involved in the stimulation of glutamate release in the substantia nigra pars reticulata following striatal NMDA receptor activation.  Intrastriatal perfusion with NMDA (1 and 10 μM) facilitated nigral glutamate release (dizocilpine- and tetrodotoxin-sensitive).  The D2 dopamine receptor antagonist raclopride increased spontaneous nigral glutamate release and caused a leftward shift in the NMDA sensitivity, lowering NMDA effective concns. to submicromolar levels.  Conversely, the D1 antagonist SCH23390 prevented the effect of NMDA (1 μM) and caused a rightward shift in the NMDA sensitivity.  It was tested whether the antagonist effects were due to dopamine receptor blockade or increased tone on D1/D2 receptors.  SCH23390 prevented the raclopride-induced enhancement of spontaneous but not NMDA-evoked glutamate release while raclopride left unchanged the SCH23390-induced inhibition.  The physiopathol. relevance of the dopaminergic modulation was strengthened by perfusing NMDA in the dopamine-depleted striatum of hemiparkinsonian rats.  Nigral glutamate responsiveness to NMDA was enhanced as with raclopride.  The authors conclude that endogenous striatal dopamine regulates both spontaneous and NMDA-induced nigral glutamate release via an opposite control mediated by D1 facilitatory and D2 inhibitory receptors.  Alterations of this control may subserve the motor symptoms of Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEwtOgDnqWbVg90H21EOLACvtfcHk0lgs6BxjjY2KTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xos1Sjur8%253D&md5=480c12d44c517b1e271658108361c9dc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2002.01169.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2002.01169.x%26sid%3Dliteratum%253Aachs%26aulast%3DMarti%26aufirst%3DM.%26aulast%3DMela%26aufirst%3DF.%26aulast%3DBianchi%26aufirst%3DC.%26aulast%3DBeani%26aufirst%3DL.%26aulast%3DMorari%26aufirst%3DM.%26atitle%3DStriatal%2520dopamine-NMDA%2520receptor%2520interactions%2520in%2520the%2520modulation%2520of%2520glutamate%2520release%2520in%2520the%2520substantia%2520nigra%2520pars%2520reticulata%2520in%2520vivo%253A%2520opposite%2520role%2520for%2520D1%2520and%2520D2%2520receptors%26jtitle%3DJ.%2520Neurochem.%26date%3D2002%26volume%3D83%26spage%3D635%26epage%3D644%26doi%3D10.1046%2Fj.1471-4159.2002.01169.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanberg, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunsey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, A. B.</span></span> <span> </span><span class="NLM_article-title">The catalepsy test: its ups and downs</span>. <i>Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1037/0735-7044.102.5.748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1037%2F0735-7044.102.5.748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=2904271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADyaL1M%252FmtF2jsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1988&pages=748-759&author=P.+R.+Sanbergauthor=M.+D.+Bunseyauthor=M.+Giordanoauthor=A.+B.+Norman&title=The+catalepsy+test%3A+its+ups+and+downs&doi=10.1037%2F0735-7044.102.5.748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The catalepsy test: its ups and downs</span></div><div class="casAuthors">Sanberg P R; Bunsey M D; Giordano M; Norman A B</div><div class="citationInfo"><span class="NLM_cas:title">Behavioral neuroscience</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">748-59</span>
        ISSN:<span class="NLM_cas:issn">0735-7044</span>.
    </div><div class="casAbstract">The typical catalepsy test consists of placing an animal into an unusual posture and recording the time taken to correct this posture.  This time is regarded as an index of the intensity of catalepsy.  Catalepsy is a robust behavior, and the lack of standardization does not usually hinder its actual detection.  However, the intensity of the cataleptic effect is influenced by minor methodological differences, and thus interpretation and comparison of results across laboratories are difficult.  The behavioral catalepsy test can use any of several different apparatus, including wire grids, parallel bars, platforms, or pegs, to situate the animals in unusual positions.  The most common, however, is the "bar test," and despite its wide use in psychopharmacological research, even parameters of this test are not standardized.  The present article reviews the wide variety of parameters chosen by investigators that measure catalepsy.  The methodological issues of repeated testing, scaling of scores, apparatus, animal weight, maximal test duration, behavioral criteria, and other influences are discussed.  In addition, a brief review of the neuropharmacological basis of catalepsy is also included.  Finally, it is argued that a universal, standardized bar test be adopted by researchers.  New data on a novel automated bar test in the Digiscan Activity Monitoring System is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQ0Z7nr9lnp9LIORRPd5lbfW6udTcc2eY5E11EXNl7Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1M%252FmtF2jsw%253D%253D&md5=222a8efe37eab467024bcc1f70b39203</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1037%2F0735-7044.102.5.748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0735-7044.102.5.748%26sid%3Dliteratum%253Aachs%26aulast%3DSanberg%26aufirst%3DP.%2BR.%26aulast%3DBunsey%26aufirst%3DM.%2BD.%26aulast%3DGiordano%26aufirst%3DM.%26aulast%3DNorman%26aufirst%3DA.%2BB.%26atitle%3DThe%2520catalepsy%2520test%253A%2520its%2520ups%2520and%2520downs%26jtitle%3DBehav.%2520Neurosci.%26date%3D1988%26volume%3D102%26spage%3D748%26epage%3D759%26doi%3D10.1037%2F0735-7044.102.5.748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schallert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ryck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whishaw, I. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teitelbaum, P.</span></span> <span> </span><span class="NLM_article-title">Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">33</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/0014-4886(79)90003-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2F0014-4886%2879%2990003-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=428497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A528%3ADyaE1MXktlaqs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1979&pages=33-43&author=T.+Schallertauthor=M.+De+Ryckauthor=I.+Q.+Whishawauthor=V.+D.+Ramirezauthor=P.+Teitelbaum&title=Excessive+bracing+reactions+and+their+control+by+atropine+and+L-DOPA+in+an+animal+analog+of+Parkinsonism&doi=10.1016%2F0014-4886%2879%2990003-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism</span></div><div class="casAuthors">Schallert, Timothy; De Ryck, Marc; Whishaw, Ian Q.; Ramirez, Victor D.; Teitelbaum, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-43</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    </div><div class="casAbstract">Atropine sulfate (I sulfate)  [55-48-1], an anticholinergic drug, administered to rats made akinetic by intraventricular application of 6-hydroxydopamine to induce a parkinsonian symptom, improved the bracing reaction and locomotor activity.  The effect of I was increased by simultaneous administration with L-dopa  [59-92-7].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCvaE443vaLVg90H21EOLACvtfcHk0ljQd0UhnhAHWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXktlaqs7s%253D&md5=b976867418534361c030bb559f766434</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0014-4886%2879%2990003-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4886%252879%252990003-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchallert%26aufirst%3DT.%26aulast%3DDe%2BRyck%26aufirst%3DM.%26aulast%3DWhishaw%26aufirst%3DI.%2BQ.%26aulast%3DRamirez%26aufirst%3DV.%2BD.%26aulast%3DTeitelbaum%26aufirst%3DP.%26atitle%3DExcessive%2520bracing%2520reactions%2520and%2520their%2520control%2520by%2520atropine%2520and%2520L-DOPA%2520in%2520an%2520animal%2520analog%2520of%2520Parkinsonism%26jtitle%3DExp.%2520Neurol.%26date%3D1979%26volume%3D64%26spage%3D33%26epage%3D43%26doi%3D10.1016%2F0014-4886%2879%2990003-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labandeira-Garcia, J. L.</span></span> <span> </span><span class="NLM_article-title">An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism</span>. <i>Brain Res. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/S1385-299X(97)00034-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=10.1016%2FS1385-299X%2897%2900034-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=9438075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;key=1%3ACAS%3A280%3ADyaK1c7gtV2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1997&pages=75-84&author=G.+Rozasauthor=M.+J.+Guerraauthor=J.+L.+Labandeira-Garcia&title=An+automated+rotarod+method+for+quantitative+drug-free+evaluation+of+overall+motor+deficits+in+rat+models+of+parkinsonism&doi=10.1016%2FS1385-299X%2897%2900034-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism</span></div><div class="casAuthors">Rozas G; Guerra M J; Labandeira-Garcia J L</div><div class="citationInfo"><span class="NLM_cas:title">Brain research. Brain research protocols</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-84</span>
        ISSN:<span class="NLM_cas:issn">1385-299X</span>.
    </div><div class="casAbstract">A variety of tests have been proposed for evaluation of motor deficits in rat models of hemiparkinsonism.  The most widely used test, the "rotational behaviour" test, is based upon motor asymmetry induced by drug administration, leading to problems of sensitization, conditioning and priming.  In addition, lesion-induced rotational behaviour is sometimes overcompensated by treatments (grafts) while other deficits are unaffected.  However, rotational behaviour is reproducible and easy to quantify.  On the contrary, most drug-free tests have proved of limited applicability because of subjective scaling, excessive interaction between the experimenter and animals, motivational effects, excessively complex tasks, etc., making it difficult to compare results from different laboratories.  In this paper, we present a rotarod based method for automated drug-free evaluation of overall motor deficits in the rat model of hemiparkinsonism, and for identifying treatment-induced changes.  Animals are pre-trained on the rotarod and then tested at a series of increasing rod speeds; from this set of values a unique score for each animal is computed (the overall rotarod performance, ORP) summarizing its performance at different speeds.  This value is easy to compute and greatly simplifies statistical comparisons.  Major advantages of the test are: (i) it does not require drugs, but is nevertheless highly objective, reproducible and easy to quantify; and (ii) falling of animals from rotating rod seems to depend on a combination of lesion-induced deficits which become more evident when rats are forced to move at faster speeds.  Since the test is not based exclusively on motor asymmetry, it may also be useful for characterization of bilaterally lesioned animals, for which drug-induced rotational behaviour tests cannot be used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEF4B2MWhtvJcXNb62YGmbfW6udTcc2ebaaKj4dQRFULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7gtV2gug%253D%253D&md5=ecf3ab7c32d8ee8c53b5e1b1c00f09e0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1385-299X%2897%2900034-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1385-299X%252897%252900034-2%26sid%3Dliteratum%253Aachs%26aulast%3DRozas%26aufirst%3DG.%26aulast%3DGuerra%26aufirst%3DM.%2BJ.%26aulast%3DLabandeira-Garcia%26aufirst%3DJ.%2BL.%26atitle%3DAn%2520automated%2520rotarod%2520method%2520for%2520quantitative%2520drug-free%2520evaluation%2520of%2520overall%2520motor%2520deficits%2520in%2520rat%2520models%2520of%2520parkinsonism%26jtitle%3DBrain%2520Res.%2520Protoc.%26date%3D1997%26volume%3D2%26spage%3D75%26epage%3D84%26doi%3D10.1016%2FS1385-299X%2897%2900034-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i66"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02134">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32877"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02134?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02134</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES data (molecular formula strings) for all final compounds along with their in vitro pharmacological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02134/suppl_file/jm9b02134_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02134/suppl_file/jm9b02134_si_001.csv">jm9b02134_si_001.csv (3.07 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02134&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02134%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02134" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e4a27c653d48","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
